
<html lang="en"     class="pb-page"  data-request-id="69beaaf8-23e8-4f68-85ca-cc4ebdb31b28"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2012.55.issue-8;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm300185p;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders" /></meta><meta name="dc.Creator" content="Youichi  Kawakita" /></meta><meta name="dc.Creator" content="Hiroshi  Banno" /></meta><meta name="dc.Creator" content="Tomohiro  Ohashi" /></meta><meta name="dc.Creator" content="Toshiya  Tamura" /></meta><meta name="dc.Creator" content="Tadashi  Yusa" /></meta><meta name="dc.Creator" content="Akiko  Nakayama" /></meta><meta name="dc.Creator" content="Hiroshi  Miki" /></meta><meta name="dc.Creator" content="Hidehisa  Iwata" /></meta><meta name="dc.Creator" content="Hidenori  Kamiguchi" /></meta><meta name="dc.Creator" content="Toshimasa  Tanaka" /></meta><meta name="dc.Creator" content="Noriyuki  Habuka" /></meta><meta name="dc.Creator" content="Satoshi  Sogabe" /></meta><meta name="dc.Creator" content="Yoshikazu  Ohta" /></meta><meta name="dc.Creator" content="Tomoyasu  Ishikawa" /></meta><meta name="dc.Description" content="To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused r..." /></meta><meta name="Description" content="To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused r..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 10, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300185p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300185p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300185p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300185p" /></link>
        
    
    

<title>Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300185p" /></meta><meta property="og:title" content="Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0001.jpeg" /></meta><meta property="og:description" content="To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused rings designed to fit the back pocket of the HER2/EGFR proteins. Among them, the 1,2-benzisothiazole (42m) ring was selected as a suitable back pocket binder because of its potent HER2/EGFR binding and cell growth inhibitory (GI) activities and pseudoirreversibility (PI) profile as well as good bioavailability (BA). Ultimately, we arrived at our preclinical candidate 51m by optimization of the N-5 side chain to improve CYP inhibition and metabolic stability profiles without a loss of potency (HER2/EGFR inhibitory activity, IC50, 0.98/2.5 nM; and GI activity BT-474 cells, GI50, 2.0 nM). Reflecting the strong in vitro activities, 51m exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4–1ST and CAL27) xenograft models in mice at oral doses of 50 mg/kg and 100 mg/kg." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300185p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300185p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300185p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300185p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300185p&amp;href=/doi/10.1021/jm300185p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3975-3991</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm300170m" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm300262w" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Pyrrolo[3,2-<i>d</i>]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Youichi++Kawakita">Youichi Kawakita</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroshi++Banno">Hiroshi Banno</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomohiro++Ohashi">Tomohiro Ohashi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Toshiya++Tamura">Toshiya Tamura</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tadashi++Yusa">Tadashi Yusa</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Akiko++Nakayama">Akiko Nakayama</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroshi++Miki">Hiroshi Miki</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hidehisa++Iwata">Hidehisa Iwata</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hidenori++Kamiguchi">Hidenori Kamiguchi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Toshimasa++Tanaka">Toshimasa Tanaka</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Noriyuki++Habuka">Noriyuki Habuka</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Satoshi++Sogabe">Satoshi Sogabe</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yoshikazu++Ohta">Yoshikazu Ohta</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomoyasu++Ishikawa">Tomoyasu Ishikawa</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div><div class="corresp-info"><strong>*</strong>(Y.K.) Tel: +81-466-32-1249. Fax: +81-466-29-4450. E-mail: <a href="/cdn-cgi/l/email-protection#652e0412040e0c11043a3c0a100c060d0c2511040e0001044b060a4b0f155f"><span class="__cf_email__" data-cfemail="86cde7f1e7edeff2e7d9dfe9f3efe5eeefc6f2e7ede3e2e7a8e5e9a8ecf6">[email protected]</span>:</a>. (T.I.) Tel: +81-466-32-1155. Fax: +81-466-29-4449. E-mail: <a href="/cdn-cgi/l/email-protection#9ad3e9f2f3f1fbedfbc5cef5f7f5e3fbe9efdaeefbf1fffefbb4f9f5b4f0ea"><span class="__cf_email__" data-cfemail="28615b404143495f49777c47454751495b5d685c49434d4c49064b47064258">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300185p&amp;href=/doi/10.1021%2Fjm300185p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3975–3991</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 22, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 February 2012</li><li><span class="item_label"><b>Published</b> online</span>10 April 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 April 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300185p" title="DOI URL">https://doi.org/10.1021/jm300185p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3975%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYouichi%2BKawakita%252C%2BHiroshi%2BBanno%252C%2BTomohiro%2BOhashi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D8%26contentID%3Djm300185p%26title%3DDesign%2Band%2BSynthesis%2Bof%2BPyrrolo%255B3%252C2-d%255Dpyrimidine%2BHuman%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B2%2B%2528HER2%2529%252FEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%2BDual%2BInhibitors%253A%2BExploration%2Bof%2BNovel%2BBack-Pocket%2BBinders%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3991%26publicationDate%3DApril%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300185p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4159</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300185p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Youichi&quot;,&quot;last_name&quot;:&quot;Kawakita&quot;},{&quot;first_name&quot;:&quot;Hiroshi&quot;,&quot;last_name&quot;:&quot;Banno&quot;},{&quot;first_name&quot;:&quot;Tomohiro&quot;,&quot;last_name&quot;:&quot;Ohashi&quot;},{&quot;first_name&quot;:&quot;Toshiya&quot;,&quot;last_name&quot;:&quot;Tamura&quot;},{&quot;first_name&quot;:&quot;Tadashi&quot;,&quot;last_name&quot;:&quot;Yusa&quot;},{&quot;first_name&quot;:&quot;Akiko&quot;,&quot;last_name&quot;:&quot;Nakayama&quot;},{&quot;first_name&quot;:&quot;Hiroshi&quot;,&quot;last_name&quot;:&quot;Miki&quot;},{&quot;first_name&quot;:&quot;Hidehisa&quot;,&quot;last_name&quot;:&quot;Iwata&quot;},{&quot;first_name&quot;:&quot;Hidenori&quot;,&quot;last_name&quot;:&quot;Kamiguchi&quot;},{&quot;first_name&quot;:&quot;Toshimasa&quot;,&quot;last_name&quot;:&quot;Tanaka&quot;},{&quot;first_name&quot;:&quot;Noriyuki&quot;,&quot;last_name&quot;:&quot;Habuka&quot;},{&quot;first_name&quot;:&quot;Satoshi&quot;,&quot;last_name&quot;:&quot;Sogabe&quot;},{&quot;first_name&quot;:&quot;Yoshikazu&quot;,&quot;last_name&quot;:&quot;Ohta&quot;},{&quot;first_name&quot;:&quot;Tomoyasu&quot;,&quot;last_name&quot;:&quot;Ishikawa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;3975-3991&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300185p&quot;},&quot;abstract&quot;:&quot;To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused rings designed to fit the back pocket of the HER2/EGFR proteins. Among them, the 1,2-benzisothiazole (42m) ring was selected as a suitable back pocket binder because of its potent HER2/EGFR binding and cell growth inhibitory (GI) activities and pseudoirreversibility (PI) profile as well as good bioavailability (BA). Ultimately, we arrived at our preclinical candidate 51m by optimization of the N-5 side chain to improve CYP inhibition and metabolic stability profiles without a loss of potency (HER2/EGFR inhibitory activity, IC50, 0.98/2.5 nM; and GI activity BT-474 cells, GI50, 2.0 nM). Reflecting the strong in vitro activities, 51m exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4–1ST and CAL27) xenograft models in mice at oral doses of 50 mg/kg and 100 mg/kg.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300185p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300185p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300185p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300185p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300185p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300185p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300185p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300185p&amp;href=/doi/10.1021/jm300185p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300185p" /></input><a href="/doi/pdf/10.1021/jm300185p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300185p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300185p%26sid%3Dliteratum%253Aachs%26pmid%3D22439974%26genre%3Darticle%26aulast%3DKawakita%26date%3D2012%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BPyrrolo%255B3%252C2-d%255Dpyrimidine%2BHuman%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B2%2B%2528HER2%2529%252FEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%2BDual%2BInhibitors%253A%2BExploration%2Bof%2BNovel%2BBack-Pocket%2BBinders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D8%26spage%3D3975%26epage%3D3991%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291687" title="Reagents">Reagents</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jmcmar.2012.55.issue-8/production/jmcmar.2012.55.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-<i>d</i>]pyrimidine derivatives bearing bicyclic fused rings designed to fit the back pocket of the HER2/EGFR proteins. Among them, the 1,2-benzisothiazole (<b>42m</b>) ring was selected as a suitable back pocket binder because of its potent HER2/EGFR binding and cell growth inhibitory (GI) activities and pseudoirreversibility (PI) profile as well as good bioavailability (BA). Ultimately, we arrived at our preclinical candidate <b>51m</b> by optimization of the <i>N</i>-5 side chain to improve CYP inhibition and metabolic stability profiles without a loss of potency (HER2/EGFR inhibitory activity, IC<sub>50</sub>, 0.98/2.5 nM; and GI activity BT-474 cells, GI<sub>50</sub>, 2.0 nM). Reflecting the strong <i>in vitro</i> activities, <b>51m</b> exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4–1ST and CAL27) xenograft models in mice at oral doses of 50 mg/kg and 100 mg/kg.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protein tyrosine kinases play a key role in signal transduction pathways that regulate numerous cellular functions including proliferation, differentiation, migration, and angiogenesis. Because signal transduction pathways are upregulated in many tumor cells, protein kinase inhibitors that target these upregulated pathways are attractive candidates for cancer therapy.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The targeting of human epidermal growth factor receptor 2 (HER2 or ErbB-2/neu) and epidermal growth factor receptor (EGFR or HER1/ErbB-1) by tyrosine kinase inhibitors (TKIs) represents one such therapeutic approach. Indeed, there are several ATP-competitive HER2/EGFR TKIs currently in clinical trials or on the market for the treatment of cancer.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">We previously reported<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> pyrrolo[3,2-<i>d</i>]pyrimidine derivatives as potent dual TKIs against HER2/EGFR, and discovered a representative clinical candidate <b>1</b> (TAK-285, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), which showed significant <i>in vivo</i> antitumor efficacy based on HER2/EGFR inhibitory activities. In addition, we have determined X-ray cocrystal structures of <b>1</b> with both HER2 and EGFR.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of <b>1</b> (TAK-285).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These studies proved that a pyrrolo[3,2-<i>d</i>]pyrimidine scaffold was an important central core for the creation of kinase inhibitors. Indeed, this scaffold was also effectively used as a hinge binder in our VEGFR2 program.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In addition, compound <b>1</b>exhibited a moderately slow off-rate, leading to a so-called “pseudo-irreversible” (PI) profile from the intracellular kinase domains of HER2 and EGFR (<i>vide infra</i>). Some reports have indicated that a slow off-rate is related to high cellular activity.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> On the basis of this knowledge, we continued our studies on the synthesis of HER2/EGFR kinase inhibitors using this unique scaffold to discover new candidates exhibiting potent antitumor activity with characteristic PI profiles. We hypothesized that a unique back pocket to accommodate the 3-trifluoromethylphenoxy group of <b>1</b>, created by the conformational shift in the <i>N</i>-terminal end of the <i>C</i>-helix, could be utilized to identify additional compounds with PI profiles. Our studies revealed that the PI profile correlates with the structure of the back pocket binder moiety.</div><div class="NLM_p">Herein, we will describe the design, synthesis, and structure–activity relationships (SAR) of back pocket binding moieties that affect PI and cellular activity and describe the biological evaluation of these molecules.</div><div class="NLM_p">A docking study suggested that a carboxamide moiety at the <i>C</i>-3 position on the terminal phenoxy ring can make hydrogen bonds with the OH of Thr798, the C═O of Ser783, and the C═O of Arg784 in the HER2 protein (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). In fact, our previously synthesized compound, <i>N</i>-<i>tert</i>-butylcarboxamide <b>3</b> revealed stronger HER2 inhibitory and growth inhibitory (GI) activities than those of <b>2</b>, which has the same anilino group as <b>1</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In order to search for appropriate configurations of the carboxamide moiety to interact with Thr798/Thr790, Ser783/Cys775, and Arg784/Arg776 in the HER2/EGFR proteins, we designed bicyclic fused amide rings <b>a</b>–<b>h</b>, which were cyclized between the terminal phenoxy <i>C</i>-3 position and the <i>C</i>-2/<i>C</i>-4 position of <b>3</b>. Furthermore, on the basis of the activities observed for <b>a</b>–<b>h</b>, we designed several compounds possessing various bicyclic fused aromatic rings <b>i</b>–<b>m</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking model of the designed compound with HER2 protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Preliminary Biological Results for Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0021.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">95% Confidence interval.</p></div></div><div></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of new back pocket binders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The <i>N</i>-<i>tert</i>-butylcarboxamide derivative <b>3</b> was synthesized as shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Condensation of commercially available 2-chloro-1-fluoro-4-nitrobenzene (<b>4</b>) with phenol <b>5</b> was carried out in the presence of potassium carbonate (K<sub>2</sub>CO<sub>3</sub>) in dimethylformamide (DMF), followed by reduction of the nitro group with platinum on carbon (Pt/C) under hydrogen atmosphere to afford substituted aniline <b>7</b> in two steps (95% yield). After reaction of the obtained aniline <b>7</b> with 2-(4-chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl benzoate (<b>8</b>),<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> the terminal benzoyl and methyl esters were hydrolyzed with 1 N aqueous sodium hydroxide (NaOH), resulting in an 88% yield of the corresponding carboxylic acid (<b>9</b>). Amidation of the carboxylic acid <b>9</b> with 2-methylpropan-2-amine in the presence of triethylamine, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), and 1-hydroxybenzotriazole monohydrate (HOBt) provided the corresponding desired carboxamide in 66% yield.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) H<sub>2</sub>, Pt/C, EtOAc, rt; (c) (i) 2-propanol, 80 °C, (ii) 1 N NaOH, MeOH, rt; (d) EDC, HOBt, Et<sub>3</sub>N, 2-methylpropan-2-amine, DMF, rt.</p></p></figure><div class="NLM_p">Anilines with a 1,3-dihydro-2<i>H</i>-indol-2-one ring (<b>14c</b>, <b>d</b>, <b>g</b>, and <b>h</b>) were prepared as shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Reaction of <b>4</b> with the commercially available 1<i>H</i>-indol derivatives <b>10c</b>, <b>d</b>, <b>g</b>, and <b>h</b> gave the corresponding nitrobenzenes <b>11c</b>, <b>d</b>, <b>g</b> and <b>h</b>, respectively. After bromination of the obtained compounds <b>11c</b>, <b>d</b>, <b>g</b>, and <b>h</b> with <i>N</i>-bromosuccinimide (NBS), hydrolysis of the 3-bromo intermediates <b>12c</b>, <b>d</b>, <b>g</b>, and <b>h</b> with 6 N HCl provided 1,3-dihydro-2<i>H</i>-indol-2-one derivatives <b>13c</b>, <b>d</b>, <b>g</b>, and <b>h</b> in 45–80% yields over two steps. Finally, the nitro groups of the compounds <b>13c</b>, <b>d</b>, <b>g</b>, and <b>h</b> were reduced with Pt/C under hydrogen atmosphere to afford desired aniline compounds <b>14c</b>, <b>d</b>, <b>g</b>, and <b>h</b> in yields of 61–96%.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0011.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Anilines Bearing a 1,3-Dihydro-2<i>H</i>-indol-2-one Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) NBS, <i>tert-</i>BuOH, THF, rt; (c) 1 N HCl, THF, 70 °C; (d) H<sub>2</sub>, Pt/C, MeOH, THF, rt.</p></p></figure><div class="NLM_p">Synthesis of the aniline compounds <b>14a</b>, <b>b</b>, <b>e</b>, and <b>f</b>, bearing the corresponding 2,3-dihydro-1<i>H</i>-isoindol-1-one ring, is shown in Schemes <a class="ref internalNav" href="#sch3" aria-label="3">3</a> to <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Reaction of the hydroxy methyl benzoates <b>15a</b> and <b>15e</b> with <b>4</b> in the presence of K<sub>2</sub>CO<sub>3</sub> resulted in 92% to 96% yields of the condensed compounds <b>16a</b> and <b>16e</b>, which were reacted with NBS to provide 37% and 70% yields, respectively, of the methyl 2-(bromomethyl)benzoate derivatives <b>17a</b> and <b>17e</b>. Amination of the benzylbromides <b>17a</b> and <b>17e</b> with 28% aqueous ammonia solution was carried out in tetrahydrofuran (THF), followed by the subsequent cyclization of the amine intermediates <i>in situ</i> to afford 2,3-dihydro-1<i>H</i>-isoindol-1-one derivatives <b>18a</b> and <b>18e</b> in yields of 82% and 96%, respectively. The obtained products <b>18a</b> and <b>18e</b> were converted to the desired aniline compounds <b>14a</b> and <b>14e</b> in 50% to 70% yields under the usual hydrogenation conditions.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0012.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Anilines Bearing a 2,3-Dihydro-1<i>H</i>-isoindol-1-one Ring (I)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) NBS, AIBN, CF<sub>3</sub>–Ph, 100 °C; (c) 28% aq. NH<sub>3</sub>, THF, rt; (d) H<sub>2</sub>, Pt/C, MeOH, THF, rt.</p></p></figure><div class="NLM_p">The 2,3-dihydro-1<i>H</i>-isoindol-1-one derivative <b>14b</b> was synthesized as shown in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Bromination of methyl 4-methoxy-2-methylbenzoate (<b>19</b>) with NBS in the presence of AIBN in trifluoromethylbenzene, followed by treatment with 28% aqueous ammonia solution, resulted in a 39% yield of cyclic compound <b>21</b>. After deprotection of the methyl group with aqueous hydrogen bromide (HBr) in 44% yield, reaction of phenol compound <b>22</b> with <b>4</b> provided coupled nitrobenzene <b>23</b> in 74% yield. Standard hydrogenation of <b>23</b> using Pt/C led to the desired aniline compound <b>14b</b> in quantitative yield.</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0013.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Aniline Bearing a 2,3-Dihydro-1<i>H</i>-isoindol-1-one Ring (II)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NBS, AIBN, CF<sub>3</sub>–Ph, 100 °C; (b) 28% aq. NH<sub>3</sub>, THF, rt; (c) 48% aq. HBr, 100 °C; (d) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (e) H<sub>2</sub>, Pt/C, MeOH, THF, rt.</p></p></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a> shows the synthesis of the aniline compound <b>14f</b>. Bromination of ethyl 2-methoxy-6-methylbenzoate (<b>24</b>) provided dibrominated benzoate <b>25</b> followed by conversion with aqueous ammonia to 4-bromo-7-methoxy-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>26</b>) in 40% yield over two steps. After removal of the methyl group in 71% yield using HBr, the obtained 4-bromo-7-hydroxy-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>27</b>) was hydrogenated with Pt/C in MeOH to give phenol derivative <b>28</b> in quantitative yield. Condensation of <b>28</b> with <b>4</b> in the presence of K<sub>2</sub>CO<sub>3</sub> provided a coupled product <b>29</b>, and subsequent reduction of the nitro group of <b>29</b> afforded the desired aniline <b>14f</b> in quantitative yield.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0014.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Aniline Bearing a 2,3-Dihydro-1<i>H</i>-isoindol-1-one Ring (III)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NBS, AIBN, CF<sub>3</sub>–Ph, 100 °C; (b) 28% aq. NH<sub>3</sub>, THF, rt; (c) 48% aq. HBr, 100 °C; (d) H<sub>2</sub>, Pt/C, MeOH, rt; (e) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (f) H<sub>2</sub>, Pt/C, MeOH, THF, rt.</p></p></figure><div class="NLM_p">As shown in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>, preparation of the aniline compound <b>14i</b> bearing an 1<i>H</i>-indole ring was achieved by reduction of the nitro group of <b>11h</b> using reduced iron and calcium chloride in EtOH (73% yield).</div><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0015.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Aniline Bearing a 1<i>H</i>-Indole Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) Fe, CaCl<sub>2</sub>, aq. EtOH, 100 °C.</p></p></figure><div class="NLM_p">The aniline compound <b>14j</b> bearing the 1-benzothiophene ring was synthesized as shown in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>. Aromatization of 6,7-dihydro-1-benzothiophen-4(5<i>H</i>)-one (<b>30</b>) was carried out with phenyltrimethylammonium tribromide in THF, followed by treatment with lithium carbonate and lithium bromide in DMF to provide 1-benzothiophene-4-ol <b>31</b> in 91% yield.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The obtained phenol compound <b>31</b> was coupled with <b>4</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to provide <b>32</b> in 67% yield. Reduction of the nitro group of <b>32</b> with reduced iron powder gave the desired aniline compound <b>14j</b> in 80% yield.</div><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0016.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Aniline Bearing a 1-Benzothiophene Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) PhMe<sub>3</sub>NBr<sub>3</sub>, THF, rt, (ii) Li<sub>2</sub>CO<sub>3</sub>, LiBr, DMF, 150 °C; (b) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (c) Fe, CaCl<sub>2</sub>, aq. EtOH, 100 °C.</p></p></figure><div class="NLM_p">The synthesis of the aniline compounds <b>14k</b> and <b>14l</b> bearing an 1<i>H</i>-indazole ring is shown in Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>. Conversion of commercially available 1<i>H</i>-indazol-4-amine <b>33</b> into 1<i>H</i>-indazol-4-ol <b>34k</b> using sodium nitrite, followed by the reaction of <b>34k</b> with <b>4</b>, afforded a coupled nitrobenzene compound <b>35k</b>. The nitro group of <b>35k</b> was reduced with Pt/C under hydrogen atmosphere to provide the desired aniline compound <b>14k</b>. Another methylated aniline derivative <b>14l</b> was synthesized in 59% yield from commercially available 1-methyl-1<i>H</i>-indazol-4-ol (<b>34l</b>) in a manner similar to the synthesis of <b>14k</b>.</div><figure id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0017.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Aniline Bearing a 1<i>H</i>-Indazole Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaNO<sub>2</sub>, H<sub>2</sub>SO<sub>4,</sub> 100 °C; (b) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (c) H<sub>2</sub>, Pt/C, AcOEt, rt.</p></p></figure><div class="NLM_p">The aniline compound <b>14m</b> bearing an 1,2-benzisothiazole ring was synthesized as shown in Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>. The coupling of commercially available 2-fluoro-6-methoxybenzaldehyde (<b>36</b>) with phenylmethanethiol was carried out in the presence of sodium <i>tert</i>-butoxide in DMF (91% yield), followed by cyclization<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> of the obtained compound <b>37</b> with hydroxylamine-<i>O</i>-sulfonic acid in the presence of thioanisole in aqueous acetonitrile to afford 1,2-benzisothiazole <b>38</b> in 85% yield. Subsequently, removal of the methyl group from <b>38</b> was achieved using pyridine hydrochloride with heating at 195 °C for 2 h in 78% yield. Attempts at demethylation of <b>38</b> and <b>39</b> using HBr resulted in decomposition to form complex mixtures. The obtained phenol derivative <b>39</b> was coupled with <b>4</b> in DMF to give nitrobenzene derivative <b>40</b> in 96% yield. Finally, the nitro group of <b>40</b> was reduced with reduced iron powder under acidic conditions to afford the desired aniline derivative <b>14m</b> in 98% yield.</div><figure id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0018.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Aniline Bearing a 1,2-Benzisothiazole Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) BnSH, <i>tert-</i>BuONa, DMF, rt; (b) H<sub>2</sub>NOSO<sub>3</sub>H, Thioanisole, CH<sub>3</sub>CN, H<sub>2</sub>O, rt; (c) PyHCl, 195 °C; (d) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (e) Fe, 1 N HCl, EtOH, 80 °C.</p></p></figure><div class="NLM_p">The synthesis of the 4,5-substituted pyrrolo[3,2-<i>d</i>]pyrimidines <b>42a</b>–<b>m</b> was conducted as shown in Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a>. The aniline derivatives <b>14a</b>–<b>m</b> were reacted with pyrrolo[3,2-<i>d</i>]pyrimidine <b>8</b> in 2-propanol at 80 °C, followed by hydrolysis of the benzoyl group to afford the desired compounds <b>42a</b>–<b>m</b> in 27–98% yield over two steps.</div><figure id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0019.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Introduction of Various Anilino Groups to the Pyrrolo[3,2-<i>d</i>]pyrimidine Scaffold<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) aniline <b>14a</b>–<b>m</b>, 2-propanol, 80 °C, (ii) 1 N NaOH, MeOH, rt.</p></p></figure><div class="NLM_p">Preparation of the <i>N</i>-5 carboxamide derivatives <b>45m</b>–<b>51m</b>is summarized in Scheme <a class="ref internalNav" href="#sch11" aria-label="11">11</a>. Condensation of <b>43</b><a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> with the aniline <b>14m</b> was carried out in 2-propanol, followed by the removal of the Boc protecting group with 4 N HCl in EtOAc to afford the key intermediate <b>44</b> in 80% yield over two steps. Amidation of <b>44</b> with a variety of carboxylic acids in the presence of EDC and HOBt provided the corresponding carboxamide derivatives (<b>45</b>–<b>48</b>, <b>50</b>–<b>51</b>)<b>m</b> in 41–80% yield. The carboxamide compound <b>46m</b> was isolated as a salt of methanesulfonic acid. In the case of <b>50m</b> and <b>51m</b>, the Boc groups of the intermediates were removed by treatment with 4 N HCl in EtOAc, and <b>50m</b> was isolated as an HCl salt in 41% yield. However, <b>51m</b> was isolated as the free form in 64% yield by neutralization. The synthesis of the carboxamide derivative <b>49m</b> was achieved using 2,2-dimethylpropanoic acid anhydride and the product isolated as a salt of methanesulfonic acid in 63% yield.</div><figure id="sch11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0020.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Optimization of 5-Caboxamido Group<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) <b>14m</b>, 2-propanol, 80 °C, (ii) 4 N HCl in EtOAc, EtOH, 80 °C; (b) RCO<sub>2</sub>H or 1-(<i>tert</i>-butoxycarbonyl)proline or <i>N</i>-(<i>tert</i>-butoxycarbonyl)-2-methylalanine, EDC, HOBt, Et<sub>3</sub>N, DMF, rt; (c) 2,2-dimethylpropanoic acid anhydride, Et<sub>3</sub>N, DMF, rt; (d) 4N HCl in EtOAc, EtOH, 80 °C or 1 N HCl, EtOH, 80 °C; (e) MsOH, EtOAc or DMSO, rt.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our designed pyrrolo[3,2-<i>d</i>]pyrimidine derivatives <b>42a</b>–<b>h</b>, containing indolone and isoindolone rings in the 4-anilino moiety, were evaluated, and their activities are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Among the compounds cyclized at the <i>C</i>-3 and <i>C</i>-4 positions (<b>42a</b>–<b>d</b>), the 6-substituted-2,3-dihydro-1<i>H</i>-isoindol-1-one derivative <b>42a</b> showed the most potent HER2/EGFR inhibitory activities and growth inhibition (GI) activity in BT-474 cells. The other compounds, <b>42b</b>–<b>d</b>, showed reduced potencies against HER2/EGFR kinases as well as reduced GI activity. It was confirmed that suitable interaction of the carboxamide moiety in the bicyclic amide ring with the HER2/EGFR proteins is important for high-level inhibitory activity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Profiles for Indolone and Isoindolone Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0022.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">The animals used in the study were female BALB/cAJcl mice (7-weeks old; CLEA Japan, Inc.). A mixture of 5 test compounds was suspended in 0.5 w/v % methylcellulose solution for oral administration at a dose of 10 mg each/10 mL/kg. The concentrations of compounds in the plasma were determined by LC/MS/MS.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">95% confidence interval.</p></div></div><div></div></div><div class="NLM_p">Among the compounds cyclized at the <i>C</i>-3 and <i>C</i>-2 positions (<b>42e</b>–<b>h</b>), compound <b>42e</b> exhibited reduced potency against the HER2/EGFR kinases, but <b>42f</b>–<b>h</b> showed potent HER2/EGFR kinase inhibitory activities similar to those of <b>42a</b>. Interestingly, among the compounds <b>42f</b>–<b>h</b>, only <b>42f</b> exhibited a reduction of GI activity in BT-474 cells. However, 4-substituted-1,3-dihydro-2<i>H</i>-indol-2-one (<b>42h</b>) showed the most potent GI activity against BT-474 cells. To understand the reason for the difference in the GI activities of <b>42f</b> and <b>42h</b>, we examined their PI profiles against HER2 and EGFR; the results are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. In Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, we present data regarding the dissociation rate of compounds <b>42f</b> and <b>42h</b> from HER2 and EGFR compared with a standard compound <b>1</b> in a 100-fold dilution assay.<a onclick="showRef(event, 'cit6d ref9'); return false;" href="javascript:void(0);" class="ref cit6d ref9">(6d, 9)</a>Enzyme and inhibitor were incubated with an inhibitor concentration of 10 times the IC<sub>50</sub> value to allow formation of an enzyme–inhibitor complex. This complex was diluted to the inhibitor concentration of 0.1 times IC<sub>50</sub> value by 100-fold dilution with the addition of reaction buffer containing high concentration ATP (1 mmol/L). The rate of the product formation in the kinase reaction with this 100-fold dilution assay reflects the PI profile based on the dissociation of the enzyme–inhibitor complex. Compound <b>42h</b> showed strong PI effects on both HER2 and EGFR kinases, which corresponds to a characteristic slow-off rate profile. However, <b>42f</b> had a weaker PI profile than that of the standard compound <b>1</b>, which corresponds to a tendency to dissociate easily from the HER2 and EGFR proteins. Similarly, we determined the PI profiles of <b>42a</b>–<b>g</b>, shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. The PI strengths of compounds <b>42a</b>–<b>h</b>, compared with <b>1</b>, are indicated by 2 asterisks (**) when the compounds showed obviously strong PI profiles and by a single asterisk (*) when the PI was weak compared with that of <b>1</b>. Our results confirmed that the GI activities of the compounds <b>42a</b>–<b>h</b> were well correlated with their PI profiles.</div><figure id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dissociation profiles of pyrrolo[3,2-<i>d</i>]pyrimidines from HER2 (A) and EGFR (B). Phosphorylation of peptide substrate as a function of time is shown. The reaction was initiated by diluting a preformed enzyme–inhibitor complex into reaction buffer. To determine the dissociation kinetics of the inhibitors from HER2 and EGFR, the recovery of enzyme activity from a preformed enzyme–inhibitor complex was evaluated using the Alphascreen system (PerkinElmer, USA). The PI strengths of compounds, compared with <b>1</b>, are indicated by 2 asterisks (**) when the compounds showed obviously strong PI profiles and by a single asterisk (*) when the PI was weak compared with that of <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the strength of the PI profile for <b>42h</b>, we constructed a docking model of this compound with the HER2 protein using Gold (ver. 2.0, the Cambridge crystallographic data center, UK). In the modeling study, the aniline portion of <b>42h</b> is oriented deeply in the back pocket of the ATP binding site, and the amide group on the terminal 1,3-dihydro-2<i>H</i>-indol-2-one ring (<b>h</b>) makes two direct hydrogen bonding interactions with the hydroxy group of Thr798 and the carbonyl group of Ser783. The two direct interactions may be an important factor for the substantial PI activity of inhibitors. On the basis of our hypothesis, we designed other back pocket binders (<b>42i</b>–<b>m</b>), which could also potentially make direct hydrogen bonding interactions with Thr798 and/or Ser783 without the presence of an amide group (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking model of indolone derivative <b>42h</b> with HER2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because the oral absorption properties of lead compound <b>42h</b> were insufficient in mice, replacements of the 1,3-dihydro-2<i>H</i>-indol-2-one ring (<b>42h</b>) with other bicyclic fused rings (<b>42i</b>–<b>m</b>) were examined to explore novel back pocket binders with the potential for both potent cellular GI activity and good pharmacokinetic PK properties.</div><div class="NLM_p">As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, the 1<i>H</i>-indole (<b>42i</b>) and the 1-benzothiophene (<b>42j</b>) derivatives showed good HER2/EGFR and cellular growth inhibitory activities based on their strong PI profiles, similar to <b>42h</b>. It was found that removal of the amide carbonyl group of <b>42h</b> did not reduce GI activity nor did it affect the PI profiles. In addition, the 1-benzothiophene derivative <b>42j</b> enhanced oral absorption in mice. The 1<i>H</i>-indazole derivative <b>42k</b>, which was formed by the introduction of a nitrogen atom into the 1<i>H</i>-indole (<b>42i</b>) and could potentially interact withboth Thr798 and Ser783, exhibited potent HER2/EGFR kinase inhibitory activities as well as cellular GI activity; however, <b>42k</b>exhibited a poor oral PK profile. Introduction of a methyl group at the <i>N</i>-1 position on the 1<i>H</i>-indazole ring of <b>42k</b>, yielding <b>42l</b>, provided improvement of the PK profile but also caused a drop in cellular GI activity based on a reduction of its PI profile. We confirmed the importance of the PI profile for cellular GI activity based on the interaction with Ser783. On the basis of these results, we next designed and synthesized a 1,2-benzisothiazole derivative <b>42m</b>, which possesses a hybrid structure of both 1-benzothiophene (<b>42j</b>) and 1<i>H</i>-indazole (<b>42k</b>). We envisioned that the good oral PK profile of <b>42j</b>, and the potent GI activity due to the PI profile of <b>42k</b>, could be combined in <b>42m</b>. As we expected, <b>42m</b> showed not only potent HER2/EGFR inhibition, PI behavior, and GI activities but also good oral absorption. These results suggested that the sulfur atom of the 1,2-benzisothiazole ring can interact with the Ser783 residue in the lipophilic back pocket as predicted by our design and that the PI profile correlates well with the GI activity (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Since the target profile was achieved, we selected the 1,2-benzisothiazole ring (<b>42m</b>) as a suitable back pocket binder for further optimization.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Profiles for Fused Hetero Aromatic Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0023.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">See corresponding footnotes in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">95% confidence interval.</p></div></div><div></div></div><figure id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Dissociation profiles of pyrrolo[3,2-<i>d</i>]pyrimidines from HER2 (A) and EGFR (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we carried out optimization of the <i>N</i>-5 substituents on the pyrrolo[3,2-<i>d</i>]pyrimidine core to improve <i>in vitro</i> oxidative metabolic stability (MS) in human hepatic microsomes, as well as the CYP3A4 inhibitory activity of 1,2-benzisothiazole derivative <b>42m</b>. On the basis of our previous research<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> on compound <b>1</b>, we believed that replacement of the hydroxy group with a carboxamide linkage at the <i>N</i>-5 position could provide favorable physicochemical properties without a loss of potency. The <i>N</i>-5 substituent was thought to be directed toward the solvent contact region based on the cocrystal structural analysis of <b>1</b>.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> These results are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. All of the various synthesized <i>N</i>-5 carboxamide derivatives (<b>45m</b>–<b>51m</b>) showed potent HER2/EGFR kinase inhibitory and BT-474 cellular GI activities comparable to those of <b>42m</b>. However, compounds <b>45m</b>–<b>48m</b> did not exhibit improved MS. In addition, these compounds retained strong CYP3A4 inhibitory properties, despite the introduction of polar substituents such as hydroxy (<b>46m</b> and <b>47m</b>) and sulfonyl (<b>48m</b>) moieties into the side chains. However, when the end of the side chain was replaced by a <i>tert</i>-butylcarbonyl group (<b>49m</b>) or a prolinyl group (<b>50m</b>), their MS and CYP3A4 inhibitory profiles were changed significantly. We found that a bulky substituent in <b>49m</b> could hinder interaction with the heme protein CYP3A4 and that the basic group in <b>50m</b> provided suitable polarity to enhance MS. On the basis of these results, we designed and synthesized the 2-aminoisobutyl (AIB) amide derivative <b>51m</b>, which shared the structural features of both the bulky <i>tert</i>-butylcarbonyl (<b>49m</b>) and basic prolinyl (<b>50m</b>) groups. As we expected, compound <b>51m</b> achieved acceptable MS and CYP3A4 profiles without loss of potency. On the basis of its <i>in vitro</i> potency and good absorption, distribution, metabolism, and excretion (ADME) profiles, compound <b>51m</b> was selected as a candidate for further investigation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biological Profiles for <i>N-</i>5 Modified Benzoisothiazole Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0024.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">See corresponding footnotes in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">95% confidence interval.</p></div></div><div></div></div><div class="NLM_p">The inhibitory activity of <b>51m</b> against various kinases is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Besides HER2 and EGFR, compound <b>51m</b> exhibited HER4 inhibitory activity with an IC<sub>50</sub> value of 79 nM. As these results show, we confirmed that <b>51m</b> is a HER family selective inhibitor.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Selectivity of <b>51m</b>, IC<sub>50</sub>(nM)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2</td><td class="colsep0 rowsep0" align="left">0.98</td><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="left">1,700</td><td class="colsep0 rowsep0" align="left">LYNB</td><td class="colsep0 rowsep0" align="left">3,000</td><td class="colsep0 rowsep0" align="left">LYNA</td><td class="colsep0 rowsep0" align="left">7,100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">c-met</td><td class="colsep0 rowsep0" align="left">1,800</td><td class="colsep0 rowsep0" align="left">TIE2</td><td class="colsep0 rowsep0" align="left">3,200</td><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">8,400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER4</td><td class="colsep0 rowsep0" align="left">79</td><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="left">2,100</td><td class="colsep0 rowsep0" align="left">CSK</td><td class="colsep0 rowsep0" align="left">3,900</td><td class="colsep0 rowsep0" colspan="2" align="left">other 27 kinases<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> > 10,000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Other kinases: c-kit, AuroraB, FGFR1, FGFR3, ASK1, FAK, MEK5, MEKK, VEGFR1, VEGFR2, PDGFRa, PDGFRb, TTK, TAK1, PLK, PKCtheta, PKA, BMX, IGF1-R, InsR, ZAP70, B-rafw, ERK1, GSK3b, IKK, JNK, and P38a.</p></div></div></div><div class="NLM_p">As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, compound <b>51m</b> was evaluated <i>in vivo</i>using a 4–1ST HER2-overexpressing human gastric cancer tumor xenograft model in mice. Reflecting its potent HER2 inhibitory activity, compound <b>51m</b> exhibited potent efficacy with complete regression (CR, tumor/control ratio [T/C]: −23%) at an oral dose of 50 mg/kg without significant body weight loss in mice. Furthermore, in accordance with its potent EGFR inhibitory activity, compound <b>51m</b> also showed regressive efficacy (T/C: −30%) against a CAL-27 EGFR-overexpressing human head and neck cancer xenograft model in mice at an oral dose of 100 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).</div><figure id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Efficacy studies of <b>51m</b> in the 4–1ST xenograft model (A) and the CAL27 xenograft model (B) in mice. (A) Dose level 50 mg/kg; <i>P</i> ≤ 0.0025 vs control at day 14 (one-tailed Shirley–Williams test). (B) Dose level 100 mg/kg; <i>P</i> ≤ 0.0025 vs control at day 14 (one-tailed Shirley–Williams test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To develop novel HER2/EGFR kinase inhibitors, we explored pyrrolo[3,2-<i>d</i>]pyrimidine derivatives bearing novel back pocket binders. Among the prepared derivatives, the 1,2-benzisothiazole (<b>42m</b>) ring was selected as a suitable back pocket binder for further optimization because of the strong cellular GI activity that arose from its PI profile. Ultimately, we reached our preclinical candidate <b>51m</b> by optimization of the <i>N</i>-5 side chain to reduce CYP inhibition and improve its MS properties. Compound <b>51m</b> showed both potent HER2/EGFR inhibitory activities (IC<sub>50</sub>, 0.98/2.5 nM), as well as breast cancer cell BT-474 GI (GI<sub>50</sub>, 2.0 nM) activity. Reflecting these strong <i>in vitro</i> activities, compound <b>51m</b> exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4–1ST and CAL27) xenograft models in mice at doses of 50 mg/kg and 100 mg/kg.</div><div class="NLM_p last">These preclinical studies demonstrated that <b>51m</b> has the potential for use as a HER2/EGFR dual kinase inhibitor to cure HER2- and EGFR-overexpressing cancer.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Chemistry Information</h3><div class="NLM_p last">Melting points were determined on a Yanagimoto micro melting point apparatus or an SRS OptiMelt melting point apparatus and are uncorrected. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Varian Gemini-200 (200 MHz) spectrometer or Varian Mercury-300 (300 MHz) spectrometer. Chemical shifts are given in parts per million (ppm) with tetramethylsilane as an internal standard, and coupling constants (<i>J</i> values) are given in Hertz (Hz). Splitting patterns and apparent multiplicities are designated as s (singlet), d (doublet), dd (double doublet), t (triplet), dt (double triplet), q (quartet), m (multiplet), and br s (broad singlet). Elemental analyses were carried out by Takeda Analytical Research Laboratories, Ltd., and the results obtained were within ±0.4% of the theoretical values. The purity of all biologically evaluated compounds was confirmed to be ≥95% by a Waters LC-MS system (ZMD-1). The column used was an L-column 2 ODS (3.0 × 50 mm I.D., CERI, Japan) with a temperature of 40 °C and a flow rate of 1.2 mL/min. Mobile phase A was 0.05% TFA in ultrapure water. Mobile phase B was 0.05% TFA in acetonitrile which was increased linearly from 5% to 90% over 2 min and 90% over the next 1.5 min, after which the column was equilibrated to 5% for 0.5 min. Column chromatography was carried out on a silica gel column (Kieselgel 60, 63–200 mesh, Merck or Chromatorex NH-DM1020, 100–200 mesh, Fuji Silysia chemical). Yields were not optimized.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Methyl 3-(2-Chloro-4-nitrophenoxy)benzoate (<b>6</b>)</h3><div class="NLM_p last">A mixture of 2-chloro-1-fluoro-4-nitrobenzene (<b>4</b>, 5.27 g, 30.0 mmol), methyl 3-hydroxybenzoate (<b>5</b>, 4.79 g, 31.5 mmol), and potassium carbonate (6.22 g, 45.0 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) (30 mL) was stirred at room temperature for 4 h. The reaction mixture was concentrated <i>in vacuo</i>, and then, to the residue was added water (100 mL). The mixture was extracted with ethyl acetate (EtOAc, 500 mL). The separated organic layer was washed with brine (100 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 1:9 to 1:4) to give <b>6</b> (9.18 g, 95%) as a pale yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.93 (3H, s), 6.92 (1H, d, <i>J</i> = 9.1 Hz), 7.28–7.34 (1H, m), 7.53 (1H, t, <i>J</i> = 8.0 Hz), 7.70–7.75 (1H, m), 7.92–7.98 (1H, m), 8.08 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 8.41 (1H, d, <i>J</i> = 2.5 Hz).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Methyl 3-(4-Amino-2-chlorophenoxy)benzoate (<b>7</b>)</h3><div class="NLM_p last">To a solution of <b>6</b> (3.08 g, 10.0 mmol) in EtOAc (30 mL) was added 5% platinum–carbon (Pt/C) (90 mg), and the reaction mixture was stirred at room temperature under hydrogen atmosphere for 4 h. The insoluble 5% Pt/C was filtered off, and the filtrate was concentrated <i>in vacuo</i>. The residual solid was purified by silica gel columnchromatography (eluent, EtOAc/hexane = 1:4 to 1:1) to give <b>7</b> (2.79 g, quant.) as gray oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.70 (2H, br s), 3.88 (3H, s), 6.58 (1H, dd, <i>J</i> = 8.5, 2.7 Hz), 6.79 (1H, d, <i>J</i> = 2.7 Hz), 6.91 (1H, d, <i>J</i> = 8.8 Hz), 7.09 (1H, ddd, <i>J</i> = 8.2, 2.7, 1.1 Hz), 7.31–7.39 (1H, m), 7.48–7.51 (1H, m), 7.70 (1H, dt, <i>J</i> = 7.7, 1.2 Hz).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 3-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)benzoic Acid (<b>9</b>)</h3><div class="NLM_p last">A solution of 2-(4-chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl benzoate<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> (<b>8</b>, 1.51 g, 5.00 mmol) and <b>7</b> (1.39 g, 5.01 mmol) in 2-propanol (20 mL) was stirred at 80 °C for 12 h. After cooling at room temperature, the reaction mixture was quenched with saturated sodium hydrogen carbonate (200 mL) and extracted with EtOAc (400 mL). The separated organic layer was washed with saturated brine (100 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was dissolved in a mixture of MeOH (30 mL) and tetrahydrofuran (THF) (6.0 mL). To the solution was added 1 N NaOH (13.5 mL), and the mixture was stirred at room temperature for 72 h. The mixture was concentrated <i>in vacuo</i>, and then, to the residue were added water (100 mL) and 1 N HCl (13.5 mL). The mixture was extracted with a mixed solvent of EtOAc (200 mL) and THF (100 mL). The separated organic layer was washed with water (100 mL) and dried over MgSO<sub>4</sub>. Insoluble MgSO<sub>4</sub> was filtered off, and the filtrate was concentrated <i>in vacuo</i>. The residue was recrystallized from acetonitrile/diethyl ether (Et<sub>2</sub>O) (1/1, 50 mL) to give <b>9</b> (1.88 g, 88%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 3.88 (2H, m), 4.50–4.60 (2H, m), 6.31 (1H, br s), 6.52 (1H, d, <i>J</i> = 3.0 Hz), 7.23–7.34 (3H, m), 7.51 (1H, t, <i>J</i> = 8.0 Hz), 7.59–7.71 (3H, m), 7.99 (1H, d, <i>J</i> = 2.7 Hz), 8.35 (1H, s), 9.90 (1H, br s).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-<i>tert</i>-Butyl-3-(2-chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)benzamide (<b>3</b>)</h3><div class="NLM_p last">A mixture of <b>9</b> (850 mg, 2.00 mmol), 2-methylpropan-2-amine (0.420 mL, 4.00 mmol), 1-hydroxybenzotriazole monohydrate (HOBt) (368 mg, 2.40 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (466 mg, 3.00 mmol) in DMF (10 mL) was stirred at room temperature for 12 h. The mixture was concentrated <i>in vacuo</i>, and then, to the residue was added water (100 mL). The mixture was extracted with EtOAc (200 mL). The organic layer was washed successively with brine (40 mL) and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure, and the residue was subjected to silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 20:80). The objective fractions were collected and concentrated under reduced pressure, and the residue was subjected to basic silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 20:80). The objective fractions were collected and concentrated under reduced pressure. The obtained residue was crystallized from EtOAc/diisopropyl ether (1/1, 25 mL) to give <b>3</b> (630 mg, 66%) as colorless crystals. mp 175–177 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.45 (9H, s), 1.66 (1H, br s), 4.08–4.16 (2H, m), 4.35–4.42 (2H, m), 5.99 (1H, br s), 6.16 (1H, d, <i>J</i> = 3.3 Hz), 6.98–7.03 (2H, m), 7.04–7.12 (1H, m), 7.30–7.37 (3H, m), 7.41 (1H, dd, <i>J</i> = 2.6, 8.8 Hz), 7.80 (1H, d, <i>J</i> = 2.6 Hz), 8.23 (1H, s), 9.68 (1H, br s). Anal. Calcd for C<sub>25</sub>H<sub>26</sub>ClN<sub>5</sub>O<sub>3</sub>: C, 62.56; H, 5.46; N, 14.59. Found: C, 62.47; H, 5.47; N, 14.57.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-(2-Chloro-4-nitrophenoxy)-1<i>H</i>-indole (<b>11h</b>)</h3><div class="NLM_p">A mixture of <b>4</b> (12.1 g, 68.7 mmol), 4-hydroxyindole (<b>10h</b>, 10.0 g, 75.3 mmol), and potassium carbonate (15.9 g, 115 mmol) in DMF (140 mL) was stirred at room temperature for 16 h. The mixture was quenched with aqueous ammonium chloride (NH<sub>4</sub>Cl) solution (200 mL), and the mixture was extracted with EtOAc (500 mL). The separated organic layer was washed with water (500 mL) and brine (100 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 1:19 to 1:1) to give <b>11h</b> (12.7 g, 64%) as yellow powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.29–6.35 (1H, m), 6.79 (1H, d, <i>J</i> = 9.2 Hz), 6.87 (1H, d, <i>J</i> = 7.5 Hz), 7.17–7.25 (2H, m), 7.35 (1H, d, <i>J</i> = 8.4 Hz), 7.97 (1H, dd, <i>J</i> = 2.7, 9.2 Hz), 8.34 (1H, br s), 8.41 (1H, d, <i>J</i> = 2.7 Hz).</div><div class="NLM_p last">The following compounds (<b>11c</b>, <b>11d</b>, and <b>11g</b>) were prepared from <b>4</b> and the corresponding phenols (<b>10c</b>, <b>10d</b>, and <b>10g</b>) by a method similar to that described for <b>11h</b>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 5-(2-Chloro-4-nitrophenoxy)-1<i>H</i>-indole (<b>11c</b>)</h3><div class="NLM_p last">Yield 87%, yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.53–6.61 (1H, m), 6.79 (1H, d, <i>J</i> = 9.1 Hz), 6.96 (1H, dd, <i>J</i> = 2.3, 8.7 Hz), 7.32 (1H, t, <i>J</i> = 2.8 Hz), 7.37 (1H, d, <i>J</i> = 2.3 Hz), 7.45 (1H, d, <i>J</i> = 8.7 Hz), 7.98 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 8.30 (1H, br s), 8.38 (1H, d, <i>J</i> = 2.7 Hz).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 6-(2-Chloro-4-nitrophenoxy)-1<i>H</i>-indole (<b>11d</b>)</h3><div class="NLM_p last">Yield 54%, yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.57–6.62 (1H, m), 6.82 (1H, d, <i>J</i> = 9.1 Hz), 6.68 (1H, dd, <i>J</i> = 2.1, 8.7 Hz), 7.13–7.17 (1H, m), 7.27 (1H, dd, <i>J</i> = 2.1 Hz, 3.2 Hz), 7.67 (1H, d, <i>J</i> = 8.7 Hz), 7.98 (1H, dd, <i>J</i> = 2.8, 9.1 Hz), 8.25 (1H, br s), 8.37 (1H, d, <i>J</i> = 2.8 Hz).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 7-(2-Chloro-4-nitrophenoxy)-1<i>H</i>-indole (<b>11g</b>)</h3><div class="NLM_p last">Yield 72%, yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.62–6.66 (1H, m), 6.88 (1H, d, <i>J</i> = 8.0 Hz), 6.90 (1H, d, <i>J</i> = 9.1 Hz), 7.12 (1H, t, <i>J</i> = 8.0 Hz), 7.21–7.25 (1H, m), 7.56 (1H, d, <i>J</i> = 8.0 Hz), 8.00 (1H, dd, <i>J</i> = 9.1, 2.8 Hz), 8.25 (1H, br s), 8.41 (1H, d, <i>J</i> = 2.8 Hz).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-(2-Chloro-4-nitrophenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>13h</b>)</h3><div class="NLM_p">To a solution of <b>11h</b> (2.51 g, 8.69 mmol) in <i>tert</i>-butanol (50 mL) was added <i>N</i>-bromosuccinimide (NBS) (1.69 g, 9.49 mmol), and the reaction mixture was stirred at room temperature for 2 h. The mixture was quenched with saturated sodium hydrogen carbonate solution (50 mL), and the mixture was extracted with EtOAc (250 mL). The separated organic layer was washed with water (50 mL) and brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 1:19 to 1:1) to give <b>12h</b> (1.63 g) as a crude product. To a solution of <b>12h</b> (1.63 g) in THF (25 mL) was added 1 N HCl solution (8 mL), and the reaction mixture was stirred at 70 °C for 70 h. The mixture was diluted with water (100 mL) and extracted with a mixed solvent of EtOAc (75 mL) and THF (75 mL). The organic layer was washed with saturated sodium hydrogen carbonate solution (50 mL) and brine (15 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residual solid was collected by filtration to give <b>13h</b> (1.08 g, 80% from <b>11h</b>) as pale gray powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.42 (2H, s), 6.65 (1H, d, <i>J</i> = 8.0 Hz), 6.79 (1H, d, <i>J</i> = 8.0 Hz), 6.96 (1H, d, <i>J</i> = 9.0 Hz), 7.28 (1H, t, <i>J</i> = 8.0 Hz), 8.00 (1H, br s), 8.09 (1H, dd, <i>J</i> = 9.0, 2.7 Hz), 8.41 (1H, d, <i>J</i> = 2.7 Hz).</div><div class="NLM_p last">The following compounds (<b>13c</b>, <b>13d</b>, and <b>13g</b>) were prepared from the corresponding 1<i>H</i>-indoles (<b>11c</b>, <b>11d</b> and <b>11g</b>) by a method similar to that described for <b>13h</b>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 5-(2-Chloro-4-nitrophenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>13c</b>)</h3><div class="NLM_p last">Yield 61%, yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.53 (2H, s), 6.90 (1H, d, <i>J</i> = 8.5 Hz), 6.94 (1H, d, <i>J</i> = 9.1 Hz), 7.04 (1H, dd, <i>J</i> = 8.5, 2.3 Hz), 7.13 (1H, d, <i>J</i> = 2.3 Hz), 8.16 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 8.45 (1H, d, <i>J</i> = 2.7 Hz), 10.50 (1H, s).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 6-(2-Chloro-4-nitrophenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>13d</b>)</h3><div class="NLM_p last">Yield 45%, brown solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.56 (2H, s), 6.63 (1H, d, <i>J</i> = 2.2 Hz), 6.72 (1H, dd, <i>J</i> = 8.0, 2.2 Hz), 6.94 (1H, d, <i>J</i> = 9.0 Hz), 7.15–7.37 (1H, m), 7.78 (1H, br s), 8.07 (1H, dd, <i>J</i> = 9.0, 2.8 Hz), 8.39 (1H, d, <i>J</i> = 2.8 Hz).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 7-(2-Chloro-4-nitrophenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>13g</b>)</h3><div class="NLM_p last">Yield 45%, pale pink solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.63 (2H, s), 6.88–6.98 (2H, m), 7.06 (1H, t, <i>J</i> = 7.8 Hz), 7.12–7.20 (1H, m), 7.60 (1H, br s), 8.08 (1H, dd, <i>J</i> = 9.1, 2.8 Hz), 8.41 (1H, d, <i>J</i> = 2.8 Hz).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 4-(4-Amino-2-chlorophenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>14h</b>)</h3><div class="NLM_p">To a solution of <b>13h</b> (1.07 g, 3.51 mmol) in a mixture of MeOH (30 mL)/THF (30 mL) was added 5% Pt/C (111 mg), and the reaction mixture was stirred at room temperature under hydrogen atmosphere for 2 h. The insoluble 5% Pt/C was filtered off, and the filtrate was concentrated <i>in vacuo</i>. The residual solid was collected by filtration to give <b>14h</b> (926 mg, 96%) as pale gray powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.46 (2H, s), 3.69 (2H, br s), 6.37 (1H, d, <i>J</i> = 8.5 Hz), 6.50–6.64 (2H, m), 6.78 (1H, d, <i>J</i> = 2.6 Hz), 6.91 (1H, d, <i>J</i> = 8.5 Hz), 7.10 (1H, t, <i>J</i> = 8.5 Hz), 7.53 (1H, br s).</div><div class="NLM_p last">The following compounds (<b>14c</b>, <b>14d</b>, and <b>14g</b>) were prepared from the corresponding 1,3-dihydro-2<i>H</i>-indol-2-ones (<b>13c</b>, <b>13d</b>, and <b>13g</b>) by a method similar to that described for <b>14h</b>.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 5-(4-Amino-2-chlorophenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>14c</b>)</h3><div class="NLM_p last">Yield 96%, white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.50 (2H, s), 3.66 (2H, br s), 6.56 (1H, dd, <i>J</i> = 8.7, 2.8 Hz), 6.72–6.84 (4H, m), 6.85 (1H, d, <i>J</i> = 8.7 Hz), 7.72 (1H, br s).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 6-(4-Amino-2-chlorophenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>14d</b>)</h3><div class="NLM_p last">Yield 61%, yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.47 (2H, s), 3.69 (2H, s), 6.41 (1H, d, <i>J</i> = 2.3 Hz), 6.52 (1H, dd, <i>J</i> = 8.0, 2.3 Hz), 6.58 (1H, dd, <i>J</i> = 8.7, 2.8 Hz), 6.78 (1H, d, <i>J</i> = 2.8 Hz), 6.91 (1H, d, <i>J</i> = 8.7 Hz), 7.09 (1H, d, <i>J</i> = 8.0 Hz), 7.68 (1H, br s).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 7-(4-Amino-2-chlorophenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>14g</b>)</h3><div class="NLM_p last">Yield 92%, brown solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.58 (2H, s), 3.69 (2H, br s), 6.49–6.64 (2H, m), 6.78 (1H, d, <i>J</i> = 2.8 Hz), 6.83–6.97 (3H, m), 7.61 (1H, br s).</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Methyl 3-(2-chloro-4-nitrophenoxy)-2-methylbenzoate (<b>16e</b>)</h3><div class="NLM_p">A mixture of <b>4</b> (4.4 g, 25.0 mmol), methyl 3-hydroxy-2-methylbenzoate (<b>15e</b>, 4.2 g, 27.1 mmol), and potassium carbonate (6.9 g, 50 mmol) in DMF (50 mL) was stirred at room temperature for 16 h. The mixture was quenched with water (200 mL), and the mixture was extracted with EtOAc (400 mL). The organic layer was washed with water (400 mL) and brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 1:1) to give <b>16e</b> (7.7 g, 96%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.40 (3H, s), 3.93 (3H, s), 6.63 (1H, d, <i>J</i> = 9.1 Hz), 7.16 (1H, dd, <i>J</i> = 8.0, 1.4 Hz), 7.33 (1H, t, <i>J</i> = 7.8 Hz), 7.82 (1H, dd, <i>J</i> = 8.0, 1.4 Hz), 8.01 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 8.39 (1H, d, <i>J</i> = 2.7 Hz).</div><div class="NLM_p last">The following compound <b>16a</b> was prepared from <b>15a</b> by methods similar to that described for <b>16e</b>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Methyl 5-(2-chloro-4-nitrophenoxy)-2-methylbenzoate (<b>16a</b>)</h3><div class="NLM_p last">Yield 92%, yellow powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.63 (3H, s), 3.89 (3H, s), 6.86 (1H, d, <i>J</i> = 9.1 Hz), 7.15 (1H, dd, <i>J</i> = 8.3, 2.7 Hz), 7.33 (1H, d, <i>J</i> = 8.3 Hz), 7.64 (1H, d, <i>J</i> = 2.7 Hz), 8.06 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 8.39 (1H, d, <i>J</i> = 2.7 Hz).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Methyl 2-(bromomethyl)-3-(2-chloro-4-nitrophenoxy)benzoate (<b>17e</b>)</h3><div class="NLM_p">A mixture of <b>16e</b> (4.8 g, 14.9 mmol), NBS (3.2 g, 10.0 mmol), and 2,2′-azobis(isobutylonitrile) (AIBN) (123 mg, 0.75 mmol) in trifluoromethylbenzene (50 mL) was stirred at 100 °C for 16 h. The mixture was allowed to cool at room temperature, and then insoluble materials were removed by filtration. The filtrate was washed with 1 N NaOH (50 mL) and brine (10 mL) successively, and the separated organic layer was dried over MgSO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 15:85 to 25:75) to give <b>17e</b> (4.2 g, 70%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.98 (3H, s), 5.05 (2H, s), 6.92 (1H, d, <i>J</i> = 9.1 Hz), 7.08 (1H, dd, <i>J</i> = 8.1, 1.2 Hz), 7.42 (1H, t, <i>J</i> = 8.0 Hz), 7.86 (1H, dd, <i>J</i> = 7.8, 1.2, Hz), 8.08 (1H, dd, <i>J</i> = 9.1, 2.6 Hz), 8.41 (1H, d, <i>J</i> = 2.6 Hz).</div><div class="NLM_p last">The following compound <b>17a</b> was prepared from <b>16a</b> by methods similar to that described for <b>17e</b>.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Methyl 2-(bromomethyl)-5-(2-chloro-4-nitrophenoxy)benzoate (<b>17a</b>)</h3><div class="NLM_p last">Yield 37%, yellow powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.94 (3H, s), 4.97 (2H, s), 6.98 (1H, d, <i>J</i> = 9.0 Hz), 7.21 (1H, dd, <i>J</i> = 8.3, 2.7 Hz), 7.55 (1H, d, <i>J</i> = 8.3 Hz), 7.65 (1H, d, <i>J</i> = 2.7 Hz), 8.11 (1H, dd, <i>J</i> = 9.0, 2.8 Hz), 8.41 (1H, d, <i>J</i> = 2.8 Hz).</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-(2-Chloro-4-nitrophenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>18e</b>)</h3><div class="NLM_p">A mixture of <b>17e</b> (601 mg, 1.50 mmol) and 28% aqueous ammonia solution (3 mL) in a mixture of THF (27 mL) and MeOH (1 mL) was stirred at room temperature for 16 h. The reaction mixture was concentrated <i>in vacuo</i>, and the residual solid was collected and washed with water (10 mL), EtOAc (10 mL), and Et<sub>2</sub>O (10 mL) successively to give <b>18e</b> (500 mg, 96%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.28 (2H, s), 7.16 (1H, d, <i>J</i> = 9.1 Hz), 7.32 (1H, dd, <i>J</i> = 7.1, 1.4 Hz), 7.54–7.65 (2H, m), 8.17 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 8.49 (1H, d, <i>J</i> = 2.7 Hz), 8.74 (1H, br s).</div><div class="NLM_p last">The following compound <b>18a</b> was prepared from <b>17a</b> by methods similar to that described for <b>18e</b>.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 6-(2-Chloro-4-nitrophenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>18a</b>)</h3><div class="NLM_p last">Yield 96%, white powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.50 (2H, s), 6.90 (1H, br s), 6.97 (1H, d, <i>J</i> = 9.1 Hz), 7.34 (1H, dd, <i>J</i> = 8.3, 2.3 Hz), 7.48 (1H, d, <i>J</i> = 2.3 Hz), 7.56 (1H, d, <i>J</i> = 8.3 Hz), 8.09 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 8.41 (1H, d, <i>J</i> = 2.7 Hz).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-(4-Amino-2-chlorophenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>14e</b>)</h3><div class="NLM_p">To a solution of <b>18e</b> (948 mg, 3.21 mmol) in a mixture of MeOH (20 mL)/THF (20 mL)/EtOAc (20 mL) was added 5% Pt/C (25 mg), and the mixture was stirred at room temperature under hydrogen atmosphere for 16 h. The insoluble 5% Pt/C was filtered off, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 20:80) to give <b>14e</b> (390 mg, 50%) as a pale gray powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.73 (2H, br s), 4.45 (2H, s), 6.58 (1H, dd, <i>J</i> = 8.7, 2.7 Hz), 6.75–6.84 (3H, m), 6.94 (1H, d, <i>J</i> = 8.7 Hz), 7.35 (1H, t, <i>J</i> = 7.8 Hz), 7.54 (1H, d, <i>J</i> = 7.7 Hz).</div><div class="NLM_p last">The following compound <b>14a</b> was prepared from <b>18a</b> by methods similar to that described for <b>14e</b>.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 6-(4-Amino-2-chlorophenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>14a</b>)</h3><div class="NLM_p last">Yield 70%, yellow powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.70 (2H, br s), 4.40 (2H, s), 6.30 (1H, br s), 6.58 (1H, dd, <i>J</i> = 8.5, 2.8 Hz), 6.78 (1H, d, <i>J</i> = 2.8 Hz), 6.93 (1H, d, <i>J</i> = 8.5 Hz), 7.15–7.30 (2H, m), 7.40 (1H, d, <i>J</i> = 8.3 Hz).</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 5-Methoxy-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>21</b>)</h3><div class="NLM_p last">Compound <b>21</b> was obtained as a white solid in 39% yield from <b>19</b> by a method similar to that described for <b>18e</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.88 (3H, s), 4.41 (2H, s), 6.39 (1H, br s), 6.90–7.05 (2H, m), 7.77 (1H, d, <i>J</i> = 8.4 Hz).</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 5-Hydroxy-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>22</b>)</h3><div class="NLM_p last">A mixture of <b>21</b> (950 mg, 5.82 mmol) and 48% aqueous hydrogen bromide solution (15 mL) was stirred at 100 °C for 48 h. The mixture was allowed to cool at room temperature. To the mixture was added brine (50 mL), and the mixture was extracted with EtOAc (150 mL). The organic layer was washed with water (50 mL) and brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residual solid was washed with EtOAc (10 mL) to give <b>22</b> (385 mg, 44%) as a pale yellow solid. <sup>1</sup>H NMR (95%CDCl<sub>3</sub> + 5%DMSO-<i>d</i><sub>6</sub>) δ 4.32 (2H, s), 6.85–6.95 (2H, m), 7.30–7.45 (1H, br s), 7.62 (1H, d, <i>J</i> = 8.7 Hz).</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 5-(2-Chloro-4-nitrophenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>23</b>)</h3><div class="NLM_p last">Compound <b>23</b> was obtained as a white solid in 74% yield from <b>22</b> by a method similar to that described for <b>16e</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.46 (2H, s), 6.47 (1H, br s), 7.03 (1H, d, <i>J</i> = 9.0 Hz), 7.10–7.20 (2H, m), 7.91 (1H, d, <i>J</i> = 8.4 Hz), 8.11 (1H, dd, <i>J</i> = 9.0, 2.7 Hz), 8.41 (1H, d, <i>J</i> = 2.7 Hz).</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 5-(4-Amino-2-chlorophenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>14b</b>)</h3><div class="NLM_p last">Compound <b>14b</b> was obtained as a white solid in quantitative yield from <b>23</b> by a method similar to that described for <b>14e</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.73 (2H, br s), 4.37 (2H, s), 6.16 (1H, br s), 6.60 (1H, dd, <i>J</i> = 8.4, 2.7 Hz), 6.80 (1H, d, <i>J</i> = 2.7 Hz), 6.85–6.90 (1H, m), 6.94 (1H, d, <i>J</i> = 8.4 Hz), 6.95–7.00 (1H, m), 7.77 (1H, d, <i>J</i> = 8.4 Hz).</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 4-Bromo-7-methoxy-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>26</b>)</h3><div class="NLM_p last">Compound <b>26</b> was obtained as a white solid in 40% yield from <b>24</b> by a method similar to that described for <b>18e</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.97 (3H, s), 4.29 (2H, s), 6.47 (1H, br s), 6.84 (1H, d, <i>J</i> = 8.7 Hz), 7.59 (1H, d, <i>J</i> = 8.7 Hz).</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 4-Bromo-7-hydroxy-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>27</b>)</h3><div class="NLM_p last">Compound <b>27</b> was obtained as a pale yellow solid in 71% yield from <b>26</b> by a method similar to that described for <b>22</b>. <sup>1</sup>H NMR (95%CDCl<sub>3</sub>+5%DMSO-<i>d</i><sub>6</sub>) δ 4.28 (2H, s), 6.77 (1H, d, <i>J</i> = 8.7 Hz), 7.46 (1H, d, <i>J</i> = 8.7 Hz), 8.13 (1H, br s).</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 7-Hydroxy-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>28</b>)</h3><div class="NLM_p last">To a solution of <b>27</b> (228 mg, 1.53 mmol) in MeOH (10 mL) was added 5% Pt/C (38 mg), and the reaction mixture was stirred at room temperature under hydrogen atmosphere for 2 h. The insoluble 5% Pt/C was filtered off, and the filtrate was concentrated <i>in vacuo</i>. The residual solid was collected by filtration to give <b>28</b> (149 mg, quant.) as a pale yellow powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>+5%DMSO-<i>d</i><sub>6</sub>) δ 4.37 (2H, s), 6.79 (1H, d, <i>J</i> = 8.4 Hz), 6.94 (1H, d, <i>J</i> = 7.5 Hz), 7.30–7.45 (1H, m), 8.20 (1H, br s).</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 7-(2-Chloro-4-nitrophenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>29</b>)</h3><div class="NLM_p last">Compound <b>29</b> was obtained as a pale gray solid in 58% yield from <b>28</b> by a method similar to that described for <b>16e</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub> + 5%DMSO-<i>d</i><sub>6</sub>) δ 4.43 (2H, s), 6.82 (1H, d, <i>J</i> = 9.3 Hz), 7.06 (1H, d, <i>J</i> = 7.8 Hz), 7.41 (1H, d, <i>J</i> = 7.8 Hz), 7.55–7.70 (1H, m), 7.95–8.10 (2H, m), 8.34 (1H, d, <i>J</i> = 2.7 Hz).</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 7-(4-Amino-2-chlorophenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>14f</b>)</h3><div class="NLM_p last">Compound <b>14f</b> was obtained as a white solid in quantitative yield from <b>29</b> by a method similar to that described for <b>14e</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.70 (2H, br s), 4.43 (2H, s), 6.37 (1H, br s), 6.52 (1H, d, <i>J</i> = 8.7 Hz), 6.55–6.60 (1H, m), 6.78 (1H, d, <i>J</i> = 2.4 Hz), 7.01 (1H, d, <i>J</i> = 8.1 Hz), 7.06 (1H, d, <i>J</i> = 7.5 Hz), 7.36 (1H, t, <i>J</i> = 8.1 Hz).</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3-Chloro-4-(1<i>H</i>-indol-4-yloxy)aniline (<b>14i</b>)</h3><div class="NLM_p last">To a solution of <b>11h</b> (1.00 g, 3.46 mmol) in EtOH (17 mL) were added calcium chloride (1.50 g, 1.08 mmol), reduced iron (750 mg, 13.4 mmol), and water (3 mL), and the mixture was refluxed at 100 °C for 8 h. The mixture was allowed to cool at room temperature. The mixture was filtered through a Celite pad, and the filtrate was concentrated <i>in vacuo</i>. The residue was partitioned between water (50 mL) and EtOAc (100 mL). The organic layer was washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 1:4 to 1:1) to give <b>14i</b> (620 mg, 73%) as a purple oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.63 (2H, br s), 6.40 (1H, dd, <i>J</i> = 7.4, 1.0 Hz), 6.50–6.64 (2H, m), 6.82 (1H, d, <i>J</i> = 2.8 Hz), 6.92 (1H, d, <i>J</i> = 8.5 Hz), 7.00–7.19 (3H, m), 8.20 (1H, br s).</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 1-Benzothiophene-4-ol (<b>31</b>)</h3><div class="NLM_p last">To a solution of 6,7-dihydro-4(5<i>H</i>)-benzothiophene (<b>30</b>, 10.0 g, 65.7 mmol) in THF (160 mL) was added phenyltrimethylammonium tribromide (27.1 g, 72.3 mmol) at 0 °C, and the mixture was stirred at 0 °C for 1.5 h and at room temperature for 2.5 h. The mixture was quenched with water (300 mL), and the mixture was extracted with EtOAc (500 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was dissolved in DMF (400 mL), and to the solution were added lithium carbonate (21.7 g, 293 mmol) and lithium bromide (25.7 g, 295 mmol). The mixture was stirred at 150 °C for 4 h, and quenched with water (400 mL). The mixture was extracted with EtOAc (800 mL). The organic layer was washed with water (800 mL) and brine (80 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 0:1 to 1:9) to give <b>31</b> (8.98 g, 91%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 5.16 (1H, s), 6.72 (1H, d, <i>J</i> = 7.6 Hz), 7.20 (1H, t, <i>J</i> = 8.0 Hz), 7.33–7.40 (1H, m), 7.42–7.54 (2H, m).</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 4-(2-Chloro-4-nitrophenoxy)-1-benzothiophene (<b>32</b>)</h3><div class="NLM_p last">A mixture of <b>31</b> (5.00 g, 33.3 mmol), <b>4</b> (5.80 g, 33.0 mmol), and potassium carbonate (5.10 mmol, 36.9 mmol) in DMF (50 mL) was stirred at room temperature for 48 h. The mixture was quenched with water (150 mL) and extracted with EtOAc (300 mL). The organic layer was washed with water (300 mL) and brine (30 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 1:19 to 1:4) to give <b>32</b> (7.80 g, 66%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 6.94 (1H, d, <i>J</i> = 9.1 Hz), 7.18 (1H, d, <i>J</i> = 8.1 Hz), 7.25 (1H, dd, <i>J</i> = 5.7, 0.8 Hz), 7.48 (1H, t, <i>J</i> = 8.1 Hz), 7.85 (1H, d, <i>J</i> = 5.7 Hz), 8.01 (1H, d, <i>J</i> = 8.1 Hz), 8.14 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 8.52 (1H, d, <i>J</i> = 2.7 Hz).</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 4-(1-Benzothiophen-4-yloxy)-3-chloroaniline (<b>14j</b>)</h3><div class="NLM_p last">Compound <b>14j</b> was obtained as a pale orange solid in 80% yield from <b>32</b> by a method similar to that described for <b>14i</b>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 3.67 (2H, br s), 6.49–6.61 (2H, m), 6.81 (1H, d, <i>J</i> = 2.8 Hz), 6.91 (1H, d, <i>J</i> = 8.5 Hz), 7.14–7.22 (1H, m), 7.39 (1H, dd, <i>J</i> = 5.5, 0.6 Hz), 7.51–7.56 (1H, m), 7.58 (1H, dd, <i>J</i> = 5.5, 0.8 Hz).</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 1<i>H</i>-Indazol-4-ol (<b>34k</b>)</h3><div class="NLM_p last">1<i>H</i>-Indazol-4-amine (<b>33</b>, 800 mg, 6.01 mmol) was dissolved in a mixture of concentrated sulfuric acid (25 mL) and water (20 mL). To the solution was added a solution of sodium nitrite (415 mg, 6.01 mmol) in water (5 mL) at 0 °C and refluxed at 100 °C for 15 h. The mixture was allowed to cool at 0 °C and neutralized with 1 N NaOH (470 mL). The mixture was partitioned between water (50 mL) and EtOAc (100 mL). The organic layer was washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 1:2 to 1:0) to give <b>34k</b> (266 mg, 32%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 6.36–6.39 (1H, m), 6.92–7.12 (2H, m), 8.02 (1H, s), 9.81 (1H, s), 12.79 (1H, s).</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 3-Chloro-4-(1<i>H</i>-indazol-4-yloxy)aniline (<b>14k</b>)</h3><div class="NLM_p last">Compound <b>14k</b> was obtained as a yellow solid in 10% yield from <b>34k</b> by a method similar to that described for <b>6</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 5.39 (2H, s), 6.19 (1H, dd, <i>J</i> = 6.3, 2.0 Hz), 6.60 (1H, dd, <i>J</i> = 8.7, 2.6 Hz), 6.77 (1H, d, <i>J</i> = 2.6 Hz), 7.01 (1H, d, <i>J</i> = 8.7 Hz), 7.13–7.28 (2H, m), 7.86 (1H, s), 13.16 (1H, br s).</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3-Chloro-4-[(1-methyl-1<i>H</i>-indazol-4-yl)oxy]aniline (<b>14l</b>)</h3><div class="NLM_p last">Compound <b>14l</b> was obtained as a yellow solid in 59% yield from commercially available <b>34l</b> by a method similar to that described for <b>6</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.64 (2H, br s), 3.96 (3H, s), 6.41 (1H, d, <i>J</i> = 6.8 Hz), 6.60 (1H, dd, <i>J</i> = 8.6, 2.0 Hz), 6.81 (1H, d, <i>J</i> = 2.0 Hz), 6.98 (1H, d, <i>J</i> = 8.5 Hz), 7.16 (1H, dd, <i>J</i> = 8.5, 6.8 Hz), 7.45–7.55 (1H, m), 7.99 (1H, s).</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 2-(Benzylsulfanyl)-6-methoxybenzaldehyde (<b>37</b>)</h3><div class="NLM_p last">To a suspension of sodium <i>tert</i>-butoxide (3.47 g, 36.1 mmol) in THF (50 mL) was added benzylmercaptan (4.24 mL, 32.2 mmol) at 0 °C, and the mixture was stirred at 0 °C for 30 min. To the reaction mixture was added dropwise a solution of 2-fluoro-6-methoxybenzaldehyde (<b>36</b>, 4.64 g, 30.1 mmol) in THF (10 mL), and the mixture was stirred at room temperature for 1 h. To the reaction mixture was added water (150 mL), and the resulting precipitate was collected by filtration. The collected solid was washed with water (20 mL) and Et<sub>2</sub>O (50 mL) successively and dried <i>in vacuo</i> to give <b>37</b> (7.08 g, 91%) as a pale yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.91 (3H, s), 4.15 (2H, s), 6.72 (1H, d, <i>J</i> = 8.3 Hz), 6.95 (1H, <i>J</i> = 8.3 Hz), 7.25 - 7.43 (6H, m), 10.59 (1H, s).</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 4-Methoxy-1,2-benzisothiazole (<b>38</b>)</h3><div class="NLM_p last">Compound <b>37</b> (18.8 g, 72.8 mmol) and thioanisole (18.0 g, 145 mmol) were dissolved in a mixed solvent of acetonitrile (175 mL) and water (175 mL), and the solution was stirred at room temperature for 30 min. To the reaction mixture was added hydroxylamine-<i>O</i>-sulfonic acid (12.4 g, 109 mmol), and the mixture was stirred at room temperature for 2 h. To the reaction mixture was added saturated sodium hydrogen carbonate (400 mL), and the mixture was extracted with EtOAc (500 mL). The organic layer was washed with water (250 mL) and dried over MgSO<sub>4</sub>. The solvent was evaporated <i>in vacuo</i>, and the residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 0:10 to 7:3) to give <b>38</b> (10.2 g, 85%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.00 (3H, s), 6.75 (1H, dd, <i>J</i> = 7.4, 0.9 Hz), 7.35 - 7.62 (2H, m), 9.02 (1H, d, <i>J</i> = 0.8 Hz).</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 1,2-Benzisothiazol-4-ol (<b>39</b>)</h3><div class="NLM_p last">A mixture of <b>38</b> (22.0 g, 133 mmol) and pyridine hydrochloride (140 g, 1.21 mol) was stirred at 195 °C for 2 h. After cooling at room temperature, water (1.0 L), 1 N HCl (12 mL), and EtOAc (1 L) were added to the mixture. After stirring at room temperature for 2 h, the separated organic layer was washed with water (500 mL) and brine (200 mL) successively, and the organic layer was dried over MgSO<sub>4</sub>. Insoluble MgSO<sub>4</sub> was filtered off, and the filtrate was concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, EtOAc/hexane = 0:10 to 10:0) to give <b>39</b> (15.7 g, 78%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.08 (1H, s), 6.74 (1H, dd, <i>J</i> = 8.0, 0.6 Hz), 7.38 (1H, t, <i>J</i> = 8.0 Hz), 7.51 (1H, dt, <i>J</i> = 8.0, 0.9 Hz), 9.06 (1H, d, <i>J</i> = 0.9 Hz).</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 4-(2-Chloro-4-nitrophenoxy)-1,2-benzisothiazole (<b>40</b>)</h3><div class="NLM_p last">To a solution of <b>4</b> (5.70 g, 32.5 mmol) and <b>39</b> (5.40 g, 35.7 mmol) in DMF (50 mL) was added potassium carbonate (9.40 g, 68.0 mmol), and the mixture was stirred at room temperature for 24 h. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (150 mL). The organic layer was washed with water (250 mL) and brine (100 mL), and dried over MgSO<sub>4</sub>. Insoluble MgSO<sub>4</sub> was filtered off, and the filtrate was concentrated under reduced pressure to give <b>40</b> (9.60 g, 96%) as a pale yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.89 (1H, dd, <i>J</i> = 8.0, 0.6 Hz), 7.04 (1H, d, <i>J</i> = 9.1 Hz), 7.53 (1H, t, <i>J</i> = 8.0 Hz), 7.83 (1H, dd, <i>J</i> = 8.0, 0.8 Hz), 8.11 (1H, dd, <i>J</i> = 9.1, 2.6 Hz), 8.46 (1H, d, <i>J</i> = 2.6 Hz), 8.95 (1H, d, <i>J</i> = 0.9 Hz).</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 4-(1,2-Benzisothiazol-4-yloxy)-3-chloroaniline (<b>14m</b>)</h3><div class="NLM_p">Compound <b>40</b> (9.60 g, 31.3 mmol) and reduced iron (20.0 g, 358 mmol) were suspended in EtOH (150 mL), and the suspension was heated at 80 °C. To the mixture was added 1 N HCl (5 mL), and the mixture was refluxed at 80 °C for 5 h. The reaction mixture was allowed to cool at room temperature. To the mixture was added 1 N NaOH (15 mL), and the reaction mixture was filtered through a Celite pad. The filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc (400 mL), and the mixture was washed with water (200 mL), saturated sodium hydrogen carbonate (200 mL), 1 N NaOH (100 mL), and brine (100 mL) successively. The separated organic layer was dried over MgSO<sub>4</sub>. The insoluble MgSO<sub>4</sub> was filtered off, and the filtrate was concentrated under reduced pressure to give <b>14m</b> (8.50 g, 98%) as a pale purple solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.74 (2H, br s), 6.49 (1H, dd, <i>J</i> = 8.0, 0.6 Hz), 6.62 (1H, dd, <i>J</i> = 8.6, 2.6 Hz), 6.83 (1H, d, <i>J</i> = 2.6 Hz), 7.01 (1H, d, <i>J</i> = 8.6 Hz), 7.35 (1H, t, <i>J</i> = 8.0 Hz), 7.57 (1H, dt, <i>J</i> = 8.0, 0.8 Hz), 9.15 (1H, d, <i>J</i> = 0.9 Hz).</div><div class="NLM_p last">The following compounds (<b>42a</b>–<b>42m</b>) were prepared from <b>8</b> and the corresponding anilines (<b>14a</b>–<b>14m</b>) by a method similar to that described for <b>9</b>.</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 6-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>42a</b>)</h3><div class="NLM_p last">Yield 71%, colorless crystals, mp 209 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.82–3.95 (2H, m), 4.34 (2H, s), 4.55 (2H, t, <i>J</i> = 4.4 Hz), 6.30 (1H, br s), 6.52 (1H, d, <i>J</i> = 3.0 Hz), 6.93 (1H, d, <i>J</i> = 2.4 Hz), 7.23–7.35 (2H, m), 7.53–7.71 (3H, m), 7.98 (1H, d, <i>J</i> = 2.4 Hz), 8.35 (1H, s), 8.64 (1H, br s), 9.89 (1H, br s). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>3</sub>, 436.117; found, 436.118.</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 5-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>42b</b>)</h3><div class="NLM_p last">Yield 54%, colorless crystals, mp 210–212 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.85–3.90 (2H, m), 4.31 (2H, s), 4.50–4.60 (2H, m), 6.32 (1H, br s), 6.51 (1H, d, <i>J</i> = 3.3 Hz), 7.00–7.10 (2H, m), 7.30 (1H, d, <i>J</i> = 9.0 Hz), 7.60–7.70 (3H, m), 7.95–8.00 (1H, m), 8.34 (1H, s), 8.41 (1H, s), 9.89 (1H, br s). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>3</sub>, 436.117; found, 436.117.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 5-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>42c</b>)</h3><div class="NLM_p last">Yield 45%, pale orange crystals, mp 253–256 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.47 (2H, s), 3.86 (2H, t, <i>J</i> = 4.5 Hz), 4.52 (2H, t, <i>J</i> = 4.5 Hz), 6.27 (1H, s), 6.50 (1H, d, <i>J</i> = 3.0 Hz), 6.75–6.80 (2H, m), 6.88 (1H, s), 7.08 (1H, d, <i>J</i> = 8.7 Hz), 7.52 (1H, dd, <i>J</i> = 9.1, 2.7 Hz), 7.65 (1H, d, <i>J</i> = 3.0 Hz), 7.91 (1H, d, <i>J</i> = 2.7 Hz), 8.31 (1H, s), 9.77 (1H, br s), 10.32 (1H, s). Anal. Calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>3</sub>: C, 60.62; H, 4.16; N, 16.07. Found: C, 60.36; H, 4.18; N, 15.94.</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 6-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>42d</b>)</h3><div class="NLM_p last">Yield 52%, pale orange crystals, mp 256–257 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.42 (2H, s), 3.87 (2H, t, <i>J</i> = 4.5 Hz), 4.53 (2H, t, <i>J</i> = 4.5 Hz), 6.29 (1H, br s), 6.31 (1H, d, <i>J</i> = 2.3 Hz), 6.46–6.56 (2H, m), 7.16 (1H, d, <i>J</i> = 8.3 Hz), 7.22 (1H, d, <i>J</i> = 8.7 Hz), 7.58 (1H, dd, <i>J</i> = 8.7, 2.7 Hz), 7.66 (1H, d, <i>J</i> = 3.0 Hz), 7.95 (1H, d, <i>J</i> = 2.7 Hz), 8.34 (1H, s), 9.85 (1H, br s), 10.29 (1H, br s). Anal. Calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>3</sub>: C, 60.62; H, 4.16; N, 16.07. Found: C, 60.40; H, 4.21; N, 15.97.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 4-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>42e</b>)</h3><div class="NLM_p last">Yield 98%, colorless crystals, mp 280 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.88 (2H, t, <i>J</i> = 4.5 Hz), 4.35 (2H, s), 4.53 (2H, t, <i>J</i> = 4.5 Hz), 6.32 (1H, br s), 6.51 (1H, d, <i>J</i> = 3.0 Hz), 6.89 (1H, dd, <i>J</i> = 7.0, 1.8 Hz), 7.30 (1H, d, <i>J</i> = 8.7 Hz), 7.39–7.48 (2H, m), 7.60 (1H, dd, <i>J</i> = 8.7, 2.5 Hz), 7.66 (1H, d, <i>J</i> = 3.0 Hz), 7.99 (1H, d, <i>J</i> = 2.5 Hz), 8.34 (1H, s), 8.68 (1H, br s), 9.88 (1H, br s). Anal. Calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>3</sub> 1.2 H<sub>2</sub>O: C, 57.76; H, 4.49; N, 15.31. Found: C, 57.73; H, 4.55; N, 15.30.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 7-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>42f</b>)</h3><div class="NLM_p last">Yield 36%, pale yellow crystals, mp 264–266 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.80–3.90 (2H, m), 4.37 (2H, s), 4.50–4.60 (2H, m), 6.30 (1H, br s), 6.50 (1H, d, <i>J</i> = 3.0 Hz), 6.59 (1H, d, <i>J</i> = 9.0 Hz), 7.14 (1H, d, <i>J</i> = 9.0 Hz), 7.20–7.30 (1H, m), 7.48 (1H, t, <i>J</i> = 7.2 Hz), 7.55–7.60 (1H, m), 7.65 (1H, d, <i>J</i> = 3.0 Hz), 7.95–8.00 (1H, m), 8.33 (1H, s), 8.42 (1H, s), 9.84 (1H, br s). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>3</sub>, 436.117. Found, 436.113.</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 7-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>42g</b>)</h3><div class="NLM_p last">Yield 50%, pale pink crystals, mp 244–246 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.57 (2H, s), 3.87 (2H, t, <i>J</i> = 4.5 Hz), 4.53 (2H, t, <i>J</i> = 4.5 Hz), 6.29 (1H, br s), 6.50 (1H, d, <i>J</i> = 3.2 Hz), 6.54 (1H, dd, <i>J</i> = 8.0, 0.9 Hz), 6.82–6.93 (1H, m), 6.99 (1H, dd, <i>J</i> = 8.0, 0.9 Hz), 7.12 (1H, d, <i>J</i> = 8.9 Hz), 7.54 (1H, dd, <i>J</i> = 8.9, 2.6 Hz), 7.66 (1H, d, <i>J</i> = 3.2 Hz), 7.94 (1H, d, <i>J</i> = 2.6 Hz), 8.32 (1H, s), 9.82 (1H, br s), 10.77 (1H, s). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>3</sub>, 436.117. Found, 436.116.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 4-(2-Chloro-4-{[5-(2-hydroxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yl]amino}phenoxy)-1,3-dihydro-2<i>H</i>-indol-2-one (<b>42h</b>)</h3><div class="NLM_p last">Yield 27%, colorless crystals, mp 259–261 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.37 (2H, s), 3.87 (2H, q, <i>J</i> = 4.4 Hz), 4.53 (2H, t, <i>J</i> = 4.3 Hz), 6.26–6.34 (2H, m), 6.50 (1H, d, <i>J</i> = 3.0 Hz), 6.59 (1H, d, <i>J</i> = 7.4 Hz), 7.13 (1H, t, <i>J</i> = 8.1 Hz), 7.20 (1H, d, <i>J</i> = 8.8 Hz), 7.56 (1H, dd, <i>J</i> = 8.8, 2.6 Hz), 7.65 (1H, d, <i>J</i> = 3.0 Hz), 7.95 (1H, d, <i>J</i> = 2.6 Hz), 8.32 (1H, s), 9.84 (1H, br s), 10.51 (1H, br s). Anal. Calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>3</sub> 0.2 H<sub>2</sub>O: C, 60.13; H, 4.22; N, 15.94. Found: C, 60.01; H, 4.29; N, 15.77.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 2-(4-{[3-Chloro-4-(1<i>H</i>-indol-4-yloxy)phenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethanol (<b>35j</b>)</h3><div class="NLM_p last">Yield 86%, colorless crystals, mp 233–235 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.86 (2H, t, <i>J</i> = 4.5 Hz), 4.54 (2H, t, <i>J</i> = 4.5 Hz), 6.31 (1H, br s), 6.34–6.49 (2H, m), 6.92–7.08 (2H, m), 7.19 (1H, d, <i>J</i> = 7.9 Hz), 7.31 (1H, t, <i>J</i> = 2.7 Hz), 7.42–7.64 (2H, m), 7.94 (1H, d, <i>J</i> = 2.3 Hz), 8.29 (1H, s), 9.83 (1H, br s), 11.28 (1H, br s). Anal. Calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>2</sub>: C, 62.93; H, 4.32; N, 16.68. Found: C, 62.78; H, 4.47; N, 16.50.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 2-(4-{[4-(1-Benzothiophen-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethanol (<b>42j</b>)</h3><div class="NLM_p last">Yield 62%, colorless crystals, mp 245–246 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.88 (2H, br s), 4.54 (2H, br s), 6.51 (1H, d, <i>J</i> = 3.0 Hz), 6.62 (1H, d, <i>J</i> = 7.1 Hz), 7.22 (1H, d, <i>J</i> = 8.8 Hz), 7.31 (1H, t, <i>J</i> = 7.9 Hz), 7.48–7.84 (5H, m), 8.00 (1H, d, <i>J</i> = 2.4 Hz), 8.34 (1H, s), 9.85 (1H, br s). Anal. Calcd for C<sub>22</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub>S 0.1 H<sub>2</sub>O: C, 60.23; H, 3.95; N, 12.77. Found: C, 60.11; H, 3.98; N, 12.73.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 2-(4-{[3-Chloro-4-(1<i>H</i>-indazol-4-yloxy)phenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethanol (<b>42k</b>)</h3><div class="NLM_p last">Yield 39%, colorless crystals, mp 195–198 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.89 (2H, br s), 4.55 (2H, br s), 6.25–6.40 (1H, m), 6.71 (1H, s), 7.15–7.35 (3H, m), 7.50–7.74 (1H, m), 7.92 (2H, s), 8.33 (1H, s), 8.79 (1H, s), 13.26 (1H, s). Anal. Calcd for C<sub>21</sub>H<sub>17</sub>ClN<sub>6</sub>O<sub>2</sub> 0.3 H<sub>2</sub>O: C, 59.17; H, 4.16; N, 19.72. Found: C, 59.45; H, 4.45; N, 19.65.</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 2-[4-({3-chloro-4-[(1-methyl-1<i>H</i>-indazol-4-yl)oxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethanol (<b>42l</b>)</h3><div class="NLM_p last">Yield 57%, colorless crystals, mp 228–229 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.89 (2H, br s), 4.06 (3H, s), 4.55 (2H, t, <i>J</i> = 4.6 Hz), 6.33 (2H, dd, <i>J</i> = 7.0, 0.7 Hz), 6.52 (1H, d, <i>J</i> = 3.0 Hz), 7.24–7.38 (3H, m), 7.57–7.70 (2H, m), 7.92 (1H, d, <i>J</i> = 0.7 Hz), 8.01 (1H, d, <i>J</i> = 2.4 Hz), 8.36 (1H, s), 9.92 (1H, s). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>19</sub>ClN<sub>6</sub>O<sub>2</sub>, 435.133. Found, 435.132.</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethanol (<b>42m</b>)</h3><div class="NLM_p last">Yield 67%, colorless crystals, mp 218–220 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.89 (2H, br s), 4.56 (2H, t, <i>J</i> = 4.5 Hz), 6.34 (1H, br s), 6.48–6.63 (2H, m), 7.42 (1H, d, <i>J</i> = 8.8 Hz), 7.53 (1H, t, <i>J</i> = 8.0 Hz), 7.60–7.76 (2H, m), 7.92 (1H, d, <i>J</i> = 8.0 Hz), 8.05 (1H, d, <i>J</i> = 2.4 Hz), 8.38 (1H, s), 9.25 (1H, s), 9.99 (1H, s). Anal. Calcd for C<sub>21</sub>H<sub>16</sub>ClN<sub>5</sub>O<sub>2</sub>S: C, 57.60; H, 3.68; N, 15.99. Found: C, 57.37; H, 3.95; N, 15.69.</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 5-(2-Aminoethyl)-<i>N</i>-[4-(1,2-benzisothiazol-4-yloxy)-3-chlorophenyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine Dihydrochloride (<b>44</b>)</h3><div class="NLM_p last">A mixture of <i>tert</i>-butyl [2-(4-chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]carbamate<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> (<b>43</b>, 2.90 g, 9.77 mmol) and <b>14m</b> (2.70 g, 9.77 mmol) in 2-propanol (50 mL) was stirred at 80 °C for 12 h. To the mixture was added saturated sodium hydrogen carbonate (150 mL), and the mixture was extracted with EtOAc (300 mL). The organic layer was washed with brine (30 mL) and dried over MgSO<sub>4</sub>. Insoluble MgSO<sub>4</sub> was filtered off, and the filtrate was concentrated <i>in vacuo</i>. The obtained residue was subjected to silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 10:90). The objective fractions were collected and concentrated under reduced pressure. To the residue were added 4 N HCl in EtOAc (15 mL) and EtOH (15 mL), and the mixture was stirred at 80 °C for 4 h. Ethyl acetate (100 mL) was added to the reaction mixture, and the resulting solid was collected by filtration to give <b>44</b> (4.00 g, 80%) as brown powder. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.27–3.37 (2H, m), 4.97–5.10 (2H, m), 6.67 (1H, d, <i>J</i> = 7.7 Hz), 6.75 (1H, d, <i>J</i> = 3.0 Hz), 7.44 (1H, d, <i>J</i> = 8.9 Hz), 7.58 (1H, t, <i>J</i> = 7.7 Hz), 7.63–7.74 (1H, m), 7.88–8.03 (2H, m), 8.06 (1H, d, <i>J</i> = 3.0 Hz), 8.29 (3H, br s), 8.74 (1H, s), 9.22 (1H, d, <i>J</i> = 0.8 Hz), 10.10 (1H, br s).</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> <i>N</i>-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]acetamide (<b>45m</b>)</h3><div class="NLM_p last">A mixture of <b>44</b> (560 mg, 1.10 mmol), acetic acid (94 mg, 1.57 mmol), triethylamine (1.5 mL), HOBt (200 mg, 1.48 mmol), and EDC(1.0 g, 4.39 mmol) in DMF (50 mL) was stirred at room temperature for 12 h. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (100 mL). The organic layer was washed successively with water (100 mL) and brine (10 mL), and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure, and the residue was subjected to silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 10:90). The objective fractions were collected and concentrated under reduced pressure, and the residue was crystallized from EtOAc/diisopropyl ether (1/1, 15 mL) to give <b>45m</b> (450 mg, 80%) as white crystals. mp 222–224 °C.<sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.80 (3H, s), 3.35–3.43 (2H, m), 4.52 (2H, br s), 6.52 (1H, d, <i>J</i> = 2.3 Hz), 6.60 (1H, d, <i>J</i> = 8.0 Hz), 7.40 (1H, d, <i>J</i> = 8.7 Hz), 7.54 (1H, t, <i>J</i> = 8.0 Hz), 7.66 (1H, d, <i>J</i> = 2.3 Hz), 7.82 (1H, dd, <i>J</i> = 8.7, 2.3 Hz), 7.92 (1H, d, <i>J</i> = 8.0 Hz), 8.10 (1H, d, <i>J</i> = 2.3 Hz), 8.27 (1H, br s), 8.36 (1H, s), 8.84 (1H, s), 9.25 (1H, s). Anal. Calcd for C<sub>23</sub>H<sub>19</sub>ClN<sub>6</sub>O<sub>2</sub>S: C, 57.68; H, 4.00; N, 17.55. Found: C, 57.56; H, 3.98; N, 17.38.</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> <i>N</i>-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]-2-hydroxy-2-methylpropanamide Methanesulfonate (<b>46m</b>)</h3><div class="NLM_p last">A solution of <b>44</b> (100 mg, 0.20 mmol), 2-hydroxy-2-methylpropanoic acid (50.0 mg, 0.48 mmol), EDC (300 mg, 1.32 mmol), HOBt (10.0 mg 0.074 mmol), and triethylamine (0.5 mL) in DMF (10 mL) was stirred at room temperature for 12 h. Water (100 mL) was added to the reaction mixture, and then, the mixture was extracted with EtOAc (100 mL). The organic layer was washed with water (100 mL) and brine (10 mL) successively, dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 10:90) to give a white solid. To a solution of the white solid in EtOAc (5 mL) was added methanesulfonic acid (20 mg, 0.21 mmol) and diethyl ether (1 mL), and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The residual crystals were collected by filtration and washed with EtOAc to give <b>46m</b> (55.0 mg, 45%) as white crystals. mp 174–176 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.12 (6H, s), 2.81 (2H, s), 3.47 (2H, t, <i>J</i> = 6.2 Hz), 4.56 (2H, t, <i>J</i> = 6.2 Hz), 6.48 (1H, d, <i>J</i> = 2.8 Hz), 6.66 (1H, d, <i>J</i> = 7.2 Hz), 7.18 (1H, d, <i>J</i> = 8.9 Hz), 7.33 (1H, t, <i>J</i> = 7.9 Hz), 7.53 (1H, dd, <i>J</i> = 5.7, 0.8, Hz), 7.57–7.85 (4H, m), 7.95–8.16 (2H, m), 8.32 (1H, s), 8.72 (1H, s). Anal. Calcd for C<sub>26</sub>H<sub>27</sub>ClN<sub>6</sub>O<sub>6</sub>S<sub>2</sub> 1.0 H<sub>2</sub>O: C, 49.01; H, 4.59; N, 13.19. Found: C, 48.79; H, 4.42; N, 13.32.</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>N</i>-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]-3-hydroxy-2,2-dimethylpropanamide (<b>47m</b>)</h3><div class="NLM_p last">Compound <b>47m</b> was obtained as pale yellow crystals in 52% yield from <b>44</b> by a method similar to that described for <b>45m</b>. mp 219–221 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 0.98 (6H, s), 3.33 (2H, s), 3.39–3.53 (2H, m), 4.53 (2H, br s), 4.85 (1H, br s), 6.50 (1H, br s), 6.61 (1H, d, <i>J</i> = 7.7 Hz), 7.39 (1H, d, <i>J</i> = 8.9 Hz), 7.44–7.70 (2H, m), 7.81–8.02 (3H, m), 8.16 (1H, br s), 8.36 (1H, s), 8.96 (1H, br s), 9.25 (1H, d, <i>J</i> = 0.9 Hz). Anal. Calcd for C<sub>26</sub>H<sub>25</sub>ClN<sub>6</sub>O<sub>3</sub>S 2.5 H<sub>2</sub>O: C, 53.65; H, 5.19; N, 14.44. Found: C, 53.94; H, 5.27; N, 14.75.</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> <i>N</i>-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]-2-methyl-2-(methylsulfonyl)propanamide (<b>48m</b>)</h3><div class="NLM_p last">Compound <b>48m</b> was obtained as white crystals in 75% yield from <b>44</b> by a method similar to that described for <b>45m</b>. mp 247–248 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.41 (6H, s), 2.96 (3H, s), 3.41–3.56 (2H, m), 4.59 (2H, t, <i>J</i> = 6.6 Hz), 6.50 (1H, d, <i>J</i> = 2.6 Hz), 6.60 (1H, d, <i>J</i> = 8.0 Hz), 7.40 (1H, d, <i>J</i> = 9.0 Hz), 7.54 (1H, t, <i>J</i> = 8.0 Hz), 7.58 (1H, d, <i>J</i> = 2.6 Hz), 7.81 (1H, dd, <i>J</i> = 9.0, 2.0 Hz), 7.92 (1H, d, <i>J</i> = 8.0 Hz), 8.06 (1H, d, <i>J</i> = 2.0 Hz), 8.22 (1H, t, <i>J</i> = 5.9 Hz), 8.36 (1H, s), 8.74 (1H, s), 9.25 (1H, d, <i>J</i> = 0.8 Hz). Anal. Calcd for C<sub>26</sub>H<sub>25</sub>ClN<sub>6</sub>O<sub>4</sub>S<sub>2</sub>: C, 53.37; H, 4.31; N, 14.36. Found: C, 53.49; H, 4.45; N, 14.12.</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> <i>N</i>-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]-2,2-dimethylpropanamide Methanesulfonate (<b>49m</b>)</h3><div class="NLM_p last">A solution of <b>44</b> (100 mg, 0.20 mmol), 2,2-dimethylpropanoic acid anhydride (55.0 mg, 0.30 mmol), and triethylamine (0.3 mL) in DMF (10 mL) was stirred at room temperature for 2 h. Water (50 mL) was added to the reaction mixture, and then, the mixture was extracted with EtOAc (100 mL). The organic layer was washed successively with water (100 mL) and brine (10 mL) and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure, and the residue was subjected to silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 10:90), and the objective fractions were collected and concentrated under reduced pressure. The residue was crystallized from EtOAc/diisopropyl ether (1/1, 5 mL) to give <i>N</i>-[2-(4-{[4-(1,2-benzoisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]-2,2-dimethylpropanamide (87.0 mg, 1.67 mmol) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.01 (9H, s), 3.64–3.74 (2H, m), 4.51 (2H, t, <i>J</i> = 7.6 Hz), 6.49 (1H, d, <i>J</i> = 3.2 Hz), 6.60 (1H, d, <i>J</i> = 7.6 Hz), 7.37 (1H, d, <i>J</i> = 8.9 Hz), 7.46–7.63 (2H, m), 7.75–7.94 (3H, m), 8.10 (1H, d, <i>J</i> = 2.5 Hz), 8.33 (1H, s), 8.90 (1H, s), 9.22 (1H, d, <i>J</i> = 0.9 Hz). The white solid (1.50 g, 2.88 mmol) was dissolved in EtOAc (100 mL), and methanesulfonic acid (300 mg, 3.12 mmol) was added to the mixture. Diethyl ether (5 mL) was added, and the precipitate was collected by filtration to give <b>49m</b> (1.30 g, 63%) as white crystals. mp 216–218 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.02 (9H, s), 2.32 (3H, s), 3.43–3.52 (2H, m), 4.62–4.69 (2H, m), 6.68 (2H, dd, <i>J</i> = 2.2, 5.4 Hz), 7.47 (1H, d, <i>J</i> = 8.9 Hz), 7.58 (1H, t, <i>J</i> = 7.9 Hz), 7.73–8.10 (5H, m), 8.77 (1H, s), 9.22 (1H, d, <i>J</i> = 0.8 Hz), 10.13 (1H, br s). Anal. Calcd for C<sub>26</sub>H<sub>25</sub>ClN<sub>6</sub>O<sub>4</sub>S<sub>2</sub>: C, 52.55; H, 4.74; N, 13.62. Found: C, 52.57; H, 4.73; N, 13.62.</div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>N</i>-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]prolinamide hydrochloride (<b>50m</b>)</h3><div class="NLM_p last">A mixture of <b>44</b> (150 mg, 0.29 mmol), 1-(<i>tert</i>-butoxycarbonyl)proline (72.0 mg, 0.33 mmol), triethylamine (1.2 mL), HOBt (20 mg, 0.15 mmol), and EDC (320 mg, 1.40 mmol) in DMF (15 mL) was stirred at room temperature for 12 h. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (100 mL). The organic layer was washed successively with water (100 mL) and brine (10 mL), and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure, and the residue was subjected to silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 10:90). The objective fractions were collected and concentrated under reduced pressure, and the residue was dissolved in EtOH (5 mL). To the solution was added 4 N HCl in EtOAc (5 mL), and the mixture was stirred at 80 °C for 2 h. After cooling at room temperature, the precipitate was collected by filtration to give <b>50m</b> (72.0 mg, 41%) as white crystals. mp 143–145 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.54–1.93 (3H, m), 2.06–2.25 (1H, m), 2.68–3.74 (4H, m), 3.96–4.10 (1H, m), 4.58–4.90 (2H, m), 6.57–6.74 (2H, m), 7.43 (1H, d, <i>J</i> = 8.9 Hz), 7.51–7.75 (2H, m), 7.84–8.01 (3H, m), 8.43 (1H, br s), 8.69 (1H, s), 8.80 (1H, t, <i>J</i> = 5.8 Hz), 9.19 (1H, d, <i>J</i> = 0.8 Hz), 9.54 (1H, br s), 9.95 (1H, br s). Anal. Calcd for C<sub>26</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>S 2.5 H<sub>2</sub>O: C, 50.73; H, 4.91; N, 15.93. Found: C, 50.73; H, 4.96; N, 15.77.</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> <i>N</i>-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]-2-methylalaninamide (<b>51m</b>)</h3><div class="NLM_p last">A mixture of <b>44</b> (2.0 g, 3.92 mmol), <i>N</i>-(<i>tert</i>-butoxycarbonyl)-2-methylalanine (1.00 g, 4.92 mmol), triethylamine (4.5 mL), HOBt (400 mg, 2.96 mmol), and EDC (3.20 g, 14.0 mmol) in DMF (200 mL) was stirred at room temperature for 12 h. Water (200 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (400 mL). The organic layer was washed successively with water (400 mL) and brine (40 mL), and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure, and the residue was subjected to silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 10:90). The objective fractions were collected and concentrated under reduced pressure, and the residue was dissolved in EtOH (100 mL). To the solution was added 1 N HCl (50 mL), and the mixture was stirred at 70 °C for 10 h. After cooling at room temperature, 1 N NaOH (400 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (400 mL). The organic layer was washed successively with water (200 mL) and brine (40 mL), and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure, and the residue was subjected to basic silica gel column chromatography (eluent, MeOH/EtOAc = 0:100 to 10:90), and the objective fractions were collected and concentrated under reduced pressure. The obtained residue was crystallized from EtOAc/diisopropyl ether (1/1, 25 mL) to give <b>51m</b> (1.30 g, 64%) as colorless crystals. mp 198 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.12 (6H, s), 1.85 (2H, br s), 3.44 (2H, t, <i>J</i> = 6.6 Hz), 4.55 (2H, t, <i>J</i> = 6.6 Hz), 6.50 (1H, d, <i>J</i> = 3.0 Hz), 6.61 (1H, d, <i>J</i> = 7.6 Hz), 7.39 (1H, d, <i>J</i> = 8.0 Hz), 7.54 (1H, t, <i>J</i> = 8.0 Hz), 7.61 (1H, d, <i>J</i> = 3.0 Hz), 7.84–7.91 (1H, m), 7.92 (1H, d, <i>J</i> = 8.0 Hz), 8.12 (1H, br s), 8.22 (1H, br s), 8.35 (1H, s), 8.90 (1H, br s), 9.26 (1H, d, <i>J</i> = 0.8 Hz). Anal. Calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>7</sub>O<sub>2</sub>S: C, 57.52; H, 4.63; N, 18.78. Found: C, 57.44; H, 4.49; N, 18.72.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89"><a href="/doi/suppl/10.1021/jm300185p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Methods used in molecular modeling, enzyme assays, cell line and animal models, pharmacokinetics, metabolic stability, and CYP inhibition. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300185p/suppl_file/jm300185p_si_001.pdf">jm300185p_si_001.pdf (111.1 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm300185p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youichi Kawakita</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4209233523292b36231d1b2d372b212a2b023623292726236c212d6c283278620b312a2b292335231d162d2f2d3b233137023623292726236c212d6c2832"><span class="__cf_email__" data-cfemail="c982a8bea8a2a0bda89690a6bca0aaa1a089bda8a2acada8e7aaa6e7a3b9">[email protected]</span>: <span class="__cf_email__" data-cfemail="a2ebd1cacbc9c3d5c3fdf6cdcfcddbc3d1d7e2d6c3c9c7c6c38cc1cd8cc8d2">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomoyasu Ishikawa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#743f1503151f1d00152b2d1b011d171c1d3400151f1110155a171b5a1e044e543d071c1d1f1503152b201b191b0d1507013400151f1110155a171b5a1e04"><span class="__cf_email__" data-cfemail="d19ab0a6b0bab8a5b08e88bea4b8b2b9b891a5b0bab4b5b0ffb2beffbba1">[email protected]</span>: <span class="__cf_email__" data-cfemail="135a607b7a787264724c477c7e7c6a726066536772787677723d707c3d7963">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroshi Banno</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomohiro Ohashi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Toshiya Tamura</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tadashi Yusa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akiko Nakayama</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroshi Miki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hidehisa Iwata</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hidenori Kamiguchi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Toshimasa Tanaka</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noriyuki Habuka</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoshi Sogabe</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshikazu Ohta</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research
Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2414e5405-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to the structural biology group members (BiChing Sang, Hua Zou, Darbi Witmer, Gyorgy Snell, Ryan Bertsch, and Jason Yano) and the management at Takeda San Diego for determining the first X-ray cocrystal structure of <b>1</b> with HER2.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i91" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i91"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl2"><div id="ac_i92" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i92"> Abbreviations Used</h2><tr><td class="NLM_term"><sup>1</sup>H NMR</td><td class="NLM_def"><p class="first last">proton nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the blood concentration time curve</p></td></tr><tr><td class="NLM_term">BA</td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">growth inhibitory</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole monohydrate</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">mCPBA</td><td class="NLM_def"><p class="first last">3-chloroperbenzoic acid</p></td></tr><tr><td class="NLM_term">MgSO<sub>4</sub></td><td class="NLM_def"><p class="first last">magnesium sulfate</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectroscopy</p></td></tr><tr><td class="NLM_term">NaOH</td><td class="NLM_def"><p class="first last">sodium hydroxide</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last">1-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">pseudoirreversibility</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">ppm</td><td class="NLM_def"><p class="first last">parts per million</p></td></tr><tr><td class="NLM_term">Pt/C</td><td class="NLM_def"><p class="first last">platinum/carbon</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TKIs</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30544" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30544" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 9 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyajima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ooi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoshima, K.</span><span> </span><span class="NLM_article-title">The erbB gene of avian erythroblastosis virus is a member of the <i>src</i> gene family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1983&pages=71-78&author=T.+Yamamotoauthor=T.+Nishidaauthor=N.+Miyajimaauthor=S.+Kawaiauthor=T.+Ooiauthor=K.+Toyoshima&title=The+erbB+gene+of+avian+erythroblastosis+virus+is+a+member+of+the+src+gene+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DMiyajima%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%26aulast%3DOoi%26aufirst%3DT.%26aulast%3DToyoshima%26aufirst%3DK.%26atitle%3DThe%2520erbB%2520gene%2520of%2520avian%2520erythroblastosis%2520virus%2520is%2520a%2520member%2520of%2520the%2520src%2520gene%2520family%26jtitle%3DCell%26date%3D1983%26volume%3D35%26spage%3D71%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Traxler, P.</span><span> </span><span class="NLM_article-title">Tyrosine kinases as targets in cancer therapy—successes and failures</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1517%2F14728222.7.2.215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=12667099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVGrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=215-234&author=P.+Traxler&title=Tyrosine+kinases+as+targets+in+cancer+therapy%E2%80%94successes+and+failures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets in cancer therapy - successes and failures</span></div><div class="casAuthors">Traxler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-234</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases play a crucial role in signal transduction and also in cellular proliferation, differentiation, and various regulatory mechanisms.  The inhibition of growth-related kinases, esp. Tyr kinases, might therefore provide new therapies for diseases such as cancer.  Due to the enormous progress that was made in the past few years in the identification of the human genome, in mol. and cell biol. technologies, in structural biol. and in bioinformatics, the no. of receptor and non-receptor Tyr kinases that were identified as valuable mol. targets has greatly increased.  Currently, > 20 different Tyr kinase targets are under evaluation in drug discovery projects in oncol.  The progress made in the crystn. of protein kinases, in most cases complexed with ATP-site-directed inhibitors, has confirmed that the ATP-binding domain of Tyr kinases is an attractive target for rational drug design; > 20 ATP-competitive, low mol. wt. inhibitors are in various phases of clin. evaluation.  Meanwhile, clin. proof-of-concept (POC) was achieved with several antibodies and small mols. targeted against Tyr kinases.  With Herceptin, Glivec, and Iressa (registered in Japan), the 1st kinase drugs have entered the market.  This review describes the preclin. and clin. status of low mol. wt. drugs targeted against different Tyr kinases (e.g., epidermal growth factor receptor [EGFR], vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], Kit, Fms-like Tyr kinase [Flt]-3), briefly describes new targets, and provides a crit. anal. of the current situation in the area of Tyr kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlyxUqnX26eLVg90H21EOLACvtfcHk0lihQ5BdH2n5Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVGrt7w%253D&md5=aac69b84205b6525b0acb4ab2a43f219</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1517%2F14728222.7.2.215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.7.2.215%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26atitle%3DTyrosine%2520kinases%2520as%2520targets%2520in%2520cancer%2520therapy%25E2%2580%2594successes%2520and%2520failures%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2003%26volume%3D7%26spage%3D215%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and Imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+Imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0li39BMoGgVMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520Imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4686</span><span class="NLM_x">–</span> <span class="NLM_lpage">4691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1016%2Fj.bmcl.2006.05.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=16777410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4686-4691&author=K.+G.+Petrovauthor=Y.+M.+Zhangauthor=M.+Carterauthor=G.+S.+Cockerillauthor=S.+Dickersonauthor=C.+A.+Gauthierauthor=Y.+Guoauthor=R.+A.+Mookauthor=D.+W.+Rusnakauthor=A.+L.+Walkerauthor=E.+R.+Woodauthor=K.+E.+Lackey&title=Optimization+and+SAR+for+dual+ErbB-1%2FErbB-2+tyrosine+kinase+inhibition+in+the+6-furanylquinazoline+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span></div><div class="casAuthors">Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4686-4691</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino structure provided the best enzyme potency and cellular selectivity.  Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy.  The discovery of lapatinib emerged from this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtejUjyH9in7Vg90H21EOLACvtfcHk0li39BMoGgVMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D&md5=946712927ab1a7940ea3ef2fea7574b5</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DDickerson%26aufirst%3DS.%26aulast%3DGauthier%26aufirst%3DC.%2BA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DOptimization%2520and%2520SAR%2520for%2520dual%2520ErbB-1%252FErbB-2%2520tyrosine%2520kinase%2520inhibition%2520in%2520the%25206-furanylquinazoline%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4686%26epage%3D4691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2s"><span><span class="NLM_label">(d) </span> Package Insert. Tykerb (Lapatinib); <span class="NLM_publisher-name">GlaxoSmithKline</span>: <span class="NLM_publisher-loc">Research Triangle Park</span>, <span class="NLM_publisher-loc">NC</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Package+Insert.+Tykerb+%28Lapatinib%29%3B+GlaxoSmithKline%3A+Research+Triangle+Park%2C+NC%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2s&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26pub%3DGlaxoSmithKline%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Iqbal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenoglio-Preiser, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danenberg, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span> </span><span class="NLM_article-title">Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2610</span><span class="NLM_x">–</span> <span class="NLM_lpage">2615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1093%2Fannonc%2Fmdr021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=21415234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fht1Wntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2610-2615&author=S.+Iqbalauthor=B.+Goldmanauthor=C.+M.+Fenoglio-Preiserauthor=H.+J.+Lenzauthor=W.+Zhangauthor=K.+D.+Danenbergauthor=S.+I.+Shibataauthor=C.+D.+Blanke&title=Southwest+Oncology+Group+study+S0413%3A+a+phase+II+trial+of+lapatinib+%28GW572016%29+as+first-line+therapy+in+patients+with+advanced+or+metastatic+gastric+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer</span></div><div class="casAuthors">Iqbal S; Goldman B; Fenoglio-Preiser C M; Lenz H J; Zhang W; Danenberg K D; Shibata S I; Blanke C D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2610-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.  PATIENTS AND METHODS:  The primary objective of this study was to assess response rate.  Secondary objectives included overall survival (OS), toxicity, and the relationship of EGFR, ErbB2, and markers of angiogenesis with clinical outcome.  Lapatinib was administered to chemonaive metastatic gastric cancer patients at a dose of 1500 mg orally daily for 28 days.  RESULTS:  The study enrolled 47 patients from February 2005 until May 2006.  Four patients (9%) had a confirmed partial response (PR), 1 (2%) had an unconfirmed PR, and 10 (23%) had stable disease.  Median (95% confidence interval) time to treatment failure was 1.9 (1.6-3.1) months and OS was 4.8 (3.2-7.4) months.  Significant adverse events: one grade 4 cardiac ischemia/infarction, one grade 4 fatigue, and one grade 4 emesis.  One treatment-related death was due to central nervous system ischemia.  An exploratory analysis of markers revealed gene expression of HER2, interleukin (IL)-8 and genomic polymorphisms IL-8, and vascular endothelial growth factor correlated with OS.  CONCLUSIONS:  Lapatinib is well tolerated, with modest single-agent activity in advanced/metastatic gastric cancer patients.  Potential molecular correlatives were identified which warrant further validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5Jcr3zdCk3kodMGTatQ7LfW6udTcc2eYbJads4k_I4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fht1Wntg%253D%253D&md5=cc244e672fe9b0eba2b4910957abfea9</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr021%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DB.%26aulast%3DFenoglio-Preiser%26aufirst%3DC.%2BM.%26aulast%3DLenz%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDanenberg%26aufirst%3DK.%2BD.%26aulast%3DShibata%26aufirst%3DS.%2BI.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26atitle%3DSouthwest%2520Oncology%2520Group%2520study%2520S0413%253A%2520a%2520phase%2520II%2520trial%2520of%2520lapatinib%2520%2528GW572016%2529%2520as%2520first-line%2520therapy%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520gastric%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2610%26epage%3D2615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Whang, Y. E.; Armstrong, A. J.; Rathmell, W. K.; Godley, P. A.; Kim, W. Y.; Pruthi, R. S.; Wallen, E. M.; Crane, J. M.; Moore, D. T.; Grigson, G.; Morris, K.; Watkins, C. P.; George, D. J.</span><span> </span><span class="NLM_article-title">A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer</span>.  <span class="citation_source-journal">Urol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">; </span>doi:<span class="refDoi"> DOI: 10.1016/j.urolonc.2010.09.018</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1016%2Fj.urolonc.2010.09.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Y.+E.+Whang&author=A.+J.+Armstrong&author=W.+K.+Rathmell&author=P.+A.+Godley&author=W.+Y.+Kim&author=R.+S.+Pruthi&author=E.+M.+Wallen&author=J.+M.+Crane&author=D.+T.+Moore&author=G.+Grigson&author=K.+Morris&author=C.+P.+Watkins&author=D.+J.+George&title=A+phase+II+study+of+lapatinib%2C+a+dual+EGFR+and+HER-2+tyrosine+kinase+inhibitor%2C+in+patients+with+castration-resistant+prostate+cancer&doi=10.1016%2Fj.urolonc.2010.09.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2010.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2010.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DY.%2BE.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520lapatinib%252C%2520a%2520dual%2520EGFR%2520and%2520HER-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DUrol.%2520Oncol.%26date%3D2011%26doi%3D10.1016%2Fj.urolonc.2010.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Mimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kono, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiba, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizukami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, H.</span><span> </span><span class="NLM_article-title">Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody dependent cellular cytoxicity (ADCC) of EGFR and HER2 over-expressing esophageal cancer cell lines</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">–</span> <span class="NLM_lpage">2416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1002%2Fijc.25896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=21207425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=2408-2416&author=K.+Mimuraauthor=K.+Konoauthor=T.+Maruyamaauthor=M.+Watanabeauthor=S.+Izawaauthor=S.+Shibaauthor=Y.+Mizukamiauthor=Y.+Kawaguchiauthor=M.+Inoueauthor=T.+Konoauthor=A.+Choudhuryauthor=R.+Kiesslingauthor=H.+Fujii&title=Lapatinib+inhibits+receptor+phosphorylation+and+cell+growth+and+enhances+antibody+dependent+cellular+cytoxicity+%28ADCC%29+of+EGFR+and+HER2+over-expressing+esophageal+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines</span></div><div class="casAuthors">Mimura, Kousaku; Kono, Koji; Maruyama, Takanori; Watanabe, Mitsuaki; Izawa, Shinichiro; Shiba, Shugo; Mizukami, Yoshiki; Kawaguchi, Yoshihiko; Inoue, Masayuki; Kono, Tetsuo; Choudhury, Aniruddha; Kiessling, Rolf; Fujii, Hideki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2408-2416</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Lapatinib is a dual tyrosine kinase inhibitor of the EGFR and HER2 tyrosine kinase domains.  EGFR is expressed in 33.3% and HER2 in 30.3% of esophageal squamous cell carcinomas (ESCCs).  To explore the potential utility of Lapatinib for therapy of ESCC patients, we evaluated the effect of Lapatinib on a panel of ESCC cell lines.  EGFR and HER2 expression by the cell lines was established, and the effects of Lapatinib on inhibition of the phosphorylation of HER2, antiproliferative effect, apoptosis-inducing activity and accumulation of HER2 and EGFR on cell surface were evaluated.  Addnl., the combined effect of Lapatinib together with Herceptin or Cetuximab on cell-mediated cytotoxicity was evaluated.  Lapatinib inhibited HER2 phosphorylation in HER2-overexpressing, HER2 gene amplification pos. ESCC cell line.  Lapatinib also inhibited cell proliferation, induced apoptosis and caused the surface accumulation of HER2 and EGFR in ESCC cell lines.  Addn. of Lapatinib increased Herceptin-mediated antibody-dependent cell-mediated cytotoxicity by 15-25% with three ESCC target cell lines.  Similarly, Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity also increased by 15-30% in two ESCC cell lines on addn. of Lapatinib.  Cumulatively, the data indicate that Lapatinib has activity in EGFR- and/or HER2-expressing ESCC cells, and the combination therapy of Lapatinib and Cetuximab/Herceptin is a promising strategy in ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT06zCkLx1hbVg90H21EOLACvtfcHk0lhEUHimjbZCzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtrfF&md5=a17f3b214307fc8f3cccb60b23bda8f5</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1002%2Fijc.25896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25896%26sid%3Dliteratum%253Aachs%26aulast%3DMimura%26aufirst%3DK.%26aulast%3DKono%26aufirst%3DK.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DIzawa%26aufirst%3DS.%26aulast%3DShiba%26aufirst%3DS.%26aulast%3DMizukami%26aufirst%3DY.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DKono%26aufirst%3DT.%26aulast%3DChoudhury%26aufirst%3DA.%26aulast%3DKiessling%26aufirst%3DR.%26aulast%3DFujii%26aufirst%3DH.%26atitle%3DLapatinib%2520inhibits%2520receptor%2520phosphorylation%2520and%2520cell%2520growth%2520and%2520enhances%2520antibody%2520dependent%2520cellular%2520cytoxicity%2520%2528ADCC%2529%2520of%2520EGFR%2520and%2520HER2%2520over-expressing%2520esophageal%2520cancer%2520cell%2520lines%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D2408%26epage%3D2416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Ross, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span> </span><span class="NLM_article-title">Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1949</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1158%2F1078-0432.CCR-08-3328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=20215545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyhurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1938-1949&author=H.+J.+Rossauthor=G.+R.+Blumenscheinauthor=J.+Aisnerauthor=N.+Damjanovauthor=A.+Dowlatiauthor=J.+Garstauthor=J.+R.+Rigasauthor=M.+Smylieauthor=H.+Hassaniauthor=K.+E.+Allenauthor=L.+Leopoldauthor=T.+Z.+Zaksauthor=F.+A.+Shepherd&title=Randomized+phase+II+multicenter+trial+of+two+schedules+of+lapatinib+as+first-+or+second-line+monotherapy+in+patients+with+advanced+or+metastatic+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Ross, Helen J.; Blumenschein, George R., Jr.; Aisner, Joseph; Damjanov, Nevena; Dowlati, Afshin; Garst, Jennifer; Rigas, James R.; Smylie, Michael; Hassani, Habib; Allen, Kimberly E.; Leopold, Lance; Zaks, Tal Z.; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1938-1949</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.  Exptl. Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance.  Patients could have had a max. of one prior systemic therapy (chemotherapy or biol. therapy) for NSCLC.  Safety and activity were assessed every 4 and 8 wk, resp.  Tumors were analyzed for EGFR and HER2 mutations and/or amplifications.  RESULTS: Of 75 patients in the nontargeted population, 1 (1.3%) had partial response and 16 (21%) had stable disease of ≥24 wk.  No complete or partial responses were obsd. in 56 patients in the targeted population; 14 (25%) had stable disease of ≥24 wk.  No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification.  No mutations in HER2 were found.  One of two patients with HER2 amplification had a 51% decrease in tumor size; however, this response was unconfirmed.  The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia.  Adverse events were similar across dosing regimens.  CONCLUSIONS: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups.  Lapatinib monotherapy did not induce a significant no. of tumor regressions in NSCLC.  Further studies may be warranted to det. whether lapatinib is active in combination with other agents in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-5ZsLpn50LrVg90H21EOLACvtfcHk0lhEUHimjbZCzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyhurY%253D&md5=0bfa99df35f30bb9e9ef0b2addb23e28</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-3328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-3328%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DH.%2BJ.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DAisner%26aufirst%3DJ.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DGarst%26aufirst%3DJ.%26aulast%3DRigas%26aufirst%3DJ.%2BR.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DHassani%26aufirst%3DH.%26aulast%3DAllen%26aufirst%3DK.%2BE.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DZaks%26aufirst%3DT.%2BZ.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DRandomized%2520phase%2520II%2520multicenter%2520trial%2520of%2520two%2520schedules%2520of%2520lapatinib%2520as%2520first-%2520or%2520second-line%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D1938%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ooi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehana, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunitomo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobashi, Y.</span><span> </span><span class="NLM_article-title">Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1038%2Fmodpathol.3800137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=15143334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=895-904&author=A.+Ooiauthor=T.+Takehanaauthor=X.+Liauthor=S.+Suzukiauthor=K.+Kunitomoauthor=H.+Iinoauthor=H.+Fujiiauthor=Y.+Takedaauthor=Y.+Dobashi&title=Protein+overexpression+and+gene+amplification+of+HER-2+and+EGFR+in+colorectal+cancers%3A+an+immunohistochemical+and+fluorescent+in+situ+hybridization+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study</span></div><div class="casAuthors">Ooi, Akishi; Takehana, Takuo; Li, Xiaoling; Suzuki, Shioto; Kunitomo, Kazuyoshi; Iino, Hiroshi; Fujii, Hideki; Takeda, Yasuhisa; Dobashi, Yoh</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">895-904</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Overexpression of HER-2 and the epidermal growth factor receptor (EGFR) has been obsd. in many cancers, sometimes accompanied by gene amplification.  To assess whether novel chemotherapies targeting these overexpressed proteins may be effective for the treatment of colorectal cancers, we examd. the exact frequency of HER-2 and EGFR overexpression, the relationship between gene amplification and protein expression, and the heterogeneity of gene amplification within and between primary and metastatic tumors.  We evaluated 244 colorectal cancers immunohistochem.  All tumors found to overexpress HER-2 or EGFR were further analyzed for gene amplification by fluorescent in situ DNA hybridization.  Overexpression of HER-2 and EGFR was found in 8 (3%) and 19 (8%) of the 244 colorectal carcinomas, resp.  Gene amplification was obsd. in 100 and 58% of the tumors exhibiting HER-2 and EGFR overexpression, resp.  HER-2 amplification in cancer cells was characterized by clusters of hybridization signals, suggesting amplicons in homogeneously staining regions that were predominant in most primary and metastatic tumors.  EGFR amplification, obsd. as scattered signals reminiscent of amplicons in double minute chromosomes, or coamplification of EGFR with the centromeric regions was obsd. as a minor population within primary tumors, and found in variety of populations in metastatic tumors.  Overexpression of HER-2 and EGFR were obsd. in only a small fraction of colorectal carcinomas, but were frequently accompanied by gene amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps8JLiZoJAWbVg90H21EOLACvtfcHk0lg4R3deUVjl_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOltrk%253D&md5=e073b560295b3ca3331a7f4fe11f59f7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.3800137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.3800137%26sid%3Dliteratum%253Aachs%26aulast%3DOoi%26aufirst%3DA.%26aulast%3DTakehana%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DKunitomo%26aufirst%3DK.%26aulast%3DIino%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DDobashi%26aufirst%3DY.%26atitle%3DProtein%2520overexpression%2520and%2520gene%2520amplification%2520of%2520HER-2%2520and%2520EGFR%2520in%2520colorectal%2520cancers%253A%2520an%2520immunohistochemical%2520and%2520fluorescent%2520in%2520situ%2520hybridization%2520study%26jtitle%3DMod.%2520Pathol.%26date%3D2004%26volume%3D17%26spage%3D895%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghlul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy</span> <span class="citation_source-journal">Cancer Cell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=81-93&author=D.+Liauthor=T.+Shimamuraauthor=H.+Jiauthor=L.+Chenauthor=H.+J.+Haringsmaauthor=K.+McNamaraauthor=M.-C.+Liangauthor=S.+A.+Pereraauthor=S.+Zaghlulauthor=C.+L.+Borgmanauthor=S.+Kuboauthor=M.+Takahashiauthor=Y.+Sunauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=N.+I.+Lindemanauthor=P.+A.+J%C3%A4nneauthor=R.+K.+Thomasauthor=M.+L.+Meyersonauthor=M.+J.+Eckauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=K.-K.+Wong&title=Bronchial+and+peripheral+murine+lung+carcinomas+induced+by+T790M-L858R+mutant+EGFR+respond+to+HKI-272+and+rapamycin+combination+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DM.-C.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DZaghlul%26aufirst%3DS.%26aulast%3DBorgman%26aufirst%3DC.%2BL.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%2BL.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DBronchial%2520and%2520peripheral%2520murine%2520lung%2520carcinomas%2520induced%2520by%2520T790M-L858R%2520mutant%2520EGFR%2520respond%2520to%2520HKI-272%2520and%2520rapamycin%2520combination%2520therapy%26jtitle%3DCancer%2520Cell.%26date%3D2007%26volume%3D12%26spage%3D81%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mom, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A. S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amelsberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1038%2Fsj.bjc.6604108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=18026190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=80-85&author=F.+A.+L.+M.+Eskensauthor=C.+H.+Momauthor=A.+S.+T.+Plantingauthor=J.+A.+Gietemaauthor=A.+Amelsbergauthor=H.+Huismanauthor=L.+van+Doornauthor=H.+Burgerauthor=P.+Stopferauthor=J.+Verweijauthor=E.+G.+de+Vries&title=A+phase+I+dose+escalation+study+of+BIBW+2992%2C+an+irreversible+dual+inhibitor+of+epidermal+growth+factor+receptor+1+%28EGFR%29+and+2+%28HER2%29+tyrosine+kinase+in+a+2-week+on%2C+2-week+off+schedule+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clin. activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992.  An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored.  Thirty-eight patients were enrolled.  Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg.  At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhea despite treatment with loperamide) occurred in two patients.  In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients.  An intermediate dose level of 85 mg was studied.  Here DLT occurred in two patients (grade 3 diarrhea despite treatment and grade 2 diarrhea lasting more than 7 days despite treatment).  An addnl. 12 patients were treated at 70 mg.  BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality.  Pharmacodynamics anal. in skin biopsies did not show significant changes in EGFR-assocd. biomarkers.  However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was obsd.  No partial or complete responses were obsd., stable disease lasting more than four cycles was seen in seven patients.  The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD.  British Journal of Cancer (2008) 98, 80-85. doi:10.1038/sj.bjc.6604108 www.bjcancer.com Published online 20 Nov. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZL8pTnjAwrVg90H21EOLACvtfcHk0ljrvYc8PZdRQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D&md5=96a0be31145bf1691640109d69ff5dc0</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604108%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DMom%26aufirst%3DC.%2BH.%26aulast%3DPlanting%26aufirst%3DA.%2BS.%2BT.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26aulast%3DAmelsberg%26aufirst%3DA.%26aulast%3DHuisman%26aufirst%3DH.%26aulast%3Dvan%2BDoorn%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%2520dual%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%25201%2520%2528EGFR%2529%2520and%25202%2520%2528HER2%2529%2520tyrosine%2520kinase%2520in%2520a%25202-week%2520on%252C%25202-week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Yokoi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaker, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebhun, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3716</span><span class="NLM_x">–</span> <span class="NLM_lpage">3725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3716-3725&author=K.+Yokoiauthor=P.+H.+Thakerauthor=S.+Yaziciauthor=R.+R.+Rebhunauthor=D.-H.+Namauthor=J.+Heauthor=S.-J.+Kimauthor=J.+L.+Abbruzzeseauthor=S.+R.+Hamiltonauthor=I.+J.+Fidler&title=Dual+inhibition+of+epidermal+growth+factor+receptor+and+vascular+endothelial+growth+factor+receptor+phosphorylation+by+AEE788+reduces+growth+and+metastasis+of+human+colon+carcinoma+in+an+orthotopic+nude+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DYazici%26aufirst%3DS.%26aulast%3DRebhun%26aufirst%3DR.%2BR.%26aulast%3DNam%26aufirst%3DD.-H.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-J.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DHamilton%26aufirst%3DS.%2BR.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DDual%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520phosphorylation%2520by%2520AEE788%2520reduces%2520growth%2520and%2520metastasis%2520of%2520human%2520colon%2520carcinoma%2520in%2520an%2520orthotopic%2520nude%2520mouse%2520model%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3716%26epage%3D3725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6186</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1158%2F1078-0432.CCR-06-0642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=17062696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6186-6193&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=C.+Yuauthor=F.+R.+Luoauthor=S.+Oppenheimerauthor=H.+Zhangauthor=R.+A.+Smyklaauthor=H.+Mastalerzauthor=B.+E.+Finkauthor=J.+T.+Huntauthor=A.+V.+Gavaiauthor=G.+D.+Vite&title=Preclinical+antitumor+activity+of+BMS-599626%2C+a+pan-HER+kinase+inhibitor+that+inhibits+HER1%2FHER2+homodimer+and+heterodimer+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling</span></div><div class="casAuthors">Wong, Tai W.; Lee, Francis Y.; Yu, Chiang; Luo, Feng R.; Oppenheimer, Simone; Zhang, Hongjian; Smykla, Richard A.; Mastalerz, Harold; Fink, Brian E.; Hunt, John T.; Gavai, Ashvinikumar V.; Vite, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6186-6193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-mol. inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on HER1 and/or HER2.  Exptl. Design: The potency and selectivity of BMS-599626 were assessed in biochem. assays using recombinant protein kinases, as well as in cell proliferation assays using tumor cell lines with varying degrees of dependence on HER1 or HER2 signaling.  Modulation of receptor signaling was detd. in cell assays by Western blot analyses of receptor autophosphorylation and downstream signaling.  The ability of BMS-599626 to inhibit receptor heterodimer signaling in tumor cells was studied by receptor coimmunopptn.  Antitumor activity of BMS-599626 was evaluated using a no. of different xenograft models that represent a spectrum of human tumors with HER1 or HER2 overexpression.  Results: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, resp., and was highly selective when tested against a broad panel of diverse protein kinases.  Biochem. studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms.  BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μmol/L.  BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors.  In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling.  BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity.  Conclusions: BMS-599626 is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling.  BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an addnl. mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.  The preclin. data support the advancement of BMS-599626 into clin. development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgsCF6GDMPbVg90H21EOLACvtfcHk0ljrvYc8PZdRQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK&md5=a8350e2eb304a091fa82f1159e44c119</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0642%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmykla%26aufirst%3DR.%2BA.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DGavai%26aufirst%3DA.%2BV.%26aulast%3DVite%26aufirst%3DG.%2BD.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-599626%252C%2520a%2520pan-HER%2520kinase%2520inhibitor%2520that%2520inhibits%2520HER1%252FHER2%2520homodimer%2520and%2520heterodimer%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6186%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dextraze, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruediger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2042</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2036-2042&author=H.+Mastalerzauthor=M.+Changauthor=P.+Chenauthor=P.+Dextrazeauthor=B.+E.+Finkauthor=A.+Gavaiauthor=B.+Goyalauthor=W.-C.+Hanauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=P.+Maratheauthor=A.+Mathurauthor=S.+Oppenheimerauthor=E.+Ruedigerauthor=J.+Tarrantauthor=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=New+C-5+substituted+pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DDextraze%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DGoyal%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DW.-C.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DRuediger%26aufirst%3DE.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DNew%2520C-5%2520substituted%2520pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2036%26epage%3D2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2m"><span><span class="NLM_label">(m) </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2828</span><span class="NLM_x">–</span> <span class="NLM_lpage">2833</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2828-2833&author=H.+Mastalerzauthor=M.+Changauthor=A.+Gavaiauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=P.+Maratheauthor=A.+Mathurauthor=S.+Oppenheimerauthor=J.+Tarrant.author=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=Novel+C-5+aminomethyl+pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DTarrant.%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DNovel%2520C-5%2520aminomethyl%2520pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2828%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2n"><span><span class="NLM_label">(n) </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleczka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4947</span><span class="NLM_x">–</span> <span class="NLM_lpage">4954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4947-4954&author=H.+Mastalerzauthor=M.+Changauthor=P.+Chenauthor=B.+E.+Finkauthor=A.+Gavaiauthor=W+C.+Hanauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=K.+Leavittauthor=P.+Maratheauthor=D.+Norrisauthor=S.+Oppenheimerauthor=B.+Sleczkaauthor=J.+Tarrantauthor=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=5-%28%284-Aminopiperidin-1-yl%29methyl%29pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2n&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DW%2BC.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3D5-%2528%25284-Aminopiperidin-1-yl%2529methyl%2529pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4947%26epage%3D4954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2o"><span><span class="NLM_label">(o) </span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafidi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessel, M. D.</span><span> </span><span class="NLM_article-title">Achieving selectivity between higly homologous tyrosine kinases anovel selective erbB2 inhibitor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=267-273&author=S.+K.+Bhattacharyaauthor=E.+D.+Coxauthor=J.+C.+Kathauthor=A.+M.+Mathiowetzauthor=J.+Morrisauthor=J.+D.+Moyerauthor=L.+R.+Pustilnikauthor=K.+Rafidiauthor=D.+T.+Richterauthor=C.+Suauthor=M.+D.+Wessel&title=Achieving+selectivity+between+higly+homologous+tyrosine+kinases+anovel+selective+erbB2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2o&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DCox%26aufirst%3DE.%2BD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26atitle%3DAchieving%2520selectivity%2520between%2520higly%2520homologous%2520tyrosine%2520kinases%2520anovel%2520selective%2520erbB2%2520inhibitor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D307%26spage%3D267%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2p"><span><span class="NLM_label">(p) </span><span class="NLM_contrib-group">Jani, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafidi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span> </span><span class="NLM_article-title">Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9887</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2p&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1158%2F0008-5472.CAN-06-3559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2p&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=17942920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2p&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9887-93&author=J.+P.+Janiauthor=R.+S.+Finnauthor=M.+Campbellauthor=K.+G.+Colemanauthor=R.+D.+Connellauthor=N.+Currierauthor=E.+O.+Emersonauthor=E.+Floydauthor=S.+Harrimanauthor=J.+C.+Kathauthor=J.+Morrisauthor=J.+D.+Moyerauthor=L.+R.+Pustilnikauthor=K.+Rafidiauthor=S.+Ralstonauthor=A.+M.+Rossiauthor=S.+J.+Steynauthor=L.+Wagnerauthor=S.+M.+Winterauthor=S.+K.+Bhattacharya&title=Discovery+and+pharmacologic+characterization+of+CP-724%2C714%2C+a+selective+ErbB2+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2pR"><div class="casContent"><span class="casTitleNuber">2p</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Jani, Jitesh P.; Finn, Richard S.; Campbell, Mary; Coleman, Kevin G.; Connell, Richard D.; Currier, Nicolas; Emerson, Erling O.; Floyd, Eugenia; Harriman, Shawn; Kath, John C.; Morris, Joel; Moyer, James D.; Pustilnik, Leslie R.; Rafidi, Kristina; Ralston, Sherry; Rossi, Ann Marie K.; Steyn, Stefanus J.; Wagner, Larry; Winter, Steven M.; Bhattacharya, Samit K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9887-9893</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amplification and overexpression of erbB2 (Her-2/neu) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary, and stomach.  It has been implicated in tumor growth, sensitivity to std. chemotherapy, prognosis of patients, and disease-free survival.  Although the clin. use of trastuzumab (Herceptin) has prolonged the survival of breast cancer patients with erbB2-overexpressing tumors, there is an urgent need for more potent and orally bioavailable small-mol. inhibitors.  CP-724,714 is a potent inhibitor of erbB2 receptor autophosphorylation in intact cells and is currently undergoing phase I clin. trials.  Here, we describe the effects of CP-724,714 in vitro and in vivo in human breast cancer models.  CP-724,714 is selective for inhibiting growth of HER2-driven cell lines.  In addn., we show that it induces G1 cell cycle block in erbB2-overexpressing BT-474 human breast carcinoma cells and inhibits erbB2 autophosphorylation in xenografts when administered p.o. to athymic mice.  It induces a marked redn. of extracellular signal-regulated kinase and Akt phosphorylation, tumor cell apoptosis, and release of caspase-3.  P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_a6qjvEZI-rVg90H21EOLACvtfcHk0lh2v-Yan2uvXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbvE&md5=21dc688108dd46aba15694d7e3159321</span></div><a href="/servlet/linkout?suffix=cit2p&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3559%26sid%3Dliteratum%253Aachs%26aulast%3DJani%26aufirst%3DJ.%2BP.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DK.%2BG.%26aulast%3DConnell%26aufirst%3DR.%2BD.%26aulast%3DCurrier%26aufirst%3DN.%26aulast%3DEmerson%26aufirst%3DE.%2BO.%26aulast%3DFloyd%26aufirst%3DE.%26aulast%3DHarriman%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DRalston%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DWagner%26aufirst%3DL.%26aulast%3DWinter%26aufirst%3DS.%2BM.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3DDiscovery%2520and%2520pharmacologic%2520characterization%2520of%2520CP-724%252C714%252C%2520a%2520selective%2520ErbB2%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9887%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2q"><span><span class="NLM_label">(q) </span><span class="NLM_contrib-group">Ripin, D. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourassa, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaldi, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massett, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raggon, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. M.,  III.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetelino, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span> </span><span class="NLM_article-title">Evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to oncology candidate CP-724,714</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">440</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/doi/10.1021/op050039u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=440-450&author=D.+H.+B.+Ripinauthor=D.+E.+Bourassaauthor=T.+Brandtauthor=M.+J.+Castaldiauthor=H.+N.+Frostauthor=J.+Hawkinsauthor=P.+J.+Johnsonauthor=S.+S.+Massettauthor=K.+Neumannauthor=J.+Phillipsauthor=J.+W.+Raggonauthor=P.+R.+Roseauthor=J.+L.+Rutherfordauthor=B.+Sitterauthor=A.+M.+Stewartauthor=M.+G.+Vetelinoauthor=L.+Wei&title=Evaluation+of+kilogram-scale+Sonagashira%2C+Suzuki%2C+and+Heck+coupling+routes+to+oncology+candidate+CP-724%2C714"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2q&amp;dbid=16384&amp;doi=10.1021%2Fop050039u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop050039u%26sid%3Dliteratum%253Aachs%26aulast%3DRipin%26aufirst%3DD.%2BH.%2BB.%26aulast%3DBourassa%26aufirst%3DD.%2BE.%26aulast%3DBrandt%26aufirst%3DT.%26aulast%3DCastaldi%26aufirst%3DM.%2BJ.%26aulast%3DFrost%26aufirst%3DH.%2BN.%26aulast%3DHawkins%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DP.%2BJ.%26aulast%3DMassett%26aufirst%3DS.%2BS.%26aulast%3DNeumann%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DJ.%26aulast%3DRaggon%26aufirst%3DJ.%2BW.%26aulast%3DRose%26aufirst%3DP.%2BR.%26aulast%3DRutherford%26aufirst%3DJ.%2BL.%26aulast%3DSitter%26aufirst%3DB.%26aulast%3DStewart%26aufirst%3DA.%2BM.%26aulast%3DVetelino%26aufirst%3DM.%2BG.%26aulast%3DWei%26aufirst%3DL.%26atitle%3DEvaluation%2520of%2520kilogram-scale%2520Sonagashira%252C%2520Suzuki%252C%2520and%2520Heck%2520coupling%2520routes%2520to%2520oncology%2520candidate%2520CP-724%252C714%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2005%26volume%3D9%26spage%3D440%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2r"><span><span class="NLM_label">(r) </span><span class="NLM_contrib-group">Lippa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungerford, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span> </span><span class="NLM_article-title">The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3081</span><span class="NLM_x">–</span> <span class="NLM_lpage">3086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3081-3086&author=B.+Lippaauthor=G.+S.+Kauffmanauthor=J.+Arcariauthor=T.+Kwanauthor=J.+Chenauthor=W.+Hungerfordauthor=S.+Bhattacharyaauthor=X.+Zhaoauthor=C.+Williamsauthor=J.+Xiaoauthor=L.+Pustilnikauthor=C.+Suauthor=J.+D.+Moyerauthor=L.+Maauthor=M.+Campbellauthor=S.+Steyn&title=The+discovery+of+highly+selective+erbB2+%28Her2%29+inhibitors+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2r&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DKauffman%26aufirst%3DG.%2BS.%26aulast%3DArcari%26aufirst%3DJ.%26aulast%3DKwan%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHungerford%26aufirst%3DW.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DPustilnik%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DSteyn%26aufirst%3DS.%26atitle%3DThe%2520discovery%2520of%2520highly%2520selective%2520erbB2%2520%2528Her2%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3081%26epage%3D3086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oorui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel HER2/EGFR dual inhibitors bearing a pyrrolo[3,2-<i>d</i>]pyrimidine scaffold</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8030</span><span class="NLM_x">–</span> <span class="NLM_lpage">8050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2008634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8030-8050&author=T.+Ishikawaauthor=M.+Setoauthor=H.+Bannoauthor=Y.+Kawakitaauthor=M.+Ooruiauthor=T.+Taniguchiauthor=Y.+Ohtaauthor=T.+Tamuraauthor=A.+Nakayamaauthor=H.+Mikiauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=N.+Habukaauthor=S.+Sogabeauthor=K.+Aertgeertsauthor=K.+Kamiyama&title=Design+and+synthesis+of+novel+HER2%2FEGFR+dual+inhibitors+bearing+a+pyrrolo%5B3%2C2-d%5Dpyrimidine+scaffold"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1021%2Fjm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DBanno%26aufirst%3DH.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DOorui%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DKamiyama%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520HER2%252FEGFR%2520dual%2520inhibitors%2520bearing%2520a%2520pyrrolo%255B3%252C2-d%255Dpyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8030%26epage%3D8050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Doi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takiuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dote, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuze, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jinno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takubo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phase, I</span><span> </span><span class="NLM_article-title">First-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients</span> <span class="citation_source-journal">Br. J. Can</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1038%2Fbjc.2011.590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=22215103" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=1-7&author=T.+Doiauthor=H.+Takiuchiauthor=A.+Ohtsuauthor=N.+Fuseauthor=M.+Gotoauthor=M.+Yoshidaauthor=N.+Doteauthor=Y.+Kuzeauthor=F.+Jinnoauthor=M.+Fujimotoauthor=T.+Takuboauthor=N.+Nakayamaauthor=R.+Tsutsumiauthor=I+Phase&title=First-in-human+study+of+TAK-285%2C+a+novel+investigational+dual+HER2%2FEGFR+inhibitor%2C+in+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.590%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DTakiuchi%26aufirst%3DH.%26aulast%3DOhtsu%26aufirst%3DA.%26aulast%3DFuse%26aufirst%3DN.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DDote%26aufirst%3DN.%26aulast%3DKuze%26aufirst%3DY.%26aulast%3DJinno%26aufirst%3DF.%26aulast%3DFujimoto%26aufirst%3DM.%26aulast%3DTakubo%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DN.%26aulast%3DTsutsumi%26aufirst%3DR.%26aulast%3DPhase%26aufirst%3DI%26atitle%3DFirst-in-human%2520study%2520of%2520TAK-285%252C%2520a%2520novel%2520investigational%2520dual%2520HER2%252FEGFR%2520inhibitor%252C%2520in%2520cancer%2520patients%26jtitle%3DBr.%2520J.%2520Can%26date%3D2012%26volume%3D106%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span> </span><span class="NLM_article-title">Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">18756</span><span class="NLM_x">–</span> <span class="NLM_lpage">18765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=18756-18765&author=K.+Aertgeertsauthor=R.+Skeneauthor=J.+Yanoauthor=B.+Sangauthor=H.+Zouauthor=G.+Snellauthor=A.+Jenningsauthor=K.+Iwamotoauthor=N.+Habukaauthor=A.+Hirokawaauthor=T.+Ishikawaauthor=T.+Tanakaauthor=H.+Mikiauthor=Y.+Ohtaauthor=S.+Sogabe&title=Structural+analysis+of+the+mechanism+of+inhibition+and+allosteric+activation+of+the+kinase+domain+of+HER2+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DHirokawa%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DSogabe%26aufirst%3DS.%26atitle%3DStructural%2520analysis%2520of%2520the%2520mechanism%2520of%2520inhibition%2520and%2520allosteric%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520HER2%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D21%26spage%3D18756%26epage%3D18765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Oguro, Y</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awazu, Y</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine derivatives: novel VEGFR kinase inhibitors binding to inactive kinase conformation</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7260</span><span class="NLM_x">–</span> <span class="NLM_lpage">7273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7260-7273&author=Y+Oguroauthor=N+Miyamotoauthor=T+Takagiauthor=K+Okadaauthor=Y+Awazuauthor=M+Mikiauthor=A+Horiauthor=K+Kamiyamaauthor=S.+Imamura&title=Design%2C+synthesis%2C+and+evaluation+of+5-methyl-4-phenoxy-5H-pyrrolo%5B3%2C2-d%5Dpyrimidine+derivatives%3A+novel+VEGFR+kinase+inhibitors+binding+to+inactive+kinase+conformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOguro%26aufirst%3DY%26aulast%3DMiyamoto%26aufirst%3DN%26aulast%3DTakagi%26aufirst%3DT%26aulast%3DOkada%26aufirst%3DK%26aulast%3DAwazu%26aufirst%3DY%26aulast%3DMiki%26aufirst%3DM%26aulast%3DHori%26aufirst%3DA%26aulast%3DKamiyama%26aufirst%3DK%26aulast%3DImamura%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%25205-methyl-4-phenoxy-5H-pyrrolo%255B3%252C2-d%255Dpyrimidine%2520derivatives%253A%2520novel%2520VEGFR%2520kinase%2520inhibitors%2520binding%2520to%2520inactive%2520kinase%2520conformation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D20%26spage%3D7260%26epage%3D7273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=12467226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=85-94&author=D.+W.+Rusnakauthor=K.+Lackeyauthor=K.+Affleckauthor=E.+R.+Woodauthor=K.+J.+Alligoodauthor=N.+Rhodesauthor=B.+R.+Keithauthor=D.+M.+Murrayauthor=K.+Glennonauthor=W.+B.+Knightauthor=R.+J.+Mullinauthor=T.+M.+Gilmer&title=The+effects+of+the+novel%2C+reversible+epidermal+growth+factor+receptor%2FErbB-2+tyrosine+kinase+inhibitor%2C+GW2016%2C+on+the+growth+of+human+normal+and+tumor-derived+cell+lines+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span></div><div class="casAuthors">Rusnak, David W.; Lackey, Karen; Affleck, Karen; Wood, Edgar R.; Alligood, Krystal J.; Rhodes, Nelson; Keith, Barry R.; Murray, Doris M.; Knight, W. Blaine; Mullin, Robert J.; Gilmer, Tona M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of cancer.  GW2016 is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, resp.  This report describes the efficacy in cell growth assays of GW2016 on human tumor cell lines overexpressing either EGFR or ErbB-2: HN5 (head and neck), A-431 (vulva), BT474 (breast), CaLu-3 (lung), and N87 (gastric).  Normal human foreskin fibroblasts, nontumorigenic epithelial cells (HB4a), and nonoverexpressing tumor cells (MCF-7 and T47D) were tested as neg. controls.  After 3 days of compd. exposure, av. IC50 values for growth inhibition in the EGFR- and ErbB-2-overexpressing tumor cell lines were <0.16 μM.  The av. selectivity for the tumor cells vs. the human foreskin fibroblast cell line was 100-fold.  Inhibition of EGFR and ErbB-2 receptor autophosphorylation and phosphorylation of the downstream modulator, AKT, was verified by Western blot anal. in the BT474 and HN5 cell lines.  As a measure of cytotoxicity vs. growth arrest, the HN5 and BT474 cells were assessed in an outgrowth assay after a transient exposure to GW2016.  The cells were treated for 3 days in five concns. of GW2016, and cell growth was monitored for an addnl. 12 days after removal of the compd.  In each of these tumor cell lines, concns. of GW2016 were reached where outgrowth did not occur.  Furthermore, growth arrest and cell death were obsd. in parallel expts., as detd. by bromodeoxyuridine incorporation and propidium iodide staining.  GW2016 treatment inhibited tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg orally, twice daily, with complete inhibition of tumor growth at the higher dose.  Together, these results indicate that GW2016 achieves excellent potency on tumor cells with selectivity for tumor vs. normal cells and suggest that GW2016 has value as a therapy for patients with tumors overexpressing either EGFR or ErbB-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5OJ41zsWu6rVg90H21EOLACvtfcHk0lj_dCPlecvk0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D&md5=64fd8cadce83eda3b9b82ab50f1e57b0</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DMurray%26aufirst%3DD.%2BM.%26aulast%3DGlennon%26aufirst%3DK.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DThe%2520effects%2520of%2520the%2520novel%252C%2520reversible%2520epidermal%2520growth%2520factor%2520receptor%252FErbB-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520GW2016%252C%2520on%2520the%2520growth%2520of%2520human%2520normal%2520and%2520tumor-derived%2520cell%2520lines%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2001%26volume%3D1%26spage%3D85%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lj_dCPlecvk0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nature Rev. Drug Discov.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNature%2520Rev.%2520Drug%2520Discov.%26date%3D2007%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span> </span><span class="NLM_article-title">Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi101777f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=738-751&author=H.+Iwataauthor=S.+Imamuraauthor=A.+Horiauthor=M.+S.+Hixonauthor=H.+Kimuraauthor=H.+Miki&title=Biochemical+characterization+of+TAK-593%2C+a+novel+VEGFR%2FPDGFR+inhibitor+with+a+two-step+slow+binding+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1021%2Fbi101777f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi101777f%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DS.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DHixon%26aufirst%3DM.%2BS.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26atitle%3DBiochemical%2520characterization%2520of%2520TAK-593%252C%2520a%2520novel%2520VEGFR%252FPDGFR%2520inhibitor%2520with%2520a%2520two-step%2520slow%2520binding%2520mechanism%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D738%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kinnick, M. D.; Lin, H.-S.; Martinelli, M. J.; Morin, J. M.; Richett, M. E.</span> Novel SPLA2 Inhibitors. PCT Int. Appl. US 20030236232 (A1), Dec.<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kinnick%2C+M.+D.%3B+Lin%2C+H.-S.%3B+Martinelli%2C+M.+J.%3B+Morin%2C+J.+M.%3B+Richett%2C+M.+E.+Novel+SPLA2+Inhibitors.+PCT+Int.+Appl.+US+20030236232+%28A1%29%2C+Dec.+2003."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKinnick%26aufirst%3DM.%2BD.%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Sutter, M.; Kunz, W.</span><span> </span><span class="NLM_article-title">Process for Preparing Nematicidal Compositions</span>. PCT Int. Appl. US 5169951 (A), Dec.<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=M.+Sutter&author=W.+Kunz&title=Process+for+Preparing+Nematicidal+Compositions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSutter%26aufirst%3DM.%26atitle%3DProcess%2520for%2520Preparing%2520Nematicidal%2520Compositions%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists</span> <span class="citation_source-journal">Methods Biochem. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=16350889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A280%3ADC%252BD2MnmtlyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=1-265&author=R.+A.+Copeland&title=Evaluation+of+enzyme+inhibitors+in+drug+discovery.+A+guide+for+medicinal+chemists+and+pharmacologists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists</span></div><div class="casAuthors">Copeland Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Methods of biochemical analysis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-265</span>
        ISSN:<span class="NLM_cas:issn">0076-6941</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR7_ubfiC0DK2q3xNe7a7QfW6udTcc2eb13yrgoNF5D7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnmtlyjsA%253D%253D&md5=4bb6759b5155aa6c2b6a462432afda7f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DEvaluation%2520of%2520enzyme%2520inhibitors%2520in%2520drug%2520discovery.%2520A%2520guide%2520for%2520medicinal%2520chemists%2520and%2520pharmacologists%26jtitle%3DMethods%2520Biochem.%2520Anal.%26date%3D2005%26volume%3D46%26spage%3D1%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c'],'ref2':['cit2a','cit2s','cit2b','cit2c','cit2d','cit2e','cit2f','cit2g','cit2h','cit2i','cit2j','cit2k','cit2l','cit2m','cit2n','cit2o','cit2p','cit2q','cit2r'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c','cit6d'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ikuo Fujimori, Takeshi Wakabayashi, Morio Murakami, Atsutoshi Okabe, Tsuyoshi Ishii, Aaron McGrath, Hua Zou, Kumar Singh Saikatendu, <span class="NLM_string-name hlFld-ContribAuthor">Hiroshi Imoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (49)
                                     , 31984-32001. <a href="https://doi.org/10.1021/acsomega.0c04900" title="DOI URL">https://doi.org/10.1021/acsomega.0c04900</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04900%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDiscovery%252Bof%252BNovel%252Band%252BHighly%252BSelective%252BCyclopropane%252BALK%252BInhibitors%252Bthrough%252Ba%252BFragment-Assisted%25252C%252BStructure-Based%252BDrug%252BDesign%26aulast%3DFujimori%26aufirst%3DIkuo%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07102020%26date%3D13112020%26date%3D30112020%26volume%3D5%26issue%3D49%26spage%3D31984%26epage%3D32001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Chen, Hao Xiong, Jing-Fang Yang, Xiao-Lei Zhu, Ren-Yu Qu, <span class="NLM_string-name hlFld-ContribAuthor">Guang-Fu Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2020,</strong> <em>68 </em>
                                    (37)
                                     , 9839-9877. <a href="https://doi.org/10.1021/acs.jafc.0c03369" title="DOI URL">https://doi.org/10.1021/acs.jafc.0c03369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.0c03369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.0c03369%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DDiaryl%252BEther%25253A%252BA%252BPrivileged%252BScaffold%252Bfor%252BDrug%252Band%252BAgrochemical%252BDiscovery%26aulast%3DChen%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27052020%26date%3D11082020%26date%3D11082020%26date%3D29082020%26date%3D11082020%26volume%3D68%26issue%3D37%26spage%3D9839%26epage%3D9877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Makoto Fushimi, Ikuo Fujimori, Takeshi Wakabayashi, Tomoaki Hasui, Youichi Kawakita, Keisuke Imamura, Tomoko Kato, Morio Murakami, Tsuyoshi Ishii, Yorifumi Kikko, Maki Kasahara, Atsushi Nakatani, Yuto Hiura, Maki Miyamoto, Kumar Saikatendu, Hua Zou, Scott Weston Lane, J. David Lawson, <span class="NLM_string-name hlFld-ContribAuthor">Hiroshi Imoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent, Selective, and Brain-Penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4915-4935. <a href="https://doi.org/10.1021/acs.jmedchem.8b01630" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01630%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%25252C%252BSelective%25252C%252Band%252BBrain-Penetrant%252B1H-Pyrazol-5-yl-1H-pyrrolo%25255B2%25252C3-b%25255Dpyridines%252Bas%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252BInhibitors%26aulast%3DFushimi%26aufirst%3DMakoto%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21102018%26date%3D03052019%26date%3D22042019%26volume%3D62%26issue%3D10%26spage%3D4915%26epage%3D4935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Sogabe</span>, <span class="hlFld-ContribAuthor ">Youichi  Kawakita</span>, <span class="hlFld-ContribAuthor ">Shigeru  Igaki</span>, <span class="hlFld-ContribAuthor ">Hidehisa  Iwata</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Miki</span>, <span class="hlFld-ContribAuthor ">Douglas R.  Cary</span>, <span class="hlFld-ContribAuthor ">Terufumi  Takagi</span>, <span class="hlFld-ContribAuthor ">Shinji  Takagi</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Ohta</span>, and <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (2)
                                     , 201-205. <a href="https://doi.org/10.1021/ml300327z" title="DOI URL">https://doi.org/10.1021/ml300327z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml300327z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml300327z%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-Based%252BApproach%252Bfor%252Bthe%252BDiscovery%252Bof%252BPyrrolo%25255B3%25252C2-d%25255Dpyrimidine-Based%252BEGFR%252BT790M%25252FL858R%252BMutant%252BInhibitors%26aulast%3DSogabe%26aufirst%3DSatoshi%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D10102012%26date%3D18122012%26date%3D21122012%26date%3D14022013%26date%3D18122012%26volume%3D4%26issue%3D2%26spage%3D201%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  Natho</span>, <span class="hlFld-ContribAuthor ">Annie B.  Rouse</span>, <span class="hlFld-ContribAuthor ">Jake L.  Greenfield</span>, <span class="hlFld-ContribAuthor ">Lewis A.T.  Allen</span>, <span class="hlFld-ContribAuthor ">Andrew J.P.  White</span>, <span class="hlFld-ContribAuthor ">Zeyu  Yang</span>, <span class="hlFld-ContribAuthor ">Philip J.  Parsons</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective synthesis of 1- and 4-tetralones from heteroaryl-3-cyclobutanols. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (47)
                                     , 131636. <a href="https://doi.org/10.1016/j.tet.2020.131636" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131636</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131636%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DRegioselective%252Bsynthesis%252Bof%252B1-%252Band%252B4-tetralones%252Bfrom%252Bheteroaryl-3-cyclobutanols%26aulast%3DNatho%26aufirst%3DPhilipp%26date%3D2020%26volume%3D76%26issue%3D47%26spage%3D131636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Az-Eddine  El Mansouri</span>, <span class="hlFld-ContribAuthor ">Mohamed  Maatallah</span>, <span class="hlFld-ContribAuthor ">Hassan  Ait Benhassou</span>, <span class="hlFld-ContribAuthor ">Abdeladim  Moumen</span>, <span class="hlFld-ContribAuthor ">Ahmad  Mehdi</span>, <span class="hlFld-ContribAuthor ">Robert  Snoeck</span>, <span class="hlFld-ContribAuthor ">Graciela  Andrei</span>, <span class="hlFld-ContribAuthor ">Mohamed  Zahouily</span>, <span class="hlFld-ContribAuthor ">Hassan B.  Lazrek</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, chemical characterization, biological evaluation, and docking study of new 1,3,4-oxadiazole homonucleoside analogs. </span><span class="cited-content_cbyCitation_journal-name">Nucleosides, Nucleotides & Nucleic Acids</span><span> <strong>2020,</strong> <em>39 </em>
                                    (8)
                                     , 1088-1107. <a href="https://doi.org/10.1080/15257770.2020.1761982" title="DOI URL">https://doi.org/10.1080/15257770.2020.1761982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15257770.2020.1761982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15257770.2020.1761982%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleosides%252C%2520Nucleotides%2520%2526%2520Nucleic%2520Acids%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bchemical%252Bcharacterization%25252C%252Bbiological%252Bevaluation%25252C%252Band%252Bdocking%252Bstudy%252Bof%252Bnew%252B1%25252C3%25252C4-oxadiazole%252Bhomonucleoside%252Banalogs%26aulast%3DEl%2BMansouri%26aufirst%3DAz-Eddine%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D8%26spage%3D1088%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shehnaz  Fatima</span>, <span class="hlFld-ContribAuthor ">Subhash Mohan  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring structural features of EGFR–HER2 dual inhibitors as anti-cancer agents using G-QSAR approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2019,</strong> <em>39 </em>
                                    (3)
                                     , 243-252. <a href="https://doi.org/10.1080/10799893.2019.1660896" title="DOI URL">https://doi.org/10.1080/10799893.2019.1660896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2019.1660896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2019.1660896%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DExploring%252Bstructural%252Bfeatures%252Bof%252BEGFR%2525E2%252580%252593HER2%252Bdual%252Binhibitors%252Bas%252Banti-cancer%252Bagents%252Busing%252BG-QSAR%252Bapproach%26aulast%3DFatima%26aufirst%3DShehnaz%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D3%26spage%3D243%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafaela  de Angelo</span>, <span class="hlFld-ContribAuthor ">Michell  Almeida</span>, <span class="hlFld-ContribAuthor ">Heberth  de Paula</span>, <span class="hlFld-ContribAuthor ">Kathia  Honorio</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on the Dual Activity of EGFR and HER-2 Inhibitors Using Structure-Based Drug Design Techniques. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (12)
                                     , 3728. <a href="https://doi.org/10.3390/ijms19123728" title="DOI URL">https://doi.org/10.3390/ijms19123728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19123728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19123728%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStudies%252Bon%252Bthe%252BDual%252BActivity%252Bof%252BEGFR%252Band%252BHER-2%252BInhibitors%252BUsing%252BStructure-Based%252BDrug%252BDesign%252BTechniques%26aulast%3Dde%2BAngelo%26aufirst%3DRafaela%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D12%26spage%3D3728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fangfang  Yan</span>, <span class="hlFld-ContribAuthor ">Xinguo  Liu</span>, <span class="hlFld-ContribAuthor ">Shaolong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Su</span>, <span class="hlFld-ContribAuthor ">Qinggang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (70)
                                     , 39797-39810. <a href="https://doi.org/10.1039/C8RA06844E" title="DOI URL">https://doi.org/10.1039/C8RA06844E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA06844E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA06844E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DEffect%252Bof%252Bdouble%252Bmutations%252BT790M%25252FL858R%252Bon%252Bconformation%252Band%252Bdrug-resistant%252Bmechanism%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Bexplored%252Bby%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DYan%26aufirst%3DFangfang%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D70%26spage%3D39797%26epage%3D39810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra N.  Milik</span>, <span class="hlFld-ContribAuthor ">Amal Kamal  Abdel-Aziz</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Saverio  Minucci</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 316-336. <a href="https://doi.org/10.1016/j.ejmech.2018.06.011" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.06.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.06.011%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSurmounting%252Bthe%252Bresistance%252Bagainst%252BEGFR%252Binhibitors%252Bthrough%252Bthe%252Bdevelopment%252Bof%252Bthieno%25255B2%25252C3-d%25255Dpyrimidine-based%252Bdual%252BEGFR%25252FHER2%252Binhibitors%26aulast%3DMilik%26aufirst%3DSandra%2BN.%26date%3D2018%26volume%3D155%26spage%3D316%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A Sravanth  Kumar</span>, <span class="hlFld-ContribAuthor ">Sai Giridhar Sarma  Kandanur</span>, <span class="hlFld-ContribAuthor ">Saikat  Sen</span>, <span class="hlFld-ContribAuthor ">Srinivas  Oruganti</span>. </span><span class="cited-content_cbyCitation_article-title">Delineating an alternate convergent synthesis of brexpiprazole: a novel use of commercial 6,7-dihydrobenzo[b]thiophen-4(5H)-one as precursor to an efficacious Buchwald–Hartwig amination step. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Sciences</span><span> <strong>2018,</strong> <em>130 </em>
                                    (6)
                                     <a href="https://doi.org/10.1007/s12039-018-1470-z" title="DOI URL">https://doi.org/10.1007/s12039-018-1470-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12039-018-1470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12039-018-1470-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Sciences%26atitle%3DDelineating%252Ban%252Balternate%252Bconvergent%252Bsynthesis%252Bof%252Bbrexpiprazole%25253A%252Ba%252Bnovel%252Buse%252Bof%252Bcommercial%252B6%25252C7-dihydrobenzo%25255Bb%25255Dthiophen-4%2525285H%252529-one%252Bas%252Bprecursor%252Bto%252Ban%252Befficacious%252BBuchwald%2525E2%252580%252593Hartwig%252Bamination%252Bstep%26aulast%3DKumar%26aufirst%3DA%2BSravanth%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinpeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Cong  Zheng</span>, <span class="hlFld-ContribAuthor ">Lijun  Lei</span>, <span class="hlFld-ContribAuthor ">Kai  Lin</span>, <span class="hlFld-ContribAuthor ">Chuanming  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2-Oxindoles from Substituted Indoles by Hypervalent-Iodine Oxidation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (12)
                                     , 1437-1442. <a href="https://doi.org/10.1002/ejoc.201701807" title="DOI URL">https://doi.org/10.1002/ejoc.201701807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201701807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201701807%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B2-Oxindoles%252Bfrom%252BSubstituted%252BIndoles%252Bby%252BHypervalent-Iodine%252BOxidation%26aulast%3DJiang%26aufirst%3DXinpeng%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D12%26spage%3D1437%26epage%3D1442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian M.  Cawrse</span>, <span class="hlFld-ContribAuthor ">Rena S.  Lapidus</span>, <span class="hlFld-ContribAuthor ">Brandon  Cooper</span>, <span class="hlFld-ContribAuthor ">Eun Yong  Choi</span>, <span class="hlFld-ContribAuthor ">Katherine L.  Seley-Radtke</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Properties of Halogenated Pyrrolo[3,2-
              d
              ]pyrimidines with Decreased Toxicity via N5 Substitution. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (2)
                                     , 178-185. <a href="https://doi.org/10.1002/cmdc.201700641" title="DOI URL">https://doi.org/10.1002/cmdc.201700641</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700641%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DAnticancer%252BProperties%252Bof%252BHalogenated%252BPyrrolo%25255B3%25252C2-%252Bd%252B%25255Dpyrimidines%252Bwith%252BDecreased%252BToxicity%252Bvia%252BN5%252BSubstitution%26aulast%3DCawrse%26aufirst%3DBrian%2BM.%26date%3D2018%26date%3D2017%26volume%3D13%26issue%3D2%26spage%3D178%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra N.  Milik</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 131-151. <a href="https://doi.org/10.1016/j.ejmech.2017.07.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHow%252Bto%252Btrain%252Byour%252Binhibitor%25253A%252BDesign%252Bstrategies%252Bto%252Bovercome%252Bresistance%252Bto%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252Binhibitors%26aulast%3DMilik%26aufirst%3DSandra%2BN.%26date%3D2017%26volume%3D142%26spage%3D131%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Qu</span>, <span class="hlFld-ContribAuthor ">A.  Yan</span>, <span class="hlFld-ContribAuthor ">J. S.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2017,</strong> <em>28 </em>
                                    (2)
                                     , 111-132. <a href="https://doi.org/10.1080/1062936X.2017.1284898" title="DOI URL">https://doi.org/10.1080/1062936X.2017.1284898</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2017.1284898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2017.1284898%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DSAR%252Band%252BQSAR%252Bstudy%252Bon%252Bthe%252Bbioactivities%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor-2%252B%252528HER2%252529%252Binhibitors%26aulast%3DQu%26aufirst%3DD.%26date%3D2017%26date%3D2017%26volume%3D28%26issue%3D2%26spage%3D111%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chang  Yang</span>, <span class="hlFld-ContribAuthor ">Tianbo  Liu</span>, <span class="hlFld-ContribAuthor ">Bairong  Xia</span>, <span class="hlFld-ContribAuthor ">Lina  Gu</span>, <span class="hlFld-ContribAuthor ">Ge  Lou</span>. </span><span class="cited-content_cbyCitation_article-title">Correlation of Collagen Triple Helix Repeat Containing 1 Overexpression With Lymph Node and Peritoneal Metastasis in Epithelial Ovarian Cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Gynecologic Cancer</span><span> <strong>2017,</strong> <em>27 </em>
                                    (1)
                                     , 22-27. <a href="https://doi.org/10.1097/IGC.0000000000000850" title="DOI URL">https://doi.org/10.1097/IGC.0000000000000850</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/IGC.0000000000000850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FIGC.0000000000000850%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Gynecologic%2520Cancer%26atitle%3DCorrelation%252Bof%252BCollagen%252BTriple%252BHelix%252BRepeat%252BContaining%252B1%252BOverexpression%252BWith%252BLymph%252BNode%252Band%252BPeritoneal%252BMetastasis%252Bin%252BEpithelial%252BOvarian%252BCancer%26aulast%3DYang%26aufirst%3DChang%26date%3D2017%26date%3D2016%26volume%3D27%26issue%3D1%26spage%3D22%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Osamu  Yabe</span>, <span class="hlFld-ContribAuthor ">Akihiro  Suzuki</span>, <span class="hlFld-ContribAuthor ">Tomomi  Ikemoto</span>. </span><span class="cited-content_cbyCitation_article-title">A Convergent Scale-up Synthesis of A HER2/EGRF Dual Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2017,</strong> <em>94 </em>
                                    (4)
                                     , 702. <a href="https://doi.org/10.3987/COM-17-13663" title="DOI URL">https://doi.org/10.3987/COM-17-13663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-17-13663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-17-13663%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DA%252BConvergent%252BScale-up%252BSynthesis%252Bof%252BA%252BHER2%25252FEGRF%252BDual%252BKinase%252BInhibitor%26aulast%3DYabe%26aufirst%3DOsamu%26date%3D2017%26volume%3D94%26issue%3D4%26spage%3D702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Xie</span>, <span class="hlFld-ContribAuthor ">Ying  Hu</span>, <span class="hlFld-ContribAuthor ">Huixin  Wan</span>, <span class="hlFld-ContribAuthor ">Yanwei  Hu</span>, <span class="hlFld-ContribAuthor ">Shaohua  Chen</span>, <span class="hlFld-ContribAuthor ">Shilei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yinan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An efficient synthesis of 4,6-substituted pyrrolo[3,2-d]pyrimidines by silver-catalyzed cyclization of acetylene amine. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2016,</strong> <em>57 </em>
                                    (22)
                                     , 2418-2421. <a href="https://doi.org/10.1016/j.tetlet.2016.04.077" title="DOI URL">https://doi.org/10.1016/j.tetlet.2016.04.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2016.04.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2016.04.077%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DAn%252Befficient%252Bsynthesis%252Bof%252B4%25252C6-substituted%252Bpyrrolo%25255B3%25252C2-d%25255Dpyrimidines%252Bby%252Bsilver-catalyzed%252Bcyclization%252Bof%252Bacetylene%252Bamine%26aulast%3DXie%26aufirst%3DRui%26date%3D2016%26volume%3D57%26issue%3D22%26spage%3D2418%26epage%3D2421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minzhi  Hou</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Cheng</span>, <span class="hlFld-ContribAuthor ">Hongwei  Shen</span>, <span class="hlFld-ContribAuthor ">Shanyang  He</span>, <span class="hlFld-ContribAuthor ">Yang  Li</span>, <span class="hlFld-ContribAuthor ">Yunping  Pan</span>, <span class="hlFld-ContribAuthor ">Chongjin  Feng</span>, <span class="hlFld-ContribAuthor ">Xinlin  Chen</span>, <span class="hlFld-ContribAuthor ">Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Millicent  Lin</span>, <span class="hlFld-ContribAuthor ">Liantang  Wang</span>, <span class="hlFld-ContribAuthor ">Zunfu  Ke</span>. </span><span class="cited-content_cbyCitation_article-title">High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2015,</strong> <em>6 </em>
                                    (34)
                                     , 35813-35829. <a href="https://doi.org/10.18632/oncotarget.5358" title="DOI URL">https://doi.org/10.18632/oncotarget.5358</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.5358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.5358%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DHigh%252Bexpression%252Bof%252BCTHRC1%252Bpromotes%252BEMT%252Bof%252Bepithelial%252Bovarian%252Bcancer%252B%252528EOC%252529%252Band%252Bis%252Bassociated%252Bwith%252Bpoor%252Bprognosis%26aulast%3DHou%26aufirst%3DMinzhi%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D34%26spage%3D35813%26epage%3D35829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kartik W.  Temburnikar</span>, <span class="hlFld-ContribAuthor ">Christina R.  Ross</span>, <span class="hlFld-ContribAuthor ">Gerald M.  Wilson</span>, <span class="hlFld-ContribAuthor ">Jan  Balzarini</span>, <span class="hlFld-ContribAuthor ">Brian M.  Cawrse</span>, <span class="hlFld-ContribAuthor ">Katherine L.  Seley-Radtke</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4354-4363. <a href="https://doi.org/10.1016/j.bmc.2015.06.025" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.06.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.06.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAntiproliferative%252Bactivities%252Bof%252Bhalogenated%252Bpyrrolo%25255B3%25252C2-d%25255Dpyrimidines%26aulast%3DTemburnikar%26aufirst%3DKartik%2BW.%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4354%26epage%3D4363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zeshan  Yousuf</span>, <span class="hlFld-ContribAuthor ">Andrew K.  Richards</span>, <span class="hlFld-ContribAuthor ">Andrew N.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Bruno  Linclau</span>, <span class="hlFld-ContribAuthor ">David C.  Harrowven</span>. </span><span class="cited-content_cbyCitation_article-title">The development of a short route to the API ropinirole hydrochloride. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2015,</strong> <em>13 </em>
                                    (42)
                                     , 10532-10539. <a href="https://doi.org/10.1039/C5OB01739D" title="DOI URL">https://doi.org/10.1039/C5OB01739D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5OB01739D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5OB01739D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DThe%252Bdevelopment%252Bof%252Ba%252Bshort%252Broute%252Bto%252Bthe%252BAPI%252Bropinirole%252Bhydrochloride%26aulast%3DYousuf%26aufirst%3DZeshan%26date%3D2015%26date%3D2015%26volume%3D13%26issue%3D42%26spage%3D10532%26epage%3D10539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Schroeder</span>, <span class="hlFld-ContribAuthor ">Cheryl  Stevens</span>, <span class="hlFld-ContribAuthor ">Jayalakshmi  Sridhar</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2014,</strong> <em>19 </em>
                                    (9)
                                     , 15196-15212. <a href="https://doi.org/10.3390/molecules190915196" title="DOI URL">https://doi.org/10.3390/molecules190915196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules190915196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules190915196%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSmall%252BMolecule%252BTyrosine%252BKinase%252BInhibitors%252Bof%252BErbB2%25252FHER2%25252FNeu%252Bin%252Bthe%252BTreatment%252Bof%252BAggressive%252BBreast%252BCancer%26aulast%3DSchroeder%26aufirst%3DRichard%26date%3D2014%26date%3D2014%26volume%3D19%26issue%3D9%26spage%3D15196%26epage%3D15212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si-Ning  Li</span>, <span class="hlFld-ContribAuthor ">Huan-Qiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor inhibitors: a patent review (2010 – present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (3)
                                     , 309-321. <a href="https://doi.org/10.1517/13543776.2014.871527" title="DOI URL">https://doi.org/10.1517/13543776.2014.871527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.871527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.871527%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DLi%26aufirst%3DSi-Ning%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D309%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liangce  Rong</span>, <span class="hlFld-ContribAuthor ">Xianyong  Wei</span>, <span class="hlFld-ContribAuthor ">Shimin  Tao</span>, <span class="hlFld-ContribAuthor ">Yao  Lu</span>, <span class="hlFld-ContribAuthor ">Ruilun  Xie</span>, <span class="hlFld-ContribAuthor ">Jun  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zong</span>. </span><span class="cited-content_cbyCitation_article-title">An efficient and convenient one-pot multicomponent synthesis of novel pyrimidine derivatives: N-(4-aryl-6-(pyridin-2-yl)pyrimidin-2-yl)cyanamides. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2013,</strong> <em>39 </em>
                                    (4)
                                     , 1907-1916. <a href="https://doi.org/10.1007/s11164-012-0724-5" title="DOI URL">https://doi.org/10.1007/s11164-012-0724-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-012-0724-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-012-0724-5%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DAn%252Befficient%252Band%252Bconvenient%252Bone-pot%252Bmulticomponent%252Bsynthesis%252Bof%252Bnovel%252Bpyrimidine%252Bderivatives%25253A%252BN-%2525284-aryl-6-%252528pyridin-2-yl%252529pyrimidin-2-yl%252529cyanamides%26aulast%3DRong%26aufirst%3DLiangce%26date%3D2013%26date%3D2012%26volume%3D39%26issue%3D4%26spage%3D1907%26epage%3D1916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youichi  Kawakita</span>, <span class="hlFld-ContribAuthor ">Masaki  Seto</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Ohashi</span>, <span class="hlFld-ContribAuthor ">Toshiya  Tamura</span>, <span class="hlFld-ContribAuthor ">Tadashi  Yusa</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Miki</span>, <span class="hlFld-ContribAuthor ">Hidehisa  Iwata</span>, <span class="hlFld-ContribAuthor ">Hidenori  Kamiguchi</span>, <span class="hlFld-ContribAuthor ">Toshimasa  Tanaka</span>, <span class="hlFld-ContribAuthor ">Satoshi  Sogabe</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Ohta</span>, <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel pyrimido[4,5- b ]azepine derivatives as HER2/EGFR dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (8)
                                     , 2250-2261. <a href="https://doi.org/10.1016/j.bmc.2013.02.014" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Bpyrimido%25255B4%25252C5-%252Bb%252B%25255Dazepine%252Bderivatives%252Bas%252BHER2%25252FEGFR%252Bdual%252Binhibitors%26aulast%3DKawakita%26aufirst%3DYouichi%26date%3D2013%26volume%3D21%26issue%3D8%26spage%3D2250%26epage%3D2261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youichi  Kawakita</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Miwa</span>, <span class="hlFld-ContribAuthor ">Masaki  Seto</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Banno</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Ohta</span>, <span class="hlFld-ContribAuthor ">Toshiya  Tamura</span>, <span class="hlFld-ContribAuthor ">Tadashi  Yusa</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Miki</span>, <span class="hlFld-ContribAuthor ">Hidenori  Kamiguchi</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Ikeda</span>, <span class="hlFld-ContribAuthor ">Toshimasa  Tanaka</span>, <span class="hlFld-ContribAuthor ">Keiji  Kamiyama</span>, <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: Improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (20)
                                     , 6171-6180. <a href="https://doi.org/10.1016/j.bmc.2012.08.002" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bpyrrolo%25255B3%25252C2-d%25255Dpyrimidine%252BHER2%25252FEGFR%252Bdual%252Binhibitors%25253A%252BImprovement%252Bof%252Bthe%252Bphysicochemical%252Band%252Bpharmacokinetic%252Bprofiles%252Bfor%252Bpotent%252Bin%252Bvivo%252Banti-tumor%252Befficacy%26aulast%3DKawakita%26aufirst%3DYouichi%26date%3D2012%26volume%3D20%26issue%3D20%26spage%3D6171%26epage%3D6180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of <b>1</b> (TAK-285).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking model of the designed compound with HER2 protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of new back pocket binders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) H<sub>2</sub>, Pt/C, EtOAc, rt; (c) (i) 2-propanol, 80 °C, (ii) 1 N NaOH, MeOH, rt; (d) EDC, HOBt, Et<sub>3</sub>N, 2-methylpropan-2-amine, DMF, rt.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0011.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Anilines Bearing a 1,3-Dihydro-2<i>H</i>-indol-2-one Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) NBS, <i>tert-</i>BuOH, THF, rt; (c) 1 N HCl, THF, 70 °C; (d) H<sub>2</sub>, Pt/C, MeOH, THF, rt.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0012.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Anilines Bearing a 2,3-Dihydro-1<i>H</i>-isoindol-1-one Ring (I)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) NBS, AIBN, CF<sub>3</sub>–Ph, 100 °C; (c) 28% aq. NH<sub>3</sub>, THF, rt; (d) H<sub>2</sub>, Pt/C, MeOH, THF, rt.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0013.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Aniline Bearing a 2,3-Dihydro-1<i>H</i>-isoindol-1-one Ring (II)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NBS, AIBN, CF<sub>3</sub>–Ph, 100 °C; (b) 28% aq. NH<sub>3</sub>, THF, rt; (c) 48% aq. HBr, 100 °C; (d) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (e) H<sub>2</sub>, Pt/C, MeOH, THF, rt.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0014.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Aniline Bearing a 2,3-Dihydro-1<i>H</i>-isoindol-1-one Ring (III)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NBS, AIBN, CF<sub>3</sub>–Ph, 100 °C; (b) 28% aq. NH<sub>3</sub>, THF, rt; (c) 48% aq. HBr, 100 °C; (d) H<sub>2</sub>, Pt/C, MeOH, rt; (e) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (f) H<sub>2</sub>, Pt/C, MeOH, THF, rt.</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0015.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Aniline Bearing a 1<i>H</i>-Indole Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) Fe, CaCl<sub>2</sub>, aq. EtOH, 100 °C.</p></p></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0016.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Aniline Bearing a 1-Benzothiophene Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) PhMe<sub>3</sub>NBr<sub>3</sub>, THF, rt, (ii) Li<sub>2</sub>CO<sub>3</sub>, LiBr, DMF, 150 °C; (b) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (c) Fe, CaCl<sub>2</sub>, aq. EtOH, 100 °C.</p></p></figure><figure data-id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0017.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Aniline Bearing a 1<i>H</i>-Indazole Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaNO<sub>2</sub>, H<sub>2</sub>SO<sub>4,</sub> 100 °C; (b) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (c) H<sub>2</sub>, Pt/C, AcOEt, rt.</p></p></figure><figure data-id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0018.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Aniline Bearing a 1,2-Benzisothiazole Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) BnSH, <i>tert-</i>BuONa, DMF, rt; (b) H<sub>2</sub>NOSO<sub>3</sub>H, Thioanisole, CH<sub>3</sub>CN, H<sub>2</sub>O, rt; (c) PyHCl, 195 °C; (d) <b>4</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (e) Fe, 1 N HCl, EtOH, 80 °C.</p></p></figure><figure data-id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0019.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Introduction of Various Anilino Groups to the Pyrrolo[3,2-<i>d</i>]pyrimidine Scaffold<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) aniline <b>14a</b>–<b>m</b>, 2-propanol, 80 °C, (ii) 1 N NaOH, MeOH, rt.</p></p></figure><figure data-id="sch11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0020.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Optimization of 5-Caboxamido Group<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) <b>14m</b>, 2-propanol, 80 °C, (ii) 4 N HCl in EtOAc, EtOH, 80 °C; (b) RCO<sub>2</sub>H or 1-(<i>tert</i>-butoxycarbonyl)proline or <i>N</i>-(<i>tert</i>-butoxycarbonyl)-2-methylalanine, EDC, HOBt, Et<sub>3</sub>N, DMF, rt; (c) 2,2-dimethylpropanoic acid anhydride, Et<sub>3</sub>N, DMF, rt; (d) 4N HCl in EtOAc, EtOH, 80 °C or 1 N HCl, EtOH, 80 °C; (e) MsOH, EtOAc or DMSO, rt.</p></p></figure><figure data-id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dissociation profiles of pyrrolo[3,2-<i>d</i>]pyrimidines from HER2 (A) and EGFR (B). Phosphorylation of peptide substrate as a function of time is shown. The reaction was initiated by diluting a preformed enzyme–inhibitor complex into reaction buffer. To determine the dissociation kinetics of the inhibitors from HER2 and EGFR, the recovery of enzyme activity from a preformed enzyme–inhibitor complex was evaluated using the Alphascreen system (PerkinElmer, USA). The PI strengths of compounds, compared with <b>1</b>, are indicated by 2 asterisks (**) when the compounds showed obviously strong PI profiles and by a single asterisk (*) when the PI was weak compared with that of <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking model of indolone derivative <b>42h</b> with HER2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Dissociation profiles of pyrrolo[3,2-<i>d</i>]pyrimidines from HER2 (A) and EGFR (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/medium/jm-2012-00185p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Efficacy studies of <b>51m</b> in the 4–1ST xenograft model (A) and the CAL27 xenograft model (B) in mice. (A) Dose level 50 mg/kg; <i>P</i> ≤ 0.0025 vs control at day 14 (one-tailed Shirley–Williams test). (B) Dose level 100 mg/kg; <i>P</i> ≤ 0.0025 vs control at day 14 (one-tailed Shirley–Williams test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300185p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 9 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyajima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ooi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoshima, K.</span><span> </span><span class="NLM_article-title">The erbB gene of avian erythroblastosis virus is a member of the <i>src</i> gene family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1983&pages=71-78&author=T.+Yamamotoauthor=T.+Nishidaauthor=N.+Miyajimaauthor=S.+Kawaiauthor=T.+Ooiauthor=K.+Toyoshima&title=The+erbB+gene+of+avian+erythroblastosis+virus+is+a+member+of+the+src+gene+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DMiyajima%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%26aulast%3DOoi%26aufirst%3DT.%26aulast%3DToyoshima%26aufirst%3DK.%26atitle%3DThe%2520erbB%2520gene%2520of%2520avian%2520erythroblastosis%2520virus%2520is%2520a%2520member%2520of%2520the%2520src%2520gene%2520family%26jtitle%3DCell%26date%3D1983%26volume%3D35%26spage%3D71%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Traxler, P.</span><span> </span><span class="NLM_article-title">Tyrosine kinases as targets in cancer therapy—successes and failures</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1517%2F14728222.7.2.215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=12667099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVGrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=215-234&author=P.+Traxler&title=Tyrosine+kinases+as+targets+in+cancer+therapy%E2%80%94successes+and+failures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets in cancer therapy - successes and failures</span></div><div class="casAuthors">Traxler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-234</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases play a crucial role in signal transduction and also in cellular proliferation, differentiation, and various regulatory mechanisms.  The inhibition of growth-related kinases, esp. Tyr kinases, might therefore provide new therapies for diseases such as cancer.  Due to the enormous progress that was made in the past few years in the identification of the human genome, in mol. and cell biol. technologies, in structural biol. and in bioinformatics, the no. of receptor and non-receptor Tyr kinases that were identified as valuable mol. targets has greatly increased.  Currently, > 20 different Tyr kinase targets are under evaluation in drug discovery projects in oncol.  The progress made in the crystn. of protein kinases, in most cases complexed with ATP-site-directed inhibitors, has confirmed that the ATP-binding domain of Tyr kinases is an attractive target for rational drug design; > 20 ATP-competitive, low mol. wt. inhibitors are in various phases of clin. evaluation.  Meanwhile, clin. proof-of-concept (POC) was achieved with several antibodies and small mols. targeted against Tyr kinases.  With Herceptin, Glivec, and Iressa (registered in Japan), the 1st kinase drugs have entered the market.  This review describes the preclin. and clin. status of low mol. wt. drugs targeted against different Tyr kinases (e.g., epidermal growth factor receptor [EGFR], vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], Kit, Fms-like Tyr kinase [Flt]-3), briefly describes new targets, and provides a crit. anal. of the current situation in the area of Tyr kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlyxUqnX26eLVg90H21EOLACvtfcHk0lhivvBHdFh5sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVGrt7w%253D&md5=aac69b84205b6525b0acb4ab2a43f219</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1517%2F14728222.7.2.215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.7.2.215%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26atitle%3DTyrosine%2520kinases%2520as%2520targets%2520in%2520cancer%2520therapy%25E2%2580%2594successes%2520and%2520failures%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2003%26volume%3D7%26spage%3D215%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and Imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+Imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0liU7eHkuKhYVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520Imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4686</span><span class="NLM_x">–</span> <span class="NLM_lpage">4691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1016%2Fj.bmcl.2006.05.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=16777410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4686-4691&author=K.+G.+Petrovauthor=Y.+M.+Zhangauthor=M.+Carterauthor=G.+S.+Cockerillauthor=S.+Dickersonauthor=C.+A.+Gauthierauthor=Y.+Guoauthor=R.+A.+Mookauthor=D.+W.+Rusnakauthor=A.+L.+Walkerauthor=E.+R.+Woodauthor=K.+E.+Lackey&title=Optimization+and+SAR+for+dual+ErbB-1%2FErbB-2+tyrosine+kinase+inhibition+in+the+6-furanylquinazoline+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span></div><div class="casAuthors">Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4686-4691</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino structure provided the best enzyme potency and cellular selectivity.  Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy.  The discovery of lapatinib emerged from this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtejUjyH9in7Vg90H21EOLACvtfcHk0liU7eHkuKhYVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D&md5=946712927ab1a7940ea3ef2fea7574b5</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DDickerson%26aufirst%3DS.%26aulast%3DGauthier%26aufirst%3DC.%2BA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DOptimization%2520and%2520SAR%2520for%2520dual%2520ErbB-1%252FErbB-2%2520tyrosine%2520kinase%2520inhibition%2520in%2520the%25206-furanylquinazoline%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4686%26epage%3D4691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2s"><span><span class="NLM_label">(d) </span> Package Insert. Tykerb (Lapatinib); <span class="NLM_publisher-name">GlaxoSmithKline</span>: <span class="NLM_publisher-loc">Research Triangle Park</span>, <span class="NLM_publisher-loc">NC</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Package+Insert.+Tykerb+%28Lapatinib%29%3B+GlaxoSmithKline%3A+Research+Triangle+Park%2C+NC%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2s&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26pub%3DGlaxoSmithKline%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Iqbal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenoglio-Preiser, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danenberg, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span> </span><span class="NLM_article-title">Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2610</span><span class="NLM_x">–</span> <span class="NLM_lpage">2615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1093%2Fannonc%2Fmdr021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=21415234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fht1Wntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2610-2615&author=S.+Iqbalauthor=B.+Goldmanauthor=C.+M.+Fenoglio-Preiserauthor=H.+J.+Lenzauthor=W.+Zhangauthor=K.+D.+Danenbergauthor=S.+I.+Shibataauthor=C.+D.+Blanke&title=Southwest+Oncology+Group+study+S0413%3A+a+phase+II+trial+of+lapatinib+%28GW572016%29+as+first-line+therapy+in+patients+with+advanced+or+metastatic+gastric+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer</span></div><div class="casAuthors">Iqbal S; Goldman B; Fenoglio-Preiser C M; Lenz H J; Zhang W; Danenberg K D; Shibata S I; Blanke C D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2610-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.  PATIENTS AND METHODS:  The primary objective of this study was to assess response rate.  Secondary objectives included overall survival (OS), toxicity, and the relationship of EGFR, ErbB2, and markers of angiogenesis with clinical outcome.  Lapatinib was administered to chemonaive metastatic gastric cancer patients at a dose of 1500 mg orally daily for 28 days.  RESULTS:  The study enrolled 47 patients from February 2005 until May 2006.  Four patients (9%) had a confirmed partial response (PR), 1 (2%) had an unconfirmed PR, and 10 (23%) had stable disease.  Median (95% confidence interval) time to treatment failure was 1.9 (1.6-3.1) months and OS was 4.8 (3.2-7.4) months.  Significant adverse events: one grade 4 cardiac ischemia/infarction, one grade 4 fatigue, and one grade 4 emesis.  One treatment-related death was due to central nervous system ischemia.  An exploratory analysis of markers revealed gene expression of HER2, interleukin (IL)-8 and genomic polymorphisms IL-8, and vascular endothelial growth factor correlated with OS.  CONCLUSIONS:  Lapatinib is well tolerated, with modest single-agent activity in advanced/metastatic gastric cancer patients.  Potential molecular correlatives were identified which warrant further validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5Jcr3zdCk3kodMGTatQ7LfW6udTcc2eZxb4gWZg7GIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fht1Wntg%253D%253D&md5=cc244e672fe9b0eba2b4910957abfea9</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr021%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DB.%26aulast%3DFenoglio-Preiser%26aufirst%3DC.%2BM.%26aulast%3DLenz%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDanenberg%26aufirst%3DK.%2BD.%26aulast%3DShibata%26aufirst%3DS.%2BI.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26atitle%3DSouthwest%2520Oncology%2520Group%2520study%2520S0413%253A%2520a%2520phase%2520II%2520trial%2520of%2520lapatinib%2520%2528GW572016%2529%2520as%2520first-line%2520therapy%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520gastric%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2610%26epage%3D2615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Whang, Y. E.; Armstrong, A. J.; Rathmell, W. K.; Godley, P. A.; Kim, W. Y.; Pruthi, R. S.; Wallen, E. M.; Crane, J. M.; Moore, D. T.; Grigson, G.; Morris, K.; Watkins, C. P.; George, D. J.</span><span> </span><span class="NLM_article-title">A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer</span>.  <span class="citation_source-journal">Urol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">; </span>doi:<span class="refDoi"> DOI: 10.1016/j.urolonc.2010.09.018</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1016%2Fj.urolonc.2010.09.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Y.+E.+Whang&author=A.+J.+Armstrong&author=W.+K.+Rathmell&author=P.+A.+Godley&author=W.+Y.+Kim&author=R.+S.+Pruthi&author=E.+M.+Wallen&author=J.+M.+Crane&author=D.+T.+Moore&author=G.+Grigson&author=K.+Morris&author=C.+P.+Watkins&author=D.+J.+George&title=A+phase+II+study+of+lapatinib%2C+a+dual+EGFR+and+HER-2+tyrosine+kinase+inhibitor%2C+in+patients+with+castration-resistant+prostate+cancer&doi=10.1016%2Fj.urolonc.2010.09.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2010.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2010.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DY.%2BE.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520lapatinib%252C%2520a%2520dual%2520EGFR%2520and%2520HER-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DUrol.%2520Oncol.%26date%3D2011%26doi%3D10.1016%2Fj.urolonc.2010.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Mimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kono, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiba, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizukami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, H.</span><span> </span><span class="NLM_article-title">Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody dependent cellular cytoxicity (ADCC) of EGFR and HER2 over-expressing esophageal cancer cell lines</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">–</span> <span class="NLM_lpage">2416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1002%2Fijc.25896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=21207425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=2408-2416&author=K.+Mimuraauthor=K.+Konoauthor=T.+Maruyamaauthor=M.+Watanabeauthor=S.+Izawaauthor=S.+Shibaauthor=Y.+Mizukamiauthor=Y.+Kawaguchiauthor=M.+Inoueauthor=T.+Konoauthor=A.+Choudhuryauthor=R.+Kiesslingauthor=H.+Fujii&title=Lapatinib+inhibits+receptor+phosphorylation+and+cell+growth+and+enhances+antibody+dependent+cellular+cytoxicity+%28ADCC%29+of+EGFR+and+HER2+over-expressing+esophageal+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines</span></div><div class="casAuthors">Mimura, Kousaku; Kono, Koji; Maruyama, Takanori; Watanabe, Mitsuaki; Izawa, Shinichiro; Shiba, Shugo; Mizukami, Yoshiki; Kawaguchi, Yoshihiko; Inoue, Masayuki; Kono, Tetsuo; Choudhury, Aniruddha; Kiessling, Rolf; Fujii, Hideki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2408-2416</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Lapatinib is a dual tyrosine kinase inhibitor of the EGFR and HER2 tyrosine kinase domains.  EGFR is expressed in 33.3% and HER2 in 30.3% of esophageal squamous cell carcinomas (ESCCs).  To explore the potential utility of Lapatinib for therapy of ESCC patients, we evaluated the effect of Lapatinib on a panel of ESCC cell lines.  EGFR and HER2 expression by the cell lines was established, and the effects of Lapatinib on inhibition of the phosphorylation of HER2, antiproliferative effect, apoptosis-inducing activity and accumulation of HER2 and EGFR on cell surface were evaluated.  Addnl., the combined effect of Lapatinib together with Herceptin or Cetuximab on cell-mediated cytotoxicity was evaluated.  Lapatinib inhibited HER2 phosphorylation in HER2-overexpressing, HER2 gene amplification pos. ESCC cell line.  Lapatinib also inhibited cell proliferation, induced apoptosis and caused the surface accumulation of HER2 and EGFR in ESCC cell lines.  Addn. of Lapatinib increased Herceptin-mediated antibody-dependent cell-mediated cytotoxicity by 15-25% with three ESCC target cell lines.  Similarly, Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity also increased by 15-30% in two ESCC cell lines on addn. of Lapatinib.  Cumulatively, the data indicate that Lapatinib has activity in EGFR- and/or HER2-expressing ESCC cells, and the combination therapy of Lapatinib and Cetuximab/Herceptin is a promising strategy in ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT06zCkLx1hbVg90H21EOLACvtfcHk0lgrzmKKzgVAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtrfF&md5=a17f3b214307fc8f3cccb60b23bda8f5</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1002%2Fijc.25896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25896%26sid%3Dliteratum%253Aachs%26aulast%3DMimura%26aufirst%3DK.%26aulast%3DKono%26aufirst%3DK.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DIzawa%26aufirst%3DS.%26aulast%3DShiba%26aufirst%3DS.%26aulast%3DMizukami%26aufirst%3DY.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DKono%26aufirst%3DT.%26aulast%3DChoudhury%26aufirst%3DA.%26aulast%3DKiessling%26aufirst%3DR.%26aulast%3DFujii%26aufirst%3DH.%26atitle%3DLapatinib%2520inhibits%2520receptor%2520phosphorylation%2520and%2520cell%2520growth%2520and%2520enhances%2520antibody%2520dependent%2520cellular%2520cytoxicity%2520%2528ADCC%2529%2520of%2520EGFR%2520and%2520HER2%2520over-expressing%2520esophageal%2520cancer%2520cell%2520lines%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D2408%26epage%3D2416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Ross, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span> </span><span class="NLM_article-title">Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1949</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1158%2F1078-0432.CCR-08-3328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=20215545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyhurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1938-1949&author=H.+J.+Rossauthor=G.+R.+Blumenscheinauthor=J.+Aisnerauthor=N.+Damjanovauthor=A.+Dowlatiauthor=J.+Garstauthor=J.+R.+Rigasauthor=M.+Smylieauthor=H.+Hassaniauthor=K.+E.+Allenauthor=L.+Leopoldauthor=T.+Z.+Zaksauthor=F.+A.+Shepherd&title=Randomized+phase+II+multicenter+trial+of+two+schedules+of+lapatinib+as+first-+or+second-line+monotherapy+in+patients+with+advanced+or+metastatic+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Ross, Helen J.; Blumenschein, George R., Jr.; Aisner, Joseph; Damjanov, Nevena; Dowlati, Afshin; Garst, Jennifer; Rigas, James R.; Smylie, Michael; Hassani, Habib; Allen, Kimberly E.; Leopold, Lance; Zaks, Tal Z.; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1938-1949</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.  Exptl. Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance.  Patients could have had a max. of one prior systemic therapy (chemotherapy or biol. therapy) for NSCLC.  Safety and activity were assessed every 4 and 8 wk, resp.  Tumors were analyzed for EGFR and HER2 mutations and/or amplifications.  RESULTS: Of 75 patients in the nontargeted population, 1 (1.3%) had partial response and 16 (21%) had stable disease of ≥24 wk.  No complete or partial responses were obsd. in 56 patients in the targeted population; 14 (25%) had stable disease of ≥24 wk.  No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification.  No mutations in HER2 were found.  One of two patients with HER2 amplification had a 51% decrease in tumor size; however, this response was unconfirmed.  The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia.  Adverse events were similar across dosing regimens.  CONCLUSIONS: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups.  Lapatinib monotherapy did not induce a significant no. of tumor regressions in NSCLC.  Further studies may be warranted to det. whether lapatinib is active in combination with other agents in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-5ZsLpn50LrVg90H21EOLACvtfcHk0lgrzmKKzgVAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyhurY%253D&md5=0bfa99df35f30bb9e9ef0b2addb23e28</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-3328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-3328%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DH.%2BJ.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DAisner%26aufirst%3DJ.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DGarst%26aufirst%3DJ.%26aulast%3DRigas%26aufirst%3DJ.%2BR.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DHassani%26aufirst%3DH.%26aulast%3DAllen%26aufirst%3DK.%2BE.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DZaks%26aufirst%3DT.%2BZ.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DRandomized%2520phase%2520II%2520multicenter%2520trial%2520of%2520two%2520schedules%2520of%2520lapatinib%2520as%2520first-%2520or%2520second-line%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D1938%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ooi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehana, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunitomo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobashi, Y.</span><span> </span><span class="NLM_article-title">Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1038%2Fmodpathol.3800137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=15143334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=895-904&author=A.+Ooiauthor=T.+Takehanaauthor=X.+Liauthor=S.+Suzukiauthor=K.+Kunitomoauthor=H.+Iinoauthor=H.+Fujiiauthor=Y.+Takedaauthor=Y.+Dobashi&title=Protein+overexpression+and+gene+amplification+of+HER-2+and+EGFR+in+colorectal+cancers%3A+an+immunohistochemical+and+fluorescent+in+situ+hybridization+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study</span></div><div class="casAuthors">Ooi, Akishi; Takehana, Takuo; Li, Xiaoling; Suzuki, Shioto; Kunitomo, Kazuyoshi; Iino, Hiroshi; Fujii, Hideki; Takeda, Yasuhisa; Dobashi, Yoh</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">895-904</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Overexpression of HER-2 and the epidermal growth factor receptor (EGFR) has been obsd. in many cancers, sometimes accompanied by gene amplification.  To assess whether novel chemotherapies targeting these overexpressed proteins may be effective for the treatment of colorectal cancers, we examd. the exact frequency of HER-2 and EGFR overexpression, the relationship between gene amplification and protein expression, and the heterogeneity of gene amplification within and between primary and metastatic tumors.  We evaluated 244 colorectal cancers immunohistochem.  All tumors found to overexpress HER-2 or EGFR were further analyzed for gene amplification by fluorescent in situ DNA hybridization.  Overexpression of HER-2 and EGFR was found in 8 (3%) and 19 (8%) of the 244 colorectal carcinomas, resp.  Gene amplification was obsd. in 100 and 58% of the tumors exhibiting HER-2 and EGFR overexpression, resp.  HER-2 amplification in cancer cells was characterized by clusters of hybridization signals, suggesting amplicons in homogeneously staining regions that were predominant in most primary and metastatic tumors.  EGFR amplification, obsd. as scattered signals reminiscent of amplicons in double minute chromosomes, or coamplification of EGFR with the centromeric regions was obsd. as a minor population within primary tumors, and found in variety of populations in metastatic tumors.  Overexpression of HER-2 and EGFR were obsd. in only a small fraction of colorectal carcinomas, but were frequently accompanied by gene amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps8JLiZoJAWbVg90H21EOLACvtfcHk0lhTM00o5GLrtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOltrk%253D&md5=e073b560295b3ca3331a7f4fe11f59f7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.3800137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.3800137%26sid%3Dliteratum%253Aachs%26aulast%3DOoi%26aufirst%3DA.%26aulast%3DTakehana%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DKunitomo%26aufirst%3DK.%26aulast%3DIino%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DDobashi%26aufirst%3DY.%26atitle%3DProtein%2520overexpression%2520and%2520gene%2520amplification%2520of%2520HER-2%2520and%2520EGFR%2520in%2520colorectal%2520cancers%253A%2520an%2520immunohistochemical%2520and%2520fluorescent%2520in%2520situ%2520hybridization%2520study%26jtitle%3DMod.%2520Pathol.%26date%3D2004%26volume%3D17%26spage%3D895%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghlul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy</span> <span class="citation_source-journal">Cancer Cell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=81-93&author=D.+Liauthor=T.+Shimamuraauthor=H.+Jiauthor=L.+Chenauthor=H.+J.+Haringsmaauthor=K.+McNamaraauthor=M.-C.+Liangauthor=S.+A.+Pereraauthor=S.+Zaghlulauthor=C.+L.+Borgmanauthor=S.+Kuboauthor=M.+Takahashiauthor=Y.+Sunauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=N.+I.+Lindemanauthor=P.+A.+J%C3%A4nneauthor=R.+K.+Thomasauthor=M.+L.+Meyersonauthor=M.+J.+Eckauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=K.-K.+Wong&title=Bronchial+and+peripheral+murine+lung+carcinomas+induced+by+T790M-L858R+mutant+EGFR+respond+to+HKI-272+and+rapamycin+combination+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DM.-C.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DZaghlul%26aufirst%3DS.%26aulast%3DBorgman%26aufirst%3DC.%2BL.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%2BL.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DBronchial%2520and%2520peripheral%2520murine%2520lung%2520carcinomas%2520induced%2520by%2520T790M-L858R%2520mutant%2520EGFR%2520respond%2520to%2520HKI-272%2520and%2520rapamycin%2520combination%2520therapy%26jtitle%3DCancer%2520Cell.%26date%3D2007%26volume%3D12%26spage%3D81%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mom, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A. S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amelsberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1038%2Fsj.bjc.6604108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=18026190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=80-85&author=F.+A.+L.+M.+Eskensauthor=C.+H.+Momauthor=A.+S.+T.+Plantingauthor=J.+A.+Gietemaauthor=A.+Amelsbergauthor=H.+Huismanauthor=L.+van+Doornauthor=H.+Burgerauthor=P.+Stopferauthor=J.+Verweijauthor=E.+G.+de+Vries&title=A+phase+I+dose+escalation+study+of+BIBW+2992%2C+an+irreversible+dual+inhibitor+of+epidermal+growth+factor+receptor+1+%28EGFR%29+and+2+%28HER2%29+tyrosine+kinase+in+a+2-week+on%2C+2-week+off+schedule+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clin. activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992.  An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored.  Thirty-eight patients were enrolled.  Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg.  At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhea despite treatment with loperamide) occurred in two patients.  In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients.  An intermediate dose level of 85 mg was studied.  Here DLT occurred in two patients (grade 3 diarrhea despite treatment and grade 2 diarrhea lasting more than 7 days despite treatment).  An addnl. 12 patients were treated at 70 mg.  BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality.  Pharmacodynamics anal. in skin biopsies did not show significant changes in EGFR-assocd. biomarkers.  However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was obsd.  No partial or complete responses were obsd., stable disease lasting more than four cycles was seen in seven patients.  The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD.  British Journal of Cancer (2008) 98, 80-85. doi:10.1038/sj.bjc.6604108 www.bjcancer.com Published online 20 Nov. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZL8pTnjAwrVg90H21EOLACvtfcHk0litF-8_Yn-HPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D&md5=96a0be31145bf1691640109d69ff5dc0</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604108%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DMom%26aufirst%3DC.%2BH.%26aulast%3DPlanting%26aufirst%3DA.%2BS.%2BT.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26aulast%3DAmelsberg%26aufirst%3DA.%26aulast%3DHuisman%26aufirst%3DH.%26aulast%3Dvan%2BDoorn%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%2520dual%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%25201%2520%2528EGFR%2529%2520and%25202%2520%2528HER2%2529%2520tyrosine%2520kinase%2520in%2520a%25202-week%2520on%252C%25202-week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Yokoi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaker, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebhun, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3716</span><span class="NLM_x">–</span> <span class="NLM_lpage">3725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3716-3725&author=K.+Yokoiauthor=P.+H.+Thakerauthor=S.+Yaziciauthor=R.+R.+Rebhunauthor=D.-H.+Namauthor=J.+Heauthor=S.-J.+Kimauthor=J.+L.+Abbruzzeseauthor=S.+R.+Hamiltonauthor=I.+J.+Fidler&title=Dual+inhibition+of+epidermal+growth+factor+receptor+and+vascular+endothelial+growth+factor+receptor+phosphorylation+by+AEE788+reduces+growth+and+metastasis+of+human+colon+carcinoma+in+an+orthotopic+nude+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DYazici%26aufirst%3DS.%26aulast%3DRebhun%26aufirst%3DR.%2BR.%26aulast%3DNam%26aufirst%3DD.-H.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-J.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DHamilton%26aufirst%3DS.%2BR.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DDual%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520phosphorylation%2520by%2520AEE788%2520reduces%2520growth%2520and%2520metastasis%2520of%2520human%2520colon%2520carcinoma%2520in%2520an%2520orthotopic%2520nude%2520mouse%2520model%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3716%26epage%3D3725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6186</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1158%2F1078-0432.CCR-06-0642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=17062696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6186-6193&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=C.+Yuauthor=F.+R.+Luoauthor=S.+Oppenheimerauthor=H.+Zhangauthor=R.+A.+Smyklaauthor=H.+Mastalerzauthor=B.+E.+Finkauthor=J.+T.+Huntauthor=A.+V.+Gavaiauthor=G.+D.+Vite&title=Preclinical+antitumor+activity+of+BMS-599626%2C+a+pan-HER+kinase+inhibitor+that+inhibits+HER1%2FHER2+homodimer+and+heterodimer+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling</span></div><div class="casAuthors">Wong, Tai W.; Lee, Francis Y.; Yu, Chiang; Luo, Feng R.; Oppenheimer, Simone; Zhang, Hongjian; Smykla, Richard A.; Mastalerz, Harold; Fink, Brian E.; Hunt, John T.; Gavai, Ashvinikumar V.; Vite, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6186-6193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-mol. inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on HER1 and/or HER2.  Exptl. Design: The potency and selectivity of BMS-599626 were assessed in biochem. assays using recombinant protein kinases, as well as in cell proliferation assays using tumor cell lines with varying degrees of dependence on HER1 or HER2 signaling.  Modulation of receptor signaling was detd. in cell assays by Western blot analyses of receptor autophosphorylation and downstream signaling.  The ability of BMS-599626 to inhibit receptor heterodimer signaling in tumor cells was studied by receptor coimmunopptn.  Antitumor activity of BMS-599626 was evaluated using a no. of different xenograft models that represent a spectrum of human tumors with HER1 or HER2 overexpression.  Results: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, resp., and was highly selective when tested against a broad panel of diverse protein kinases.  Biochem. studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms.  BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μmol/L.  BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors.  In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling.  BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity.  Conclusions: BMS-599626 is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling.  BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an addnl. mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.  The preclin. data support the advancement of BMS-599626 into clin. development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgsCF6GDMPbVg90H21EOLACvtfcHk0lhXjVbcM-urZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK&md5=a8350e2eb304a091fa82f1159e44c119</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0642%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmykla%26aufirst%3DR.%2BA.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DGavai%26aufirst%3DA.%2BV.%26aulast%3DVite%26aufirst%3DG.%2BD.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-599626%252C%2520a%2520pan-HER%2520kinase%2520inhibitor%2520that%2520inhibits%2520HER1%252FHER2%2520homodimer%2520and%2520heterodimer%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6186%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dextraze, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruediger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2042</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2036-2042&author=H.+Mastalerzauthor=M.+Changauthor=P.+Chenauthor=P.+Dextrazeauthor=B.+E.+Finkauthor=A.+Gavaiauthor=B.+Goyalauthor=W.-C.+Hanauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=P.+Maratheauthor=A.+Mathurauthor=S.+Oppenheimerauthor=E.+Ruedigerauthor=J.+Tarrantauthor=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=New+C-5+substituted+pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DDextraze%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DGoyal%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DW.-C.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DRuediger%26aufirst%3DE.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DNew%2520C-5%2520substituted%2520pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2036%26epage%3D2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2m"><span><span class="NLM_label">(m) </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2828</span><span class="NLM_x">–</span> <span class="NLM_lpage">2833</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2828-2833&author=H.+Mastalerzauthor=M.+Changauthor=A.+Gavaiauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=P.+Maratheauthor=A.+Mathurauthor=S.+Oppenheimerauthor=J.+Tarrant.author=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=Novel+C-5+aminomethyl+pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DTarrant.%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DNovel%2520C-5%2520aminomethyl%2520pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2828%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2n"><span><span class="NLM_label">(n) </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleczka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4947</span><span class="NLM_x">–</span> <span class="NLM_lpage">4954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4947-4954&author=H.+Mastalerzauthor=M.+Changauthor=P.+Chenauthor=B.+E.+Finkauthor=A.+Gavaiauthor=W+C.+Hanauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=K.+Leavittauthor=P.+Maratheauthor=D.+Norrisauthor=S.+Oppenheimerauthor=B.+Sleczkaauthor=J.+Tarrantauthor=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=5-%28%284-Aminopiperidin-1-yl%29methyl%29pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2n&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DW%2BC.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3D5-%2528%25284-Aminopiperidin-1-yl%2529methyl%2529pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4947%26epage%3D4954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2o"><span><span class="NLM_label">(o) </span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafidi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessel, M. D.</span><span> </span><span class="NLM_article-title">Achieving selectivity between higly homologous tyrosine kinases anovel selective erbB2 inhibitor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=267-273&author=S.+K.+Bhattacharyaauthor=E.+D.+Coxauthor=J.+C.+Kathauthor=A.+M.+Mathiowetzauthor=J.+Morrisauthor=J.+D.+Moyerauthor=L.+R.+Pustilnikauthor=K.+Rafidiauthor=D.+T.+Richterauthor=C.+Suauthor=M.+D.+Wessel&title=Achieving+selectivity+between+higly+homologous+tyrosine+kinases+anovel+selective+erbB2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2o&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DCox%26aufirst%3DE.%2BD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26atitle%3DAchieving%2520selectivity%2520between%2520higly%2520homologous%2520tyrosine%2520kinases%2520anovel%2520selective%2520erbB2%2520inhibitor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D307%26spage%3D267%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2p"><span><span class="NLM_label">(p) </span><span class="NLM_contrib-group">Jani, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafidi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span> </span><span class="NLM_article-title">Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9887</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2p&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1158%2F0008-5472.CAN-06-3559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2p&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=17942920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2p&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9887-93&author=J.+P.+Janiauthor=R.+S.+Finnauthor=M.+Campbellauthor=K.+G.+Colemanauthor=R.+D.+Connellauthor=N.+Currierauthor=E.+O.+Emersonauthor=E.+Floydauthor=S.+Harrimanauthor=J.+C.+Kathauthor=J.+Morrisauthor=J.+D.+Moyerauthor=L.+R.+Pustilnikauthor=K.+Rafidiauthor=S.+Ralstonauthor=A.+M.+Rossiauthor=S.+J.+Steynauthor=L.+Wagnerauthor=S.+M.+Winterauthor=S.+K.+Bhattacharya&title=Discovery+and+pharmacologic+characterization+of+CP-724%2C714%2C+a+selective+ErbB2+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2pR"><div class="casContent"><span class="casTitleNuber">2p</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Jani, Jitesh P.; Finn, Richard S.; Campbell, Mary; Coleman, Kevin G.; Connell, Richard D.; Currier, Nicolas; Emerson, Erling O.; Floyd, Eugenia; Harriman, Shawn; Kath, John C.; Morris, Joel; Moyer, James D.; Pustilnik, Leslie R.; Rafidi, Kristina; Ralston, Sherry; Rossi, Ann Marie K.; Steyn, Stefanus J.; Wagner, Larry; Winter, Steven M.; Bhattacharya, Samit K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9887-9893</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amplification and overexpression of erbB2 (Her-2/neu) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary, and stomach.  It has been implicated in tumor growth, sensitivity to std. chemotherapy, prognosis of patients, and disease-free survival.  Although the clin. use of trastuzumab (Herceptin) has prolonged the survival of breast cancer patients with erbB2-overexpressing tumors, there is an urgent need for more potent and orally bioavailable small-mol. inhibitors.  CP-724,714 is a potent inhibitor of erbB2 receptor autophosphorylation in intact cells and is currently undergoing phase I clin. trials.  Here, we describe the effects of CP-724,714 in vitro and in vivo in human breast cancer models.  CP-724,714 is selective for inhibiting growth of HER2-driven cell lines.  In addn., we show that it induces G1 cell cycle block in erbB2-overexpressing BT-474 human breast carcinoma cells and inhibits erbB2 autophosphorylation in xenografts when administered p.o. to athymic mice.  It induces a marked redn. of extracellular signal-regulated kinase and Akt phosphorylation, tumor cell apoptosis, and release of caspase-3.  P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_a6qjvEZI-rVg90H21EOLACvtfcHk0lilspqrUiAzCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbvE&md5=21dc688108dd46aba15694d7e3159321</span></div><a href="/servlet/linkout?suffix=cit2p&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3559%26sid%3Dliteratum%253Aachs%26aulast%3DJani%26aufirst%3DJ.%2BP.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DK.%2BG.%26aulast%3DConnell%26aufirst%3DR.%2BD.%26aulast%3DCurrier%26aufirst%3DN.%26aulast%3DEmerson%26aufirst%3DE.%2BO.%26aulast%3DFloyd%26aufirst%3DE.%26aulast%3DHarriman%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DRalston%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DWagner%26aufirst%3DL.%26aulast%3DWinter%26aufirst%3DS.%2BM.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3DDiscovery%2520and%2520pharmacologic%2520characterization%2520of%2520CP-724%252C714%252C%2520a%2520selective%2520ErbB2%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9887%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2q"><span><span class="NLM_label">(q) </span><span class="NLM_contrib-group">Ripin, D. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourassa, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaldi, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massett, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raggon, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. M.,  III.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetelino, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span> </span><span class="NLM_article-title">Evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to oncology candidate CP-724,714</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">440</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/doi/10.1021/op050039u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=440-450&author=D.+H.+B.+Ripinauthor=D.+E.+Bourassaauthor=T.+Brandtauthor=M.+J.+Castaldiauthor=H.+N.+Frostauthor=J.+Hawkinsauthor=P.+J.+Johnsonauthor=S.+S.+Massettauthor=K.+Neumannauthor=J.+Phillipsauthor=J.+W.+Raggonauthor=P.+R.+Roseauthor=J.+L.+Rutherfordauthor=B.+Sitterauthor=A.+M.+Stewartauthor=M.+G.+Vetelinoauthor=L.+Wei&title=Evaluation+of+kilogram-scale+Sonagashira%2C+Suzuki%2C+and+Heck+coupling+routes+to+oncology+candidate+CP-724%2C714"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2q&amp;dbid=16384&amp;doi=10.1021%2Fop050039u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop050039u%26sid%3Dliteratum%253Aachs%26aulast%3DRipin%26aufirst%3DD.%2BH.%2BB.%26aulast%3DBourassa%26aufirst%3DD.%2BE.%26aulast%3DBrandt%26aufirst%3DT.%26aulast%3DCastaldi%26aufirst%3DM.%2BJ.%26aulast%3DFrost%26aufirst%3DH.%2BN.%26aulast%3DHawkins%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DP.%2BJ.%26aulast%3DMassett%26aufirst%3DS.%2BS.%26aulast%3DNeumann%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DJ.%26aulast%3DRaggon%26aufirst%3DJ.%2BW.%26aulast%3DRose%26aufirst%3DP.%2BR.%26aulast%3DRutherford%26aufirst%3DJ.%2BL.%26aulast%3DSitter%26aufirst%3DB.%26aulast%3DStewart%26aufirst%3DA.%2BM.%26aulast%3DVetelino%26aufirst%3DM.%2BG.%26aulast%3DWei%26aufirst%3DL.%26atitle%3DEvaluation%2520of%2520kilogram-scale%2520Sonagashira%252C%2520Suzuki%252C%2520and%2520Heck%2520coupling%2520routes%2520to%2520oncology%2520candidate%2520CP-724%252C714%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2005%26volume%3D9%26spage%3D440%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2r"><span><span class="NLM_label">(r) </span><span class="NLM_contrib-group">Lippa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungerford, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span> </span><span class="NLM_article-title">The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3081</span><span class="NLM_x">–</span> <span class="NLM_lpage">3086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3081-3086&author=B.+Lippaauthor=G.+S.+Kauffmanauthor=J.+Arcariauthor=T.+Kwanauthor=J.+Chenauthor=W.+Hungerfordauthor=S.+Bhattacharyaauthor=X.+Zhaoauthor=C.+Williamsauthor=J.+Xiaoauthor=L.+Pustilnikauthor=C.+Suauthor=J.+D.+Moyerauthor=L.+Maauthor=M.+Campbellauthor=S.+Steyn&title=The+discovery+of+highly+selective+erbB2+%28Her2%29+inhibitors+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2r&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DKauffman%26aufirst%3DG.%2BS.%26aulast%3DArcari%26aufirst%3DJ.%26aulast%3DKwan%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHungerford%26aufirst%3DW.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DPustilnik%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DSteyn%26aufirst%3DS.%26atitle%3DThe%2520discovery%2520of%2520highly%2520selective%2520erbB2%2520%2528Her2%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3081%26epage%3D3086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oorui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel HER2/EGFR dual inhibitors bearing a pyrrolo[3,2-<i>d</i>]pyrimidine scaffold</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8030</span><span class="NLM_x">–</span> <span class="NLM_lpage">8050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2008634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8030-8050&author=T.+Ishikawaauthor=M.+Setoauthor=H.+Bannoauthor=Y.+Kawakitaauthor=M.+Ooruiauthor=T.+Taniguchiauthor=Y.+Ohtaauthor=T.+Tamuraauthor=A.+Nakayamaauthor=H.+Mikiauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=N.+Habukaauthor=S.+Sogabeauthor=K.+Aertgeertsauthor=K.+Kamiyama&title=Design+and+synthesis+of+novel+HER2%2FEGFR+dual+inhibitors+bearing+a+pyrrolo%5B3%2C2-d%5Dpyrimidine+scaffold"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1021%2Fjm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DBanno%26aufirst%3DH.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DOorui%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DKamiyama%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520HER2%252FEGFR%2520dual%2520inhibitors%2520bearing%2520a%2520pyrrolo%255B3%252C2-d%255Dpyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8030%26epage%3D8050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Doi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takiuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dote, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuze, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jinno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takubo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phase, I</span><span> </span><span class="NLM_article-title">First-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients</span> <span class="citation_source-journal">Br. J. Can</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1038%2Fbjc.2011.590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=22215103" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=1-7&author=T.+Doiauthor=H.+Takiuchiauthor=A.+Ohtsuauthor=N.+Fuseauthor=M.+Gotoauthor=M.+Yoshidaauthor=N.+Doteauthor=Y.+Kuzeauthor=F.+Jinnoauthor=M.+Fujimotoauthor=T.+Takuboauthor=N.+Nakayamaauthor=R.+Tsutsumiauthor=I+Phase&title=First-in-human+study+of+TAK-285%2C+a+novel+investigational+dual+HER2%2FEGFR+inhibitor%2C+in+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.590%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DTakiuchi%26aufirst%3DH.%26aulast%3DOhtsu%26aufirst%3DA.%26aulast%3DFuse%26aufirst%3DN.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DDote%26aufirst%3DN.%26aulast%3DKuze%26aufirst%3DY.%26aulast%3DJinno%26aufirst%3DF.%26aulast%3DFujimoto%26aufirst%3DM.%26aulast%3DTakubo%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DN.%26aulast%3DTsutsumi%26aufirst%3DR.%26aulast%3DPhase%26aufirst%3DI%26atitle%3DFirst-in-human%2520study%2520of%2520TAK-285%252C%2520a%2520novel%2520investigational%2520dual%2520HER2%252FEGFR%2520inhibitor%252C%2520in%2520cancer%2520patients%26jtitle%3DBr.%2520J.%2520Can%26date%3D2012%26volume%3D106%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span> </span><span class="NLM_article-title">Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">18756</span><span class="NLM_x">–</span> <span class="NLM_lpage">18765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=18756-18765&author=K.+Aertgeertsauthor=R.+Skeneauthor=J.+Yanoauthor=B.+Sangauthor=H.+Zouauthor=G.+Snellauthor=A.+Jenningsauthor=K.+Iwamotoauthor=N.+Habukaauthor=A.+Hirokawaauthor=T.+Ishikawaauthor=T.+Tanakaauthor=H.+Mikiauthor=Y.+Ohtaauthor=S.+Sogabe&title=Structural+analysis+of+the+mechanism+of+inhibition+and+allosteric+activation+of+the+kinase+domain+of+HER2+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DHirokawa%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DSogabe%26aufirst%3DS.%26atitle%3DStructural%2520analysis%2520of%2520the%2520mechanism%2520of%2520inhibition%2520and%2520allosteric%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520HER2%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D21%26spage%3D18756%26epage%3D18765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Oguro, Y</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awazu, Y</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine derivatives: novel VEGFR kinase inhibitors binding to inactive kinase conformation</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7260</span><span class="NLM_x">–</span> <span class="NLM_lpage">7273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7260-7273&author=Y+Oguroauthor=N+Miyamotoauthor=T+Takagiauthor=K+Okadaauthor=Y+Awazuauthor=M+Mikiauthor=A+Horiauthor=K+Kamiyamaauthor=S.+Imamura&title=Design%2C+synthesis%2C+and+evaluation+of+5-methyl-4-phenoxy-5H-pyrrolo%5B3%2C2-d%5Dpyrimidine+derivatives%3A+novel+VEGFR+kinase+inhibitors+binding+to+inactive+kinase+conformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOguro%26aufirst%3DY%26aulast%3DMiyamoto%26aufirst%3DN%26aulast%3DTakagi%26aufirst%3DT%26aulast%3DOkada%26aufirst%3DK%26aulast%3DAwazu%26aufirst%3DY%26aulast%3DMiki%26aufirst%3DM%26aulast%3DHori%26aufirst%3DA%26aulast%3DKamiyama%26aufirst%3DK%26aulast%3DImamura%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%25205-methyl-4-phenoxy-5H-pyrrolo%255B3%252C2-d%255Dpyrimidine%2520derivatives%253A%2520novel%2520VEGFR%2520kinase%2520inhibitors%2520binding%2520to%2520inactive%2520kinase%2520conformation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D20%26spage%3D7260%26epage%3D7273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=12467226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=85-94&author=D.+W.+Rusnakauthor=K.+Lackeyauthor=K.+Affleckauthor=E.+R.+Woodauthor=K.+J.+Alligoodauthor=N.+Rhodesauthor=B.+R.+Keithauthor=D.+M.+Murrayauthor=K.+Glennonauthor=W.+B.+Knightauthor=R.+J.+Mullinauthor=T.+M.+Gilmer&title=The+effects+of+the+novel%2C+reversible+epidermal+growth+factor+receptor%2FErbB-2+tyrosine+kinase+inhibitor%2C+GW2016%2C+on+the+growth+of+human+normal+and+tumor-derived+cell+lines+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span></div><div class="casAuthors">Rusnak, David W.; Lackey, Karen; Affleck, Karen; Wood, Edgar R.; Alligood, Krystal J.; Rhodes, Nelson; Keith, Barry R.; Murray, Doris M.; Knight, W. Blaine; Mullin, Robert J.; Gilmer, Tona M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of cancer.  GW2016 is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, resp.  This report describes the efficacy in cell growth assays of GW2016 on human tumor cell lines overexpressing either EGFR or ErbB-2: HN5 (head and neck), A-431 (vulva), BT474 (breast), CaLu-3 (lung), and N87 (gastric).  Normal human foreskin fibroblasts, nontumorigenic epithelial cells (HB4a), and nonoverexpressing tumor cells (MCF-7 and T47D) were tested as neg. controls.  After 3 days of compd. exposure, av. IC50 values for growth inhibition in the EGFR- and ErbB-2-overexpressing tumor cell lines were <0.16 μM.  The av. selectivity for the tumor cells vs. the human foreskin fibroblast cell line was 100-fold.  Inhibition of EGFR and ErbB-2 receptor autophosphorylation and phosphorylation of the downstream modulator, AKT, was verified by Western blot anal. in the BT474 and HN5 cell lines.  As a measure of cytotoxicity vs. growth arrest, the HN5 and BT474 cells were assessed in an outgrowth assay after a transient exposure to GW2016.  The cells were treated for 3 days in five concns. of GW2016, and cell growth was monitored for an addnl. 12 days after removal of the compd.  In each of these tumor cell lines, concns. of GW2016 were reached where outgrowth did not occur.  Furthermore, growth arrest and cell death were obsd. in parallel expts., as detd. by bromodeoxyuridine incorporation and propidium iodide staining.  GW2016 treatment inhibited tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg orally, twice daily, with complete inhibition of tumor growth at the higher dose.  Together, these results indicate that GW2016 achieves excellent potency on tumor cells with selectivity for tumor vs. normal cells and suggest that GW2016 has value as a therapy for patients with tumors overexpressing either EGFR or ErbB-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5OJ41zsWu6rVg90H21EOLACvtfcHk0liTUuHkx-IKfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D&md5=64fd8cadce83eda3b9b82ab50f1e57b0</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DMurray%26aufirst%3DD.%2BM.%26aulast%3DGlennon%26aufirst%3DK.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DThe%2520effects%2520of%2520the%2520novel%252C%2520reversible%2520epidermal%2520growth%2520factor%2520receptor%252FErbB-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520GW2016%252C%2520on%2520the%2520growth%2520of%2520human%2520normal%2520and%2520tumor-derived%2520cell%2520lines%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2001%26volume%3D1%26spage%3D85%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0liCcz9GTYVJDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nature Rev. Drug Discov.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm300185p&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNature%2520Rev.%2520Drug%2520Discov.%26date%3D2007%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span> </span><span class="NLM_article-title">Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi101777f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=738-751&author=H.+Iwataauthor=S.+Imamuraauthor=A.+Horiauthor=M.+S.+Hixonauthor=H.+Kimuraauthor=H.+Miki&title=Biochemical+characterization+of+TAK-593%2C+a+novel+VEGFR%2FPDGFR+inhibitor+with+a+two-step+slow+binding+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1021%2Fbi101777f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi101777f%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DS.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DHixon%26aufirst%3DM.%2BS.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26atitle%3DBiochemical%2520characterization%2520of%2520TAK-593%252C%2520a%2520novel%2520VEGFR%252FPDGFR%2520inhibitor%2520with%2520a%2520two-step%2520slow%2520binding%2520mechanism%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D738%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kinnick, M. D.; Lin, H.-S.; Martinelli, M. J.; Morin, J. M.; Richett, M. E.</span> Novel SPLA2 Inhibitors. PCT Int. Appl. US 20030236232 (A1), Dec.<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kinnick%2C+M.+D.%3B+Lin%2C+H.-S.%3B+Martinelli%2C+M.+J.%3B+Morin%2C+J.+M.%3B+Richett%2C+M.+E.+Novel+SPLA2+Inhibitors.+PCT+Int.+Appl.+US+20030236232+%28A1%29%2C+Dec.+2003."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKinnick%26aufirst%3DM.%2BD.%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Sutter, M.; Kunz, W.</span><span> </span><span class="NLM_article-title">Process for Preparing Nematicidal Compositions</span>. PCT Int. Appl. US 5169951 (A), Dec.<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=M.+Sutter&author=W.+Kunz&title=Process+for+Preparing+Nematicidal+Compositions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSutter%26aufirst%3DM.%26atitle%3DProcess%2520for%2520Preparing%2520Nematicidal%2520Compositions%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists</span> <span class="citation_source-journal">Methods Biochem. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300185p&amp;key=16350889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300185p&amp;key=1%3ACAS%3A280%3ADC%252BD2MnmtlyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=1-265&author=R.+A.+Copeland&title=Evaluation+of+enzyme+inhibitors+in+drug+discovery.+A+guide+for+medicinal+chemists+and+pharmacologists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists</span></div><div class="casAuthors">Copeland Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Methods of biochemical analysis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-265</span>
        ISSN:<span class="NLM_cas:issn">0076-6941</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR7_ubfiC0DK2q3xNe7a7QfW6udTcc2ebioFqXfQOocLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnmtlyjsA%253D%253D&md5=4bb6759b5155aa6c2b6a462432afda7f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DEvaluation%2520of%2520enzyme%2520inhibitors%2520in%2520drug%2520discovery.%2520A%2520guide%2520for%2520medicinal%2520chemists%2520and%2520pharmacologists%26jtitle%3DMethods%2520Biochem.%2520Anal.%26date%3D2005%26volume%3D46%26spage%3D1%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i89"><a href="/doi/suppl/10.1021/jm300185p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_35047"></div></div></div></div></div><hr /></hr><p class="last">Methods used in molecular modeling, enzyme assays, cell line and animal models, pharmacokinetics, metabolic stability, and CYP inhibition. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300185p/suppl_file/jm300185p_si_001.pdf">jm300185p_si_001.pdf (111.1 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300185p&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-8%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm300185p%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300185p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a61e87bc332c1","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
